{
  "questions": [
    {
      "id": "63f73f1b33942b094c000008",
      "type": "yesno",
      "body": "Is erenumab effective for trigeminal neuralgia?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29066316",
          "text": "al neuralgia; however, its utility in bilateral trigeminal neuralgia is unclear. Here, we report our experience with MVD in 13 cases of primary bilate",
          "offsetInBeginSection": 163,
          "offsetInEndSection": 313,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34484889",
          "text": "tion, which adversely affects the lives of patients. Current treatments are only mildly effective. Anti-calcitonin gene-related peptide (CGRP) monoclo",
          "offsetInBeginSection": 78,
          "offsetInEndSection": 228,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3716698",
          "text": "cupuncture in patients with trigeminal neuralgia should be used differentially. It is effective only in patients with peripheral trigeminal neuralgia.",
          "offsetInBeginSection": 359,
          "offsetInEndSection": 509,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22383125",
          "text": "Mean response rate was 55% with greatest efficacy in trigeminal (75%) and occipital neuralgia (100%) and less efficacy in trigeminal neuropathic pain (50%) and persistent idiopathic facial pain (20%).",
          "offsetInBeginSection": 516,
          "offsetInEndSection": 716,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14621949",
          "text": "Although medical therapy is available, it gradually becomes less effective because of the progressive nature of trigeminal neuralgia.",
          "offsetInBeginSection": 412,
          "offsetInEndSection": 545,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28905370",
          "text": "Pharmacologic therapies are not effective in some cases and often cause side effects, some substantial.",
          "offsetInBeginSection": 417,
          "offsetInEndSection": 520,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36113495",
          "text": "Well tolerated, effective treatments in trigeminal neuralgia are still needed.",
          "offsetInBeginSection": 3029,
          "offsetInEndSection": 3107,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28829200",
          "text": "rd drugs for treating patients with trigeminal neuralgia. They are effective in most patients. The undesired effects however cause withdrawal from tre",
          "offsetInBeginSection": 803,
          "offsetInEndSection": 953,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26722633",
          "text": "mon severe and chronic facial neuralgia which requires accurate diagnosis and effective therapy. With typical clinical symptoms, normal neurological s",
          "offsetInBeginSection": 1449,
          "offsetInEndSection": 1599,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6487105",
          "text": "al data tend to favor a central mechanism. Drugs that are effective in the treatment of trigeminal neuralgia facilitate segmental inhibition in the tr",
          "offsetInBeginSection": 150,
          "offsetInEndSection": 300,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/14621949",
        "http://www.ncbi.nlm.nih.gov/pubmed/3716698",
        "http://www.ncbi.nlm.nih.gov/pubmed/28905370",
        "http://www.ncbi.nlm.nih.gov/pubmed/36113495",
        "http://www.ncbi.nlm.nih.gov/pubmed/28829200",
        "http://www.ncbi.nlm.nih.gov/pubmed/26722633",
        "http://www.ncbi.nlm.nih.gov/pubmed/29066316",
        "http://www.ncbi.nlm.nih.gov/pubmed/6487105",
        "http://www.ncbi.nlm.nih.gov/pubmed/34484889",
        "http://www.ncbi.nlm.nih.gov/pubmed/22383125"
      ]
    },
    {
      "id": "643d41e757b1c7a315000037",
      "type": "list",
      "body": "What is the first indication for lurasidone?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34860899",
          "text": "Background: Lurasidone is an atypical antipsychotic approved for the treatment of schizophrenia in 2010.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 104,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36002828",
          "text": "CONCLUSIONS\nLurasidone is a cost-saving first-line treatment for schizophrenia for both adolescents and adults.",
          "offsetInBeginSection": 1899,
          "offsetInEndSection": 2010,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22364325",
          "text": "otics approved in the recent past by the US FDA for the treatment of schizophrenia. Several Phase II and III studies have established that lurasidone ",
          "offsetInBeginSection": 38,
          "offsetInEndSection": 188,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26771990",
          "text": "antipsychotic drug that was initially developed for the treatment of schizophrenia. Since no previous atypical antipsychotic development program had p",
          "offsetInBeginSection": 426,
          "offsetInEndSection": 576,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36187655",
          "text": "Objective\nTo evaluate the cost-effectiveness of lurasidone compared with olanzapine and risperidone in the first-line treatment of patients with schizophrenia from a Chinese healthcare system perspective.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 204,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25838997",
          "text": "Lurasidone HCl (LRD) is an antipsychotic agent specially used in the treatments of schizophrenia and is a good example of the problems associated with low aqueous solubility.",
          "offsetInBeginSection": 102,
          "offsetInEndSection": 276,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25698146",
          "text": "Lurasidone (Latuda(\u00ae)), a benzisothiazole derivative antipsychotic, is approved in the USA and Canada for the treatment of adults with major depressive episodes (MDE) associated with bipolar I disorder; this article reviews studies of lurasidone in this indication.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 265,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32124704",
          "text": "Lurasidone was approved by the United States Food and Drug Administration (FDA) for the treatment of schizophrenia, as well as for the treatment of bipolar depression.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33588674",
          "text": ", p<.001) than the cariprazine cohort.\n\n\nCONCLUSIONS\nPatients with bipolar disorder treated with lurasidone had greater reductions in hospitalizations",
          "offsetInBeginSection": 1914,
          "offsetInEndSection": 2064,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35038851",
          "text": "Lurasidone is one of the newest antipsychotics approved for use in childhood.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 77,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27203278",
        "http://www.ncbi.nlm.nih.gov/pubmed/20404009",
        "http://www.ncbi.nlm.nih.gov/pubmed/35038851",
        "http://www.ncbi.nlm.nih.gov/pubmed/25698146",
        "http://www.ncbi.nlm.nih.gov/pubmed/29730043",
        "http://www.ncbi.nlm.nih.gov/pubmed/19780705",
        "http://www.ncbi.nlm.nih.gov/pubmed/26771990",
        "http://www.ncbi.nlm.nih.gov/pubmed/36002828",
        "http://www.ncbi.nlm.nih.gov/pubmed/26603973",
        "http://www.ncbi.nlm.nih.gov/pubmed/25765597"
      ]
    },
    {
      "id": "643c88a257b1c7a315000030",
      "type": "yesno",
      "body": "Can other vaccines be given with COVID-19 vaccine?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35417663",
          "text": "This study aimed to investigate the changes in the willingness of guardians to administer the COVID-19 vaccine to their children, allow the coadministration of other vaccines, and administer the COVID-19 vaccine booster dose.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 225,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35797995",
          "text": "ith the coronavirus disease (COVID-19) pandemic. However, vaccine hesitancy can limit uptake. We examined the specific coronavirus beliefs that person",
          "offsetInBeginSection": 62,
          "offsetInEndSection": 212,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36439898",
          "text": "arning about this novel disease, although multiple vaccines have been shown to be effective against COVID-19. However, we report a case of unique clin",
          "offsetInBeginSection": 1734,
          "offsetInEndSection": 1884,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35848521",
          "text": "CONCLUSION\nEven in a high-risk population, most patients can be vaccinated with available COVID-19 vaccines.",
          "offsetInBeginSection": 1682,
          "offsetInEndSection": 1790,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34304240",
          "text": "The reason for delay in immune response with co-administration of COVID-19 vaccines with other vaccines is unknown and further studies are needed.",
          "offsetInBeginSection": 1388,
          "offsetInEndSection": 1534,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36439898",
          "text": "e continuously learning about this novel disease, although multiple vaccines have been shown to be effective against COVID-19. However, we report a ca",
          "offsetInBeginSection": 1717,
          "offsetInEndSection": 1867,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35136470",
          "text": "ieties about blood donation after COVID-19 vaccination, all types of COVID-19 vaccines included. We also present some experiences of blood transfusion",
          "offsetInBeginSection": 1162,
          "offsetInEndSection": 1312,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36334965",
          "text": "ians, however, remain hesitant about COVID-19 vaccines, while others outright refuse them. We conducted focus groups to gauge perceptions and attitude",
          "offsetInBeginSection": 108,
          "offsetInEndSection": 258,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36246547",
          "text": "nths of the COVID-19 vaccination campaign: Most COVID-19 vaccines require two doses given 3 or 4 weeks apart. Given the severely limited supply and mo",
          "offsetInBeginSection": 245,
          "offsetInEndSection": 395,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36414475",
          "text": "es have now been licensed for human use, with other candidate vaccines in different stages of development. Effective and safe vaccines against COVID-1",
          "offsetInBeginSection": 35,
          "offsetInEndSection": 185,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34078215",
        "http://www.ncbi.nlm.nih.gov/pubmed/35148322",
        "http://www.ncbi.nlm.nih.gov/pubmed/35226563",
        "http://www.ncbi.nlm.nih.gov/pubmed/36439898",
        "http://www.ncbi.nlm.nih.gov/pubmed/36334965",
        "http://www.ncbi.nlm.nih.gov/pubmed/34304240",
        "http://www.ncbi.nlm.nih.gov/pubmed/33907510",
        "http://www.ncbi.nlm.nih.gov/pubmed/35136470",
        "http://www.ncbi.nlm.nih.gov/pubmed/35417663",
        "http://www.ncbi.nlm.nih.gov/pubmed/35848521"
      ]
    },
    {
      "id": "64403c4257b1c7a31500004f",
      "type": "summary",
      "body": "What is Sublocade?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35999975",
          "text": "Related to opioid dependence, the formulations developed were subcutaneous extended release (Sublocade\u00ae), subdermal implant (Probuphine\u00ae), and sublingual tablets (Subutex\u00ae).",
          "offsetInBeginSection": 487,
          "offsetInEndSection": 660,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31399813",
          "text": "In addition to the novel weekly and monthly subcutaneously injectable buprenorphine depot CAM 2038 (Buvidal\u00ae), which is already available in Germany, two other long-acting buprenorphine formulations may be introduced in the near future: the monthly depot formulation RBP-6000 (Sublocade\u2122) and a\u00a06-month buprenorphine depot implant (Probuphine\u2122).",
          "offsetInBeginSection": 123,
          "offsetInEndSection": 468,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32724686",
          "text": "Sublingual buprenorphine is one option, but subcutaneous extended-release buprenorphine (Sublocade\u00ae) is an alternate form administered in monthly injections.",
          "offsetInBeginSection": 95,
          "offsetInEndSection": 252,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33212514",
          "text": " depot formulations CAM 2038 (Buvidal\u00ae), the monthly depot formulation RBP-6000 (Sublocade\u2122), and a 6-month buprenorphine implant (Probuphine\u2122). Clini",
          "offsetInBeginSection": 276,
          "offsetInEndSection": 426,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34631459",
          "text": "Three long-acting buprenorphine depot or implant formulations are currently available for the treatment of OUDs: (1) CAM 2038 (Buvidal) for subcutaneous weekly and monthly application; (2) RBP-6000 (Sublocade\u2122) as a monthly depot formulation; and (3) A six-month buprenorphine implant [Probuphine\u2122].",
          "offsetInBeginSection": 122,
          "offsetInEndSection": 421,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34238190",
          "text": "OBJECTIVE\nCurrent in-situ injectable implants of buprenorphine (BP) such as Sublocade\u00ae consist of N-methyl-2-pyrrolidone (NMP)-dissolved PLGA.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34631459",
        "http://www.ncbi.nlm.nih.gov/pubmed/35999975",
        "http://www.ncbi.nlm.nih.gov/pubmed/33212514",
        "http://www.ncbi.nlm.nih.gov/pubmed/34238190",
        "http://www.ncbi.nlm.nih.gov/pubmed/32724686",
        "http://www.ncbi.nlm.nih.gov/pubmed/31399813"
      ]
    },
    {
      "id": "6441302d57b1c7a315000056",
      "type": "yesno",
      "body": "Is music therapy effective for pain management in neonates?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10742370",
          "text": "evels (Wilk's lambda =.481; F [2,27] = 37.42; eta2 =.51), and reduced their pain behavior (Wilk's lambda =.312; F [2,27] = 76.42; eta2 =.68). Posthoc ",
          "offsetInBeginSection": 900,
          "offsetInEndSection": 1050,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33280783",
          "text": "CONCLUSIONS\nIn this study of music therapy during cardiac device lead extractions, no effect was found on patient satisfaction with pain management or average pain level.",
          "offsetInBeginSection": 1301,
          "offsetInEndSection": 1471,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25467598",
          "text": "No significant difference in pain response was found between BF groups with or without music therapy.",
          "offsetInBeginSection": 1352,
          "offsetInEndSection": 1453,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29144240",
          "text": "CONCLUSIONS\nIn relatively stable and mature neonates, the combination of music therapy with sucrose provided better pain relief during heel prick than when sucrose or music was used alone.",
          "offsetInBeginSection": 1288,
          "offsetInEndSection": 1476,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28105524",
          "text": "PURPOSE\nEvidence shows that music therapy aids in symptom management and improves quality of life for palliative medicine and hospice patients.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29144240",
        "http://www.ncbi.nlm.nih.gov/pubmed/28105524",
        "http://www.ncbi.nlm.nih.gov/pubmed/33280783",
        "http://www.ncbi.nlm.nih.gov/pubmed/10742370",
        "http://www.ncbi.nlm.nih.gov/pubmed/25467598"
      ]
    },
    {
      "id": "63f042e2f36125a426000022",
      "type": "summary",
      "body": "What is the mechanisms of action of Gilteritinib?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33340276",
          "text": "Overall, these data suggest that gilteritinib can induce deep molecular responses in patients with FLT3-ITD+ R/R AML, and in the setting of CRc or CR/CRh, these responses may be associated with prolonged survival.",
          "offsetInBeginSection": 1526,
          "offsetInEndSection": 1739,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33214069",
          "text": "Gilteritinib is a second-generation FLT3 inhibitor with activity against ITD and high affinity toward the FLT3 receptor, thereby showing therapeutic potential for relapsed/refractory FLT3-mutated AML.",
          "offsetInBeginSection": 164,
          "offsetInEndSection": 364,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32546970",
          "text": "P3A4 inhibitors (fluconazole and itraconazole) could influence the pharmacokinetics of gilteritinib from a drug-drug interaction study in rats. Sample",
          "offsetInBeginSection": 475,
          "offsetInEndSection": 625,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35739428",
          "text": "Gilteritinib is a FLT3 tyrosine kinase inhibitor (TKI) recently approved for patients with R/R AML.",
          "offsetInBeginSection": 110,
          "offsetInEndSection": 209,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32850078",
          "text": "INTRODUCTION\nGilteritinib is a FLT3 kinase inhibitor approved for FLT3-mutated acute myeloid leukemia (AML).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 108,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33175659",
          "text": "DISCUSSION\nGiven that gilteritinib is metabolized by the liver and eliminated primarily in the feces, one does not expect an increase in toxicity related to impaired renal function.",
          "offsetInBeginSection": 1181,
          "offsetInEndSection": 1362,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30039554",
          "text": "In conclusion, gilteritinib was well tolerated and demonstrated antileukemic activity in a Japanese R/R AML population.",
          "offsetInBeginSection": 1615,
          "offsetInEndSection": 1734,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30039554",
          "text": "d creatine phosphokinase (n\u00a0=\u00a03 [12.5%]). Gilteritinib had a dose-proportional PK profile. Among patients with mutated fms-like tyrosine kinase 3, the",
          "offsetInBeginSection": 1098,
          "offsetInEndSection": 1248,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35849791",
          "text": "utated (FLT3) acute myeloid leukemia (AML) but seldom reduces FLT3 burden or induces sustained efficacy. Gilteritinib combines synergistically with th",
          "offsetInBeginSection": 122,
          "offsetInEndSection": 272,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32975130",
          "text": "We discuss clinical development, efficacy, safety and mechanisms of resistance of gilteritinib in the treatment of R/R patients with FLT3 mutated AML.",
          "offsetInBeginSection": 880,
          "offsetInEndSection": 1030,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28516360",
        "http://www.ncbi.nlm.nih.gov/pubmed/35130342",
        "http://www.ncbi.nlm.nih.gov/pubmed/31692922",
        "http://www.ncbi.nlm.nih.gov/pubmed/31320594",
        "http://www.ncbi.nlm.nih.gov/pubmed/32975130",
        "http://www.ncbi.nlm.nih.gov/pubmed/32154636",
        "http://www.ncbi.nlm.nih.gov/pubmed/31069015",
        "http://www.ncbi.nlm.nih.gov/pubmed/36296409",
        "http://www.ncbi.nlm.nih.gov/pubmed/32850078",
        "http://www.ncbi.nlm.nih.gov/pubmed/35797240"
      ]
    },
    {
      "id": "64184483690f196b51000038",
      "type": "summary",
      "body": "What is the reason for N-acetylgalactosamine (GalNAc) conjugation of siRNAs?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35795486",
          "text": "The effects were more pronounced for conjugates with low lipophilicity (e.g., N-Acetylgalactosamine [GalNAc]), where significant improvement in uptake by hepatocytes and dose-dependent silencing in the liver was observed.",
          "offsetInBeginSection": 1288,
          "offsetInEndSection": 1509,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27903888",
          "text": "This observation also explains improved binding affinity of the 5\u0384-E-VP -modified siRNA to human Argonaute-2 in-vitro, as well as the enhanced silencing in the context of the trivalent N-acetylgalactosamine (GalNAc)-conjugated siRNA in mice relative to the un-modified siRNA.",
          "offsetInBeginSection": 707,
          "offsetInEndSection": 982,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35867041",
          "text": "Small interfering RNAs (siRNAs) with N-acetylgalactosamine (GalNAc) conjugation for improved liver uptake represent an emerging class of drugs to treat liver diseases.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33861634",
          "text": "conjugated to the N-acetylgalactosamine (GalNAc) ligand bind to proteins present in circulation. However, it is not known if these protein interaction",
          "offsetInBeginSection": 461,
          "offsetInEndSection": 611,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36345805",
          "text": "ine (GalNAc) moieties to ASOs or siRNAs facilitates receptor-mediated uptake by the asialoglycoprotein receptor. In summary, ATTR is a progressive dis",
          "offsetInBeginSection": 1380,
          "offsetInEndSection": 1530,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29792572",
          "text": "development of N-acetylgalactosamine (GalNAc) siRNA conjugates for delivery to liver. Tris-GalNAc binds to the Asialoglycoprotein receptor that is hig",
          "offsetInBeginSection": 507,
          "offsetInEndSection": 657,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29360004",
          "text": "We selected two ligands, cholesterol and N-acetylgalactosamine (GalNAc), with the purpose of reducing renal distribution and liver targeting, and then designed a series of cholesterol-GalNAc dual conjugated ASOs.",
          "offsetInBeginSection": 344,
          "offsetInEndSection": 556,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32771924",
          "text": "This is particularly the result of successful and efficient delivery of N-acetylgalactosamine (GalNAc)-conjugated siRNAs to the liver.",
          "offsetInBeginSection": 106,
          "offsetInEndSection": 240,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34413198",
          "text": "Conjugation of small interfering RNA (siRNA) to tris N-acetylgalactosamine [(GalNAc)3] can enable highly selective, potent, and durable knockdown of targeted proteins in the liver.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 180,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31270142",
          "text": "been conducted during nonclinical drug development to elucidate the potential clinical DDI liability. GalNAc siRNAs were evaluated as substrates, inhi",
          "offsetInBeginSection": 651,
          "offsetInEndSection": 801,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31529782",
        "http://www.ncbi.nlm.nih.gov/pubmed/33861634",
        "http://www.ncbi.nlm.nih.gov/pubmed/34091052",
        "http://www.ncbi.nlm.nih.gov/pubmed/28129130",
        "http://www.ncbi.nlm.nih.gov/pubmed/31393218",
        "http://www.ncbi.nlm.nih.gov/pubmed/36345805",
        "http://www.ncbi.nlm.nih.gov/pubmed/30820542",
        "http://www.ncbi.nlm.nih.gov/pubmed/29792572",
        "http://www.ncbi.nlm.nih.gov/pubmed/34316717",
        "http://www.ncbi.nlm.nih.gov/pubmed/34413198"
      ]
    },
    {
      "id": "643de76757b1c7a315000039",
      "type": "summary",
      "body": "What is synthetic lethality?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34589394",
          "text": "Synthetic lethality is a proven effective antitumor strategy that has attracted great attention.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 96,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22107871",
          "text": "Exploiting a phenomenon known as synthetic lethality, in which simultaneous loss of two interacting genes leads to loss of viability, aids in the investigation of these interactions.",
          "offsetInBeginSection": 184,
          "offsetInEndSection": 366,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18789146",
          "text": "BACKGROUND\nSynthetic lethality defines a genetic interaction where the combination of mutations in two or more genes leads to cell death.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 137,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17189863",
          "text": "One such genetic interaction is synthetic lethality, in which the combination of two non-lethal mutations leads to loss of organism viability.",
          "offsetInBeginSection": 123,
          "offsetInEndSection": 265,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30125975",
          "text": "Synthetic lethality is the synthesis of mutations leading to cell death. Tumor-specific synthetic lethality has been targeted in research to improve c",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34070674",
          "text": "Synthetic lethality refers to cell death caused by simultaneous perturbations of two genes while change of any one of them alone is nonlethal.",
          "offsetInBeginSection": 416,
          "offsetInEndSection": 558,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22864477",
          "text": "Synthetic lethality is a promising strategy for specific targeting of cancer cells that carry mutations that are absent in normal cells.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26803999",
          "text": "This constitutes the premise of synthetic lethality, an attractive therapeutic strategy already demonstrating clinical success in patients with breast and ovarian cancers.",
          "offsetInBeginSection": 390,
          "offsetInEndSection": 561,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26211783",
          "text": "ment of novel anticancer therapies. SL can be described as lethality (cell death) resulting from the combination of the two mutations, wherein the mut",
          "offsetInBeginSection": 199,
          "offsetInEndSection": 349,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33422376",
          "text": "Synthetic lethality is a promising approach that targets MYC-dependent vulnerabilities in cancer.",
          "offsetInBeginSection": 326,
          "offsetInEndSection": 423,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33627666",
        "http://www.ncbi.nlm.nih.gov/pubmed/24568598",
        "http://www.ncbi.nlm.nih.gov/pubmed/24893124",
        "http://www.ncbi.nlm.nih.gov/pubmed/26630128",
        "http://www.ncbi.nlm.nih.gov/pubmed/30555636",
        "http://www.ncbi.nlm.nih.gov/pubmed/34050264",
        "http://www.ncbi.nlm.nih.gov/pubmed/26803999",
        "http://www.ncbi.nlm.nih.gov/pubmed/31627702",
        "http://www.ncbi.nlm.nih.gov/pubmed/16362917",
        "http://www.ncbi.nlm.nih.gov/pubmed/32037829"
      ]
    },
    {
      "id": "64403ab057b1c7a31500004d",
      "type": "factoid",
      "body": "How many injections of CLS-TA did the patients participating in the PEACHTREE trial receive?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34322164",
          "text": "Recent results from the PEACHTREE trial (ClinicalTrials.gov Identifier: NCT02595398), a phase III trial with two suprachoroidal injections of CLS-TA at 0 and 12 weeks with follow up lasting 24 weeks, showed the significant improvement in visual acuity and reduction in central subfield thickness, all without increasing the risk of elevated intraocular pressure or accelerated cataract progression.",
          "offsetInBeginSection": 711,
          "offsetInEndSection": 1109,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36399237",
          "text": "Patients received SCS-TA 4.0\u00a0mg (0.1\u00a0ml of 40\u00a0mg/ml) or control at baseline and week 12.",
          "offsetInBeginSection": 712,
          "offsetInEndSection": 800,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30113933",
          "text": "The primary endpoint was met in subjects who received suprachoroidal injection of CLS-TA 4.0 mg, mean central subfield thickness significantly decreased from baseline by 135 \u00b5m and 164 \u00b5m at Month 1 (P = 0.0056) and Month 2 (P = 0.0017), respectively.",
          "offsetInBeginSection": 575,
          "offsetInEndSection": 826,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32173113",
          "text": "METHODS\nPatients were randomized 3:2 to suprachoroidally injected CLS-TA or sham treatment, with administrations at day 0 and week\u00a012.",
          "offsetInBeginSection": 962,
          "offsetInEndSection": 1096,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33547034",
          "text": "METHODS\nTreatment consisted of two suprachoroidal injections of CLS-TA 4\u2009mg, 12 weeks apart.",
          "offsetInBeginSection": 328,
          "offsetInEndSection": 420,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36138388",
          "text": "While the participating students administered 62 (51.7%) injections, the experienced dentist administered 58 (48.3%) injections.",
          "offsetInBeginSection": 985,
          "offsetInEndSection": 1113,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33547034",
        "http://www.ncbi.nlm.nih.gov/pubmed/36399237",
        "http://www.ncbi.nlm.nih.gov/pubmed/30113933",
        "http://www.ncbi.nlm.nih.gov/pubmed/34322164",
        "http://www.ncbi.nlm.nih.gov/pubmed/36138388",
        "http://www.ncbi.nlm.nih.gov/pubmed/32173113"
      ]
    },
    {
      "id": "64179139690f196b5100002f",
      "type": "list",
      "body": "What are the most commonly used diagnostic tests for the diagnosis of Duchenne muscular dystrophy?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6545595",
          "text": "Serum creatine kinase activity is the most useful test for Duchenne muscular dystrophy carrier detection, but only in 50-80% the carriers do have increased serum creatine kinase activity.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 187,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22583668",
          "text": "Muscle biopsy is currently the diagnostic instrument of choice in sporadic patients.",
          "offsetInBeginSection": 176,
          "offsetInEndSection": 260,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7056028",
          "text": "AMP, ADP, ATP, IMP, GDP, GTP and adenylosuccinate have been measured by high pressure liquid chromatography in three types of animal muscular dystrophy and in a human patient with Duchenne muscular dystrophy.",
          "offsetInBeginSection": 3,
          "offsetInEndSection": 211,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12398835",
          "text": "s in these 30% of Duchenne muscular dystrophy patients. Denaturing gradient gel electrophoresis showed a high mutation detection rate (100%) for Duche",
          "offsetInBeginSection": 973,
          "offsetInEndSection": 1123,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18974550",
          "text": "The application of molecular diagnostic techniques has greatly improved the diagnosis, carrier detection, prenatal testing and genetic counseling for families with Duchenne and Becker muscular dystrophy (D/BMD) in India.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 220,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/468274",
          "text": "Measurement of serum creatine phosphokinase (CPK) is the most commonly applied test for carrier detection in Duchenne muscular dystrophy.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 137,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31009620",
          "text": " leads to progressive muscle weakness mainly in the lower limbs. Motor function tests help to monitor disease progression. Can low-cost, simple assess",
          "offsetInBeginSection": 67,
          "offsetInEndSection": 217,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2347279",
          "text": "This was considered the first case of antenatal fetal Duchenne muscular dystrophy diagnosed with the aid of fetoscope and needle muscle biopsy.",
          "offsetInBeginSection": 1019,
          "offsetInEndSection": 1162,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2669113",
          "text": "cation (X-autosome), always at the same site, Xp21. Diagnostic use of Xp21 probes is now as necessary as EMG, muscle biopsy and serum CK assay for the",
          "offsetInBeginSection": 520,
          "offsetInEndSection": 670,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31542086",
          "text": "For the DMD gene, being the longest gene in the human genome, methods of direct sequencing is often unpractical and time-consuming, instead, STR analysis for linkage analysis would be a cost-effective option and have been used routinely for prenatal diagnosis of DMD.",
          "offsetInBeginSection": 651,
          "offsetInEndSection": 918,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32409939",
        "http://www.ncbi.nlm.nih.gov/pubmed/12398835",
        "http://www.ncbi.nlm.nih.gov/pubmed/1549217",
        "http://www.ncbi.nlm.nih.gov/pubmed/34064562",
        "http://www.ncbi.nlm.nih.gov/pubmed/7547371",
        "http://www.ncbi.nlm.nih.gov/pubmed/31542086",
        "http://www.ncbi.nlm.nih.gov/pubmed/2347279",
        "http://www.ncbi.nlm.nih.gov/pubmed/33012180",
        "http://www.ncbi.nlm.nih.gov/pubmed/33057110",
        "http://www.ncbi.nlm.nih.gov/pubmed/7056028"
      ]
    },
    {
      "id": "63f02b50f36125a426000014",
      "type": "yesno",
      "body": "Is there any association between Tripe palms and cancer?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11812096",
          "text": "CONCLUSION\nTripe palms can be associated with endometrial carcinoma and may be the first sign of malignancy.",
          "offsetInBeginSection": 1341,
          "offsetInEndSection": 1449,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9190991",
          "text": "nigricans and tripe palms with endometrial adenocarcinoma is found extremely rarely. Although the survival time of adenocarcinoma patients with malign",
          "offsetInBeginSection": 1291,
          "offsetInEndSection": 1441,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10640836",
          "text": "ntly associated with gastric and pulmonary carcinoma. The pathogenetic mechanism remains unknown.\n\n\nOBJECTIVE\nTo determine the influence of receptor t",
          "offsetInBeginSection": 111,
          "offsetInEndSection": 261,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2651581",
          "text": "pe palms occurred in patients with cancer; only five patients showed no evidence of an associated malignancy. Tripe palms were frequently seen in conj",
          "offsetInBeginSection": 326,
          "offsetInEndSection": 476,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21978503",
          "text": "prompting repetition of the biopsy which ultimately revealed a neuroendocrine carcinoma. Skeletal scintigraphy showed periosteal proliferation with hy",
          "offsetInBeginSection": 564,
          "offsetInEndSection": 714,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8638207",
          "text": "Approximately 90% of patients with tripe palms have an associated cancer, most commonly involving the lung or the stomach.",
          "offsetInBeginSection": 138,
          "offsetInEndSection": 260,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7560439",
          "text": "Tripe palms is a distinctive paraneoplastic cutaneous sign which is frequently associated with internal malignancy, specially carcinomas of the lung and stomach.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/2651581",
        "http://www.ncbi.nlm.nih.gov/pubmed/8638207",
        "http://www.ncbi.nlm.nih.gov/pubmed/10640836",
        "http://www.ncbi.nlm.nih.gov/pubmed/9190991",
        "http://www.ncbi.nlm.nih.gov/pubmed/21978503",
        "http://www.ncbi.nlm.nih.gov/pubmed/7560439",
        "http://www.ncbi.nlm.nih.gov/pubmed/11812096"
      ]
    },
    {
      "id": "6411b678201352f04a000036",
      "type": "factoid",
      "body": "is prosopagnosia inherited or  acquired?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33392335",
          "text": "BACKGROUND\nAcquired prosopagnosia is a rare condition characterized by the loss of familiarity with previously known faces and the inability to recognize new ones.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26933872",
          "text": "Three key findings emerged: (a) Individuals with more severe prosopagnosia spent less time examining the internal facial region, (b) as observed in acquired prosopagnosia, some DPs spent less time examining the eyes and more time examining the mouth than controls, and (c) SRs spent more time examining the nose-a measure that also correlated with face recognition ability in controls.",
          "offsetInBeginSection": 545,
          "offsetInEndSection": 930,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32648048",
          "text": "Acquired prosopagnosia is usually a consequence of bilateral or right hemisphere lesions and is often associated with topographical disorientation and dyschromatopsia.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19823580",
          "text": "Prosopagnosia is a deficit in recognizing people from their faces. Acquired prosopagnosia results after brain damage, developmental or congenital pros",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20689639",
          "text": "Cases of acquired prosopagnosia have often been described over the last century.",
          "offsetInBeginSection": 117,
          "offsetInEndSection": 197,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24389150",
          "text": "ows a network of regions involved in face processing. Reflecting this, acquired prosopagnosia is not a single entity but a family of disorders with di",
          "offsetInBeginSection": 117,
          "offsetInEndSection": 267,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18374372",
          "text": "Acquired prosopagnosia is usually associated with bilateral or right-sided lesions of the occipital or temporal lobes.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30947609",
          "text": "Most subjects with developmental prosopagnosia were normal on the Old/New Tests: for acquired prosopagnosia, subjects with occipitotemporal lesions often showed impairments while those with anterior temporal lesions did not.",
          "offsetInBeginSection": 640,
          "offsetInEndSection": 864,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21414330",
          "text": "We studied a male with acquired prosopagnosia using a battery of Implicit Association Tests (IATs) to investigate whether observing faces varying by social category would activate the patient's implicit social biases.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 217,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7091286",
          "text": "Three patients with prosopagnosia, and acquired inability to recognize familiar faces usually resulting from cerebrovascular insufficiency, had left-sided visual field defects and color vision abnormalities of central origin.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 225,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20657764",
        "http://www.ncbi.nlm.nih.gov/pubmed/26933872",
        "http://www.ncbi.nlm.nih.gov/pubmed/7091286",
        "http://www.ncbi.nlm.nih.gov/pubmed/26874939",
        "http://www.ncbi.nlm.nih.gov/pubmed/28539812",
        "http://www.ncbi.nlm.nih.gov/pubmed/31231507",
        "http://www.ncbi.nlm.nih.gov/pubmed/26393348",
        "http://www.ncbi.nlm.nih.gov/pubmed/33274147",
        "http://www.ncbi.nlm.nih.gov/pubmed/24151479",
        "http://www.ncbi.nlm.nih.gov/pubmed/33392335"
      ]
    },
    {
      "id": "643bc8f957b1c7a31500002b",
      "type": "factoid",
      "body": "Where are promoters typically found in DNA?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33227813",
          "text": "y RNA polymerase initiates, which is typically located proximal to the transcription start site (TSS). How to correctly identify the gene TSS and the ",
          "offsetInBeginSection": 91,
          "offsetInEndSection": 241,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25448745",
          "text": "Most of these promoters display the changes of DNA methylation in their Ups-regions, which are between +500 and +2000 bp upstream from the transcription start site (TSS) of the genes.",
          "offsetInBeginSection": 674,
          "offsetInEndSection": 857,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24283192",
          "text": "The cell-free transcription-translation of multiple proteins typically exploits genes placed behind strong transcriptional promoters that reside on separate pieces of DNA so that protein levels can be easily controlled by changing DNA template concentration.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 258,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19258451",
          "text": "d in promoters, which are regions of variable length upstream of the open reading frames of genes. Here, we report that promoter length and gene funct",
          "offsetInBeginSection": 147,
          "offsetInEndSection": 297,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20602769",
          "text": "CONCLUSIONS\nHuman promoters containing a CpG island tend to remain nucleosome-free as well as methylation-free.",
          "offsetInBeginSection": 1404,
          "offsetInEndSection": 1515,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20602769",
          "text": "Nucleosome-free regions were observed only in promoters containing a CpG island.",
          "offsetInBeginSection": 592,
          "offsetInEndSection": 672,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34071849",
          "text": "rs are fundamental components of synthetic gene circuits. They are DNA segments where transcription initiation takes place. New constitutive and regul",
          "offsetInBeginSection": 7,
          "offsetInEndSection": 157,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25239471",
          "text": "Enhancers, which function by bringing activating complexes to promoters through chromosomal looping, are also modulated by a combination of DNA methylation and histone modifications.",
          "offsetInBeginSection": 604,
          "offsetInEndSection": 786,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8367283",
          "text": "ound that sigma s-regulated promoters are located in regions where DNA shows intrinsic curvatures. This feature does not appear in a stationary-phase-",
          "offsetInBeginSection": 387,
          "offsetInEndSection": 537,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18831794",
          "text": "BACKGROUND\nBidirectional promoters lie between adjacent genes, which are transcribed from opposite strands of DNA.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/18831794",
        "http://www.ncbi.nlm.nih.gov/pubmed/27311442",
        "http://www.ncbi.nlm.nih.gov/pubmed/20602769",
        "http://www.ncbi.nlm.nih.gov/pubmed/6473101",
        "http://www.ncbi.nlm.nih.gov/pubmed/34071849",
        "http://www.ncbi.nlm.nih.gov/pubmed/20161746",
        "http://www.ncbi.nlm.nih.gov/pubmed/24283192",
        "http://www.ncbi.nlm.nih.gov/pubmed/25448745",
        "http://www.ncbi.nlm.nih.gov/pubmed/33227813",
        "http://www.ncbi.nlm.nih.gov/pubmed/19393174"
      ]
    },
    {
      "id": "64403be357b1c7a31500004e",
      "type": "factoid",
      "body": "What was the duration of the follow-up period of patients in the PEACHTREE clinical trial?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23722119",
          "text": "The median time of follow-up was 19 months (range: 2-57), during which 31% of patients healed and 39% succumbed.",
          "offsetInBeginSection": 993,
          "offsetInEndSection": 1105,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23722119"
      ]
    },
    {
      "id": "644289c457b1c7a31500005e",
      "type": "list",
      "body": "Which are some symptoms of FSHD?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14659411",
          "text": "onset facioscapulohumeral muscular dystrophy (FSHD) present epilepsy and mental retardation. This suggests a functional involvement of central nervous",
          "offsetInBeginSection": 61,
          "offsetInEndSection": 211,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32008231",
          "text": "The major symptom of FSHD is progressive weakening and loss of skeletal muscles.",
          "offsetInBeginSection": 138,
          "offsetInEndSection": 218,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34559225",
          "text": "nherited myopathy clinically characterized by weakness in the facial, shoulder girdle and upper a muscles. FSHD is caused by chromatin relaxation of t",
          "offsetInBeginSection": 53,
          "offsetInEndSection": 203,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34675094",
          "text": "nal capacity may still occur as the child grows up. Pain, fatigue, and a decreased quality of life were common symptoms and need to be addressed in th",
          "offsetInBeginSection": 1713,
          "offsetInEndSection": 1863,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27530735",
          "text": "This subgroup is regarded as severely affected and extra-muscular symptoms, such as hearing loss and retinopathy, are frequently described.",
          "offsetInBeginSection": 491,
          "offsetInEndSection": 630,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30508665",
          "text": " who presented to us with symptoms such as weakness in her eyes, mouth, shoulder, and upper and lower limbs. Muscle atrophy could be found in multiple",
          "offsetInBeginSection": 380,
          "offsetInEndSection": 530,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36030628",
          "text": "phy (FSHD) is an autosomal dominant disorder characterized by progressive muscle weakness. Adenine nucleotide translocator 1 (ANT1), the only 4q35 gen",
          "offsetInBeginSection": 35,
          "offsetInEndSection": 185,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23225386",
          "text": "Symptoms associated with mobility impairment, activity limitation, and social role limitation were most frequently mentioned by participants.",
          "offsetInBeginSection": 735,
          "offsetInEndSection": 876,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33096728",
          "text": "netic myopathy with variable onset of symptoms, distribution of muscle weakness, and clinical severity. While much is known about the clinical course ",
          "offsetInBeginSection": 236,
          "offsetInEndSection": 386,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15050443",
          "text": "l symptoms are extremely variable including facial sparing type, limb-girdle type, and distal myopathy type. Most of the FSHD patients have a deletion",
          "offsetInBeginSection": 258,
          "offsetInEndSection": 408,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31025273",
        "http://www.ncbi.nlm.nih.gov/pubmed/15050443",
        "http://www.ncbi.nlm.nih.gov/pubmed/10864616",
        "http://www.ncbi.nlm.nih.gov/pubmed/36030628",
        "http://www.ncbi.nlm.nih.gov/pubmed/14659411",
        "http://www.ncbi.nlm.nih.gov/pubmed/22907234",
        "http://www.ncbi.nlm.nih.gov/pubmed/1908258",
        "http://www.ncbi.nlm.nih.gov/pubmed/32278354",
        "http://www.ncbi.nlm.nih.gov/pubmed/10711987",
        "http://www.ncbi.nlm.nih.gov/pubmed/22796148"
      ]
    },
    {
      "id": "63f02ec1f36125a426000017",
      "type": "summary",
      "body": "What is the mechanism of action of Adagrasib?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35167329",
          "text": "CONCLUSION\nAdagrasib 600 mg twice a day was well tolerated and exhibited antitumor activity in patients with advanced solid tumors harboring the KRAS mutation.",
          "offsetInBeginSection": 1790,
          "offsetInEndSection": 1949,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35658005",
          "text": "eated KRAS -mutated NSCLC, adagrasib showed clinical efficacy without new safety signals. (Funded by Mirati Therapeutics; ClinicalTrials.gov number, N",
          "offsetInBeginSection": 1766,
          "offsetInEndSection": 1916,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35167329",
          "text": "PURPOSE\nAdagrasib (MRTX849) is an oral, highly selective, small-molecule, covalent inhibitor of KRASG12C.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 105,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35608481",
          "text": "tential of adagrasib (MRTX849) to penetrate the central nervous system and provide control of KRASG12C brain metastases. See related article by Sabari",
          "offsetInBeginSection": 207,
          "offsetInEndSection": 357,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36387582",
          "text": "Here we discuss the mechanism of action, pharmacokinetic and pharmacodynamic properties, efficacy, and tolerability of adagrasib (MRTX849).",
          "offsetInBeginSection": 396,
          "offsetInEndSection": 535,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35658005",
          "text": "BACKGROUND\nAdagrasib, a KRASG12C inhibitor, irreversibly and selectively binds KRASG12C, locking it in its inactive state.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35404402",
          "text": "olecule KRASG12C inhibitor, irreversibly and selectively binds KRASG12C, locking it in its inactive state. Adagrasib has been optimized for favorable ",
          "offsetInBeginSection": 161,
          "offsetInEndSection": 311,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35167329",
        "http://www.ncbi.nlm.nih.gov/pubmed/35658005",
        "http://www.ncbi.nlm.nih.gov/pubmed/35404402",
        "http://www.ncbi.nlm.nih.gov/pubmed/35608481",
        "http://www.ncbi.nlm.nih.gov/pubmed/36387582"
      ]
    },
    {
      "id": "641c516d690f196b5100003f",
      "type": "yesno",
      "body": "Can Amyotrophic Lateral Sclerosis (ALS) be associated with a mutation of the Super Oxide Dismutase 1 (SOD) gene?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10869061",
          "text": "To delineate ALS associated with this particular CuZn-SOD mutation from ALS without mutations, we performed a detailed neurophysiological study of the corticomotoneuronal function using peristimulus time histograms (PSTHs) in eight ALS patients homozygous for the D90A CuZn-SOD mutation.",
          "offsetInBeginSection": 702,
          "offsetInEndSection": 989,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12402272",
          "text": "ateral sclerosis (ALS) cases, but no definite report of a mutation in a \"truly\" sporadic case of ALS has been proved. We present the first case of a n",
          "offsetInBeginSection": 102,
          "offsetInEndSection": 252,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31928838",
          "text": "It has been reported that mutations in the superoxide dismutase (SOD) 1 gene can lead to ALS.",
          "offsetInBeginSection": 208,
          "offsetInEndSection": 301,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10202988",
          "text": "We report the absence of superoxide dismutase (SOD-1) gene mutations in 30 patients with amyotrophic lateral sclerosis (ALS) including individuals with a confirmed family history of ALS (familial ALS/FALS), ALS with an unclear family history (UFALS) and sporadic ALS (SALS).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 274,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20385392",
          "text": "Mutations in the superoxide dismutase-1 (SOD1) gene have been found in 12%-23% of patients diagnosed with familial ALS.",
          "offsetInBeginSection": 134,
          "offsetInEndSection": 253,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11284995",
          "text": "Two patients (10%) with the amyotrophic lateral sclerosis (ALS) form of the disease were found to have a disease-related mutation.",
          "offsetInBeginSection": 170,
          "offsetInEndSection": 300,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11675874",
          "text": "INTRODUCTION\nMutations in the gene encoding the free radical scavenging enzyme CuZn-superoxide dismutase have been associated with amyotrophic lateral sclerosis (ALS).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9455977",
          "text": "Mutations of the SOD1 gene, which encodes the enzyme copper/zinc superoxide dismutase, are associated with familial amyotrophic lateral sclerosis (ALS).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15679043",
          "text": "Up to 20% of ALS cases are inherited (familial, fALS) and associated with mutations, usually of the superoxide dismutase type 1 (SOD-1) gene.",
          "offsetInBeginSection": 121,
          "offsetInEndSection": 262,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12480087",
          "text": "However, these cases, especially those with SOD1 gene mutations, have not been reported in Korea.",
          "offsetInBeginSection": 153,
          "offsetInEndSection": 250,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/15189359",
        "http://www.ncbi.nlm.nih.gov/pubmed/20385392",
        "http://www.ncbi.nlm.nih.gov/pubmed/15814196",
        "http://www.ncbi.nlm.nih.gov/pubmed/15079798",
        "http://www.ncbi.nlm.nih.gov/pubmed/12402272",
        "http://www.ncbi.nlm.nih.gov/pubmed/15679043",
        "http://www.ncbi.nlm.nih.gov/pubmed/12480087",
        "http://www.ncbi.nlm.nih.gov/pubmed/11284995",
        "http://www.ncbi.nlm.nih.gov/pubmed/10869061",
        "http://www.ncbi.nlm.nih.gov/pubmed/7820674"
      ]
    },
    {
      "id": "64371c5957b1c7a31500002a",
      "type": "summary",
      "body": "What are enhancers?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30033119",
          "text": "Enhancers are genetic elements that regulate spatiotemporal gene expression.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 76,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35906072",
          "text": "Poised enhancers share many attributes of active enhancers, such as open chromatin, but are marked by repressive histone H3 lysine 27 (H3K27) trimethylation rather than H3K27 acetylation.",
          "offsetInBeginSection": 583,
          "offsetInEndSection": 770,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35128025",
          "text": "INTRODUCTION\nCognitive enhancers (ie, cholinesterase inhibitors and memantine) can provide symptomatic benefit for some individuals with dementia; however, there are circumstances in which the risks of continuing treatment may potentially outweigh benefits.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 257,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23473601",
          "text": "ecific variation in gene expression patterns, mediated by specialized cis-regulatory elements called enhancers. Recent large-scale epigenomic mapping ",
          "offsetInBeginSection": 109,
          "offsetInEndSection": 259,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35552697",
          "text": "Enhancers are regulatory elements of genomes that determine spatio-temporal patterns of gene expression.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 104,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34749786",
          "text": "BACKGROUND\nEnhancers are non-coding regions of the genome that control the activity of target genes.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 100,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32804082",
          "text": "Shadow enhancers, groups of seemingly redundant enhancers, are found in a wide range of organisms and are critical for robust developmental patterning.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34879086",
          "text": "BACKGROUND\nEnhancers regulate transcription of target genes, causing a change in expression level.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 98,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30979870",
          "text": "Enhancers are critical for developmental stage-specific gene expression, but their dynamic regulation in plants remains poorly understood.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 138,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25705179",
          "text": "The go-to cognitive enhancers of today are those that are widely available rather than optimal for the user, including drugs typically prescribed for treatment of ADHD (e.g., methylphenidate) and sleep disturbances such as narcolepsy (modafinil).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 246,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/15124201",
        "http://www.ncbi.nlm.nih.gov/pubmed/32197056",
        "http://www.ncbi.nlm.nih.gov/pubmed/27895109",
        "http://www.ncbi.nlm.nih.gov/pubmed/35552697",
        "http://www.ncbi.nlm.nih.gov/pubmed/30979870",
        "http://www.ncbi.nlm.nih.gov/pubmed/34290042",
        "http://www.ncbi.nlm.nih.gov/pubmed/34879086",
        "http://www.ncbi.nlm.nih.gov/pubmed/20206554",
        "http://www.ncbi.nlm.nih.gov/pubmed/30758829",
        "http://www.ncbi.nlm.nih.gov/pubmed/32952117"
      ]
    },
    {
      "id": "6440396957b1c7a31500004b",
      "type": "factoid",
      "body": "What is the mode of delivery of the drug XIPERE?",
      "snippets": [],
      "documents": []
    },
    {
      "id": "641791ca690f196b51000031",
      "type": "list",
      "body": "What are the most common muscular dystrophies?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30215857",
          "text": "We discuss the involvement of the immune system in the most common muscular dystrophy, Duchenne muscular dystrophy, and show that the immune system influences muscle death and fibrosis as disease progresses.",
          "offsetInBeginSection": 856,
          "offsetInEndSection": 1063,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27340611",
          "text": "AREAS COVERED\nDuchenne muscular dystrophy is the most common muscular dystrophy.",
          "offsetInBeginSection": 548,
          "offsetInEndSection": 628,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29971759",
          "text": "There are several clinical forms, the most frequent being Duchenne's muscular dystrophy and Becker muscular dystrophy.",
          "offsetInBeginSection": 171,
          "offsetInEndSection": 289,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27340611",
          "text": "AREAS COVERED\nDuchenne muscular dystrophy is the most common muscular dystrophy.",
          "offsetInBeginSection": 548,
          "offsetInEndSection": 628,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35089797",
          "text": "Duchenne muscular dystrophy (DMD), the most common muscular dystrophy, is a severe muscle disorder, causing muscle weakness, loss of independence, and premature death.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25955813",
          "text": "Duchenne muscular dystrophy (DMD), the most common and most severe form of all muscular dystrophies, leads to progressive muscle fiber necrosis, fibroblast proliferation, and growth of fibrous tissue and fat.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 208,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24213305",
          "text": "Duchenne and Becker muscular dystrophies are the most common clinical forms of muscular dystrophies.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 100,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23733645",
          "text": " cause exercise intolerance to some degree. Here, we focus on Duchenne muscular dystrophy (DMD), the most common form of muscular dystrophy, as a para",
          "offsetInBeginSection": 235,
          "offsetInEndSection": 385,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27073590",
          "text": "ied by progressive skeletal muscle weakness and degeneration. Duchenne muscular dystrophy (DMD) is the most common and severe form of muscular dystrop",
          "offsetInBeginSection": 62,
          "offsetInEndSection": 212,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35360042",
          "text": " debilitating disorders caused by progressive muscle wasting. Duchenne muscular dystrophy (DMD) is the most common type. DMD is a well-characterized g",
          "offsetInBeginSection": 36,
          "offsetInEndSection": 186,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/15938568",
        "http://www.ncbi.nlm.nih.gov/pubmed/33200426",
        "http://www.ncbi.nlm.nih.gov/pubmed/21436158",
        "http://www.ncbi.nlm.nih.gov/pubmed/32409939",
        "http://www.ncbi.nlm.nih.gov/pubmed/33669654",
        "http://www.ncbi.nlm.nih.gov/pubmed/30215857",
        "http://www.ncbi.nlm.nih.gov/pubmed/21484336",
        "http://www.ncbi.nlm.nih.gov/pubmed/15318222",
        "http://www.ncbi.nlm.nih.gov/pubmed/23622361",
        "http://www.ncbi.nlm.nih.gov/pubmed/23733645"
      ]
    },
    {
      "id": "63eef7eff36125a42600000e",
      "type": "summary",
      "body": "Which disease is targeted by Fazirsiran?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35748699",
          "text": "fficacy of fazirsiran, an RNA interference therapeutic, in patients with liver disease associated with AAT deficiency.\n\n\nMETHODS\nWe assigned adults wi",
          "offsetInBeginSection": 345,
          "offsetInEndSection": 495,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35748699"
      ]
    },
    {
      "id": "6431708a57b1c7a315000017",
      "type": "factoid",
      "body": "Where does Brain (or B type) Natriuretic Protein, BNP usually originate from?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30120963",
          "text": "riuretic peptide (BNP) are primarily produced by, and secreted from, heart tissue. They maintain cardiovascular homeostasis by binding to natriuretic ",
          "offsetInBeginSection": 98,
          "offsetInEndSection": 248,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18706401",
          "text": "However, there is an accumulating evidence that B-type natriuretic peptide (BNP) and its N-terminal fragment (NT-proBNP) may originate from right ventricle and their concentrations are elevated in patients with acute pulmonary embolism (APE) especially when resulting in right ventricular dysfunction (RVD).",
          "offsetInBeginSection": 111,
          "offsetInEndSection": 418,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15478621",
          "text": "Atrial natriuretic peptide (ANP) and brain (or B-type) natriuretic peptide (BNP) are secreted from cardiomyocytes in response to atrial or ventricular wall stretch.",
          "offsetInBeginSection": 145,
          "offsetInEndSection": 309,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14621189",
          "text": "Atrial and brain (B-type) natriuretic peptides (ANP and BNP, respectively) are known to exert various cardioprotective effects.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12084525",
          "text": "B-type natriuretic peptide (BNP) is a hormone mainly secreted by cardiac ventricle myocytes and which is increased in cardiac diseases.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14987573",
          "text": "rom atrial tissue, BNP related peptides are produced mainly from ventricular myocytes. Ventricular (NT-pro)BNP production is strongly upregulated in c",
          "offsetInBeginSection": 744,
          "offsetInEndSection": 894,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11558673",
          "text": "tic and renin-angiotensin systems. Although originally isolated from porcine brain, the BNP gene is expressed in a specific manner in cardiac myocytes",
          "offsetInBeginSection": 289,
          "offsetInEndSection": 439,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16689366",
          "text": "vasoconstrictive molecules. The major source of plasma BNP is the cardiac ventricles. Elevated plasma BNP concentrations correlate with increased left",
          "offsetInBeginSection": 191,
          "offsetInEndSection": 341,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23022110",
          "text": "ardiac peptide hormone. The principal stimulus for BNP synthesis is myocyte stretch. BNP binds to the natriuretic peptide receptor-A causing increased",
          "offsetInBeginSection": 68,
          "offsetInEndSection": 218,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14574050",
          "text": "de (ANP) and brain (or B-type) natriuretic peptide (BNP) are of myocardial cell origin. BNP is released mainly from the left ventricle in response to ",
          "offsetInBeginSection": 484,
          "offsetInEndSection": 634,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/16289003",
        "http://www.ncbi.nlm.nih.gov/pubmed/12084525",
        "http://www.ncbi.nlm.nih.gov/pubmed/14621189",
        "http://www.ncbi.nlm.nih.gov/pubmed/16689366",
        "http://www.ncbi.nlm.nih.gov/pubmed/7768034",
        "http://www.ncbi.nlm.nih.gov/pubmed/30120963",
        "http://www.ncbi.nlm.nih.gov/pubmed/14574050",
        "http://www.ncbi.nlm.nih.gov/pubmed/14987573",
        "http://www.ncbi.nlm.nih.gov/pubmed/18410972",
        "http://www.ncbi.nlm.nih.gov/pubmed/22776607"
      ]
    },
    {
      "id": "643c396457b1c7a31500002d",
      "type": "yesno",
      "body": "Are any medications available to prevent COVID-19 following exposure?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35521985",
          "text": "Although several therapeutic options have been used to control COVID-19, none of these medications have been proven to be a definitive cure.",
          "offsetInBeginSection": 144,
          "offsetInEndSection": 284,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36126225",
          "text": "g COVID-19 in inpatient settings with moderate to severe disease No studies available. Nirmatrelvir/ritonavir for preventing SARS-CoV-2 infection (PrE",
          "offsetInBeginSection": 6032,
          "offsetInEndSection": 6182,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35529020",
          "text": "ants (aOR\u00a0=\u00a00.43, CI: 0.21-0.88). Exposure to the immigration enforcement system may undermine public health efforts to prevent further transmission o",
          "offsetInBeginSection": 1256,
          "offsetInEndSection": 1406,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36126225",
          "text": "Prohibited prior or concomitant therapies included medications highly dependent on CYP3A4 for clearance and CYP3A4 inducers.",
          "offsetInBeginSection": 3102,
          "offsetInEndSection": 3226,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33516648",
          "text": "No other reflux medications were found to be significant predictors for laboratory-confirmed or suspected COVID-19 (P> 0.05).",
          "offsetInBeginSection": 1721,
          "offsetInEndSection": 1846,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34531332",
          "text": "We included RPCTs comparing 49 medications and placebo in the treatment of severe and non-severe patients (aged 18 years or older) with COVID-19 infection.",
          "offsetInBeginSection": 601,
          "offsetInEndSection": 756,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33354578",
          "text": "To date, no intervention is available to prevent COVID-19 and its manifestations.",
          "offsetInBeginSection": 220,
          "offsetInEndSection": 301,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32612804",
          "text": "As yet, no agents have been approved for the treatment of COVID-19, although several experimental drugs are being used off licence.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34361227",
          "text": "They can be designed to boost the efficacy of currently available antiviral medications or to trigger a rapid immune response against COVID-19.",
          "offsetInBeginSection": 968,
          "offsetInEndSection": 1111,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36438440",
          "text": "smission to the fetus, and newborns can pick up COVID-19 when exposed. Vaccines are proved to be safe for pregnant women and help prevent both mother ",
          "offsetInBeginSection": 475,
          "offsetInEndSection": 625,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32844337",
        "http://www.ncbi.nlm.nih.gov/pubmed/36126225",
        "http://www.ncbi.nlm.nih.gov/pubmed/32383125",
        "http://www.ncbi.nlm.nih.gov/pubmed/36402712",
        "http://www.ncbi.nlm.nih.gov/pubmed/36254081",
        "http://www.ncbi.nlm.nih.gov/pubmed/36438440",
        "http://www.ncbi.nlm.nih.gov/pubmed/34361227",
        "http://www.ncbi.nlm.nih.gov/pubmed/33516648",
        "http://www.ncbi.nlm.nih.gov/pubmed/34010282",
        "http://www.ncbi.nlm.nih.gov/pubmed/35079984"
      ]
    },
    {
      "id": "6440092d57b1c7a315000040",
      "type": "yesno",
      "body": "Has RTA 408 received FDA approval?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31185608",
          "text": "el synthetic triterpenoid, has been shown to possess anti-oxidant and anti-inflammatory properties in various types of cells. Here, we evaluated the e",
          "offsetInBeginSection": 549,
          "offsetInEndSection": 699,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35285087",
          "text": "growth in various cancer models, the utility of this class of drugs in the treatment of SCC has not been investigated. Given the dual anti-inflammator",
          "offsetInBeginSection": 263,
          "offsetInEndSection": 413,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26773873",
          "text": "Previous studies have shown that RTA 408, a synthetic triterpenoid compound, potently activates Nrf2.",
          "offsetInBeginSection": 156,
          "offsetInEndSection": 257,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34573098",
          "text": "f TGF-\u03b2 and Ym1 + 2 in the retina and optic nerve. However, these effects were not observed after RTA 408 treatment. Our results provide explicit evid",
          "offsetInBeginSection": 1392,
          "offsetInEndSection": 1542,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27242339",
          "text": "uch as RTA 402 (bardoxolone methyl) and RTA 408 have been tested in clinical trials. RTA 408 lotion is currently being tested in patients at risk for ",
          "offsetInBeginSection": 285,
          "offsetInEndSection": 435,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27242339",
        "http://www.ncbi.nlm.nih.gov/pubmed/35285087",
        "http://www.ncbi.nlm.nih.gov/pubmed/34573098",
        "http://www.ncbi.nlm.nih.gov/pubmed/31185608",
        "http://www.ncbi.nlm.nih.gov/pubmed/26773873"
      ]
    },
    {
      "id": "644291fa57b1c7a31500005f",
      "type": "list",
      "body": "Which are the types of myotonic dystrophy?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30186217",
          "text": "ers of subjects, sometimes even not separating Myotonic Dystrophy Type 1 from Type 2. But this heterogeneity may also support the current point of vie",
          "offsetInBeginSection": 1613,
          "offsetInEndSection": 1763,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31750030",
          "text": "RECENT FINDINGS\nThe Myotonic Dystrophy Foundation recruited 11 international clinicians who are experienced with congenital and childhood-onset myotonic dystrophy to create consensus-based care recommendations.",
          "offsetInBeginSection": 505,
          "offsetInEndSection": 715,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32067592",
          "text": "The 2 major genetic forms of myotonic dystrophy, type 1 and type 2, differ in genetic etiology yet share clinical features.",
          "offsetInBeginSection": 203,
          "offsetInEndSection": 326,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22995693",
          "text": "Despite clinical and genetic similarities, myotonic dystrophy type 1 and type 2 are distinct disorders requiring different diagnostic and management strategies.",
          "offsetInBeginSection": 1081,
          "offsetInEndSection": 1241,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25121518",
          "text": "RECENT FINDINGS\nAn active approach to screening and management of myotonic dystrophies type 1 and type 2 requires a multidisciplinary medical, rehabilitative and social team.",
          "offsetInBeginSection": 901,
          "offsetInEndSection": 1075,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6639233",
          "text": "o show two phenotypes of myotonic dystrophy: those with and those without substantial cardiac involvement. Besides the 29% incidence of asymptomatic m",
          "offsetInBeginSection": 187,
          "offsetInEndSection": 337,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25121518",
          "text": "PURPOSE OF REVIEW\nMyotonic dystrophies type 1 and type 2 are progressive multisystem genetic disorders with clinical and genetic features in common.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17885447",
          "text": "rogress in elucidating the disease mechanism in myotonic dystrophy type 1 and type 2.\n\n\nRECENT FINDINGS\nResearch on myotonic dystrophy has led to the ",
          "offsetInBeginSection": 65,
          "offsetInEndSection": 215,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8337494",
          "text": "Of the eyes studied, 26 (26.6%) had butterfly-shaped macular pigmentary changes, 24 (24.5%) had reticular pigmentary retinal changes, and 43 (43.9%) had peripheral atrophic polygonal-shaped changes.",
          "offsetInBeginSection": 337,
          "offsetInEndSection": 535,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34840883",
          "text": "BACKGROUND AND OBJECTIVE\nMyotonic dystrophy types 1 and 2 are progressive multisystem genetic disorders whose core clinical feature is myotonia.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34840883",
        "http://www.ncbi.nlm.nih.gov/pubmed/21630234",
        "http://www.ncbi.nlm.nih.gov/pubmed/30906607",
        "http://www.ncbi.nlm.nih.gov/pubmed/25121518",
        "http://www.ncbi.nlm.nih.gov/pubmed/8337494",
        "http://www.ncbi.nlm.nih.gov/pubmed/11102902",
        "http://www.ncbi.nlm.nih.gov/pubmed/35205411",
        "http://www.ncbi.nlm.nih.gov/pubmed/10996776",
        "http://www.ncbi.nlm.nih.gov/pubmed/22995693",
        "http://www.ncbi.nlm.nih.gov/pubmed/28535832"
      ]
    },
    {
      "id": "63f741a633942b094c000009",
      "type": "list",
      "body": "What are the active components of Opdualag?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23967064",
          "text": "BACKGROUND\nIncreasing active travel (primarily walking and cycling) has been widely advocated for reducing obesity levels and achieving other population health benefits.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8719180",
          "text": "We build on the developmental approaches of previous researchers and propose that the individual components of active sleep (e.g., myoclonic twitches, rapid eye movements) exhibit unique developmental and phylogenetic histories and may serve independent functions in the developing organism.",
          "offsetInBeginSection": 319,
          "offsetInEndSection": 610,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35543970",
          "text": " multiple types of advanced cancers. Both drugs are immunoglobulin G4 (IgG4) monoclonal antibodies developed to target immune checkpoints, with nivolu",
          "offsetInBeginSection": 182,
          "offsetInEndSection": 332,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23433172",
          "text": "rhage and commonly entails prophylactic administration of a uterotonic agent, controlled cord traction, and uterine massage. While oxytocin is the fir",
          "offsetInBeginSection": 111,
          "offsetInEndSection": 261,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22940581",
          "text": "her flexibility at the physiological temperature. The flexible loop A, loop B and His loop system at the active site is the main regulator of substrat",
          "offsetInBeginSection": 1304,
          "offsetInEndSection": 1454,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28663910",
          "text": "Our results suggest collagen, elastin, keratin, cell nucleus, triolein, ceramide, melanin and water are the most important model components.",
          "offsetInBeginSection": 1065,
          "offsetInEndSection": 1205,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22940581",
          "text": "s. A flexible loop structure comprising loop A (res. 189-209) and loop B (res. 577-608) at the domain interface is implicated in substrate entry to th",
          "offsetInBeginSection": 81,
          "offsetInEndSection": 231,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/8719180",
        "http://www.ncbi.nlm.nih.gov/pubmed/28663910",
        "http://www.ncbi.nlm.nih.gov/pubmed/35543970",
        "http://www.ncbi.nlm.nih.gov/pubmed/23967064",
        "http://www.ncbi.nlm.nih.gov/pubmed/22940581",
        "http://www.ncbi.nlm.nih.gov/pubmed/23433172"
      ]
    },
    {
      "id": "640f8641201352f04a00002c",
      "type": "factoid",
      "body": "Where in the body would  Schlemm's canal be found",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29691920",
          "text": "RESULTS\nSubjects with high myopia had a significantly larger Schlemm's canal diameter in the nasal (188.1\u00a0\u00b1\u00a085.6\u00a0\u03bcm vs 127.4\u00a0\u00b1\u00a046.7\u00a0\u03bcm, P\u00a0<\u00a00.001), temporal (200.1\u00a0\u00b1\u00a07.2\u00a0\u03bcm vs 147.6\u00a0\u00b1\u00a068.1\u00a0\u03bcm, P\u00a0=\u00a00.001) quadrants and average value (173.1\u00a0\u00b1\u00a048.1\u00a0\u03bcm vs 137.3\u00a0\u00b1\u00a039.6\u00a0\u03bcm, P\u00a0=\u00a00.001), and larger Schlemm's canal area in the nasal (7333.2\u00a0\u00b1\u00a03877.7\u00a0\u03bcm2 vs 3833.2\u00a0\u00b1\u00a02094.7\u00a0\u03bcm2 , P\u00a0<\u00a00.001), temporal (7274.8\u00a0\u00b1\u00a03247.4\u00a0\u03bcm2 vs 4631.1\u00a0\u00b1\u00a02431.9\u00a0\u03bcm2 , P\u00a0<\u00a00.001) inferior (5512\u00a0\u00b1\u00a02504.9\u00a0\u03bcm2 vs 3922.6\u00a0\u00b1\u00a01935.6\u00a0\u03bcm2 , P\u00a0=\u00a00.003) quadrants and average value(6165.4\u00a0\u00b1\u00a02080.5\u00a0\u03bcm2 vs 4044.4\u00a0\u00b1\u00a01581.1\u00a0\u03bcm2 , P\u00a0<\u00a00.001).",
          "offsetInBeginSection": 671,
          "offsetInEndSection": 1269,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28613427",
          "text": "d on the basis of these data. Schlemm's canal was detected in 21 of the 23 examined eyes. The mean distance from the anterior chamber angle was 1.3\u2009\u00b1\u2009",
          "offsetInBeginSection": 507,
          "offsetInEndSection": 657,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1426078",
          "text": "We have tried to answer the question of whether the endothelium of Schlemm's canal is derived from and retains properties of blood vessels by studying: (1) the development of Schlemm's canal in human fetal eyes; (2) the existence of Weibel-Palade bodies in human neonatal, adult human and adult monkey eyes; and (3) the presence of blood coagulation Factor VIII-related antigen in adult human and monkey eyes.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 409,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15512946",
          "text": ", on permeability of cultured human Schlemm's canal cell monolayers in isolation. Human Schlemm's Canal cells were isolated, cultured and then seeded ",
          "offsetInBeginSection": 714,
          "offsetInEndSection": 864,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1426078",
          "text": "(2) Weibel-Palade bodies were found in the endothelium of aqueous veins and in the inner and outer wall endothelium of Schlemm's canal.",
          "offsetInBeginSection": 1122,
          "offsetInEndSection": 1257,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28527653",
          "text": "ts (<18\u00a0years of age) the diameter of Schlemm's canal in nonglaucomatous and glaucomatous eyes was compared. An 80\u00a0MHz iUltrasound probe (iScience Int",
          "offsetInBeginSection": 227,
          "offsetInEndSection": 377,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10581564",
          "text": "Differences in parameters of ciliary body and Schlemm's canal in different meridians of the eyeball has been described using histotopographic methods on 20 eyeballs of human corpses.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 182,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9761282",
          "text": "form two morphologically and functionally distinct populations in the inner wall of Schlemm's canal. The dependence of intracellular pore density on p",
          "offsetInBeginSection": 1394,
          "offsetInEndSection": 1544,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26997786",
          "text": "ated by the small physiological size and the location several hundred microns beneath the sclera. Noninvasive imaging of Schlemm's canal and Trabecula",
          "offsetInBeginSection": 52,
          "offsetInEndSection": 202,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1521580",
          "text": "When the microcannula was introduced into the juxtacanalicular tissue to locations at about 7 and 14 microns from the inner wall of Schlemm's canal the pressure measured at 7 microns was 16.9 +/- 1.3 and at 14 microns it was 18.9 +/- 1.4 cmH2O--that is, 5.2 +/- 0.8 and 7.2 +/- 1.0 cmH2O respectively, higher than the PSc.",
          "offsetInBeginSection": 1001,
          "offsetInEndSection": 1323,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/15512946",
        "http://www.ncbi.nlm.nih.gov/pubmed/28613427",
        "http://www.ncbi.nlm.nih.gov/pubmed/29691920",
        "http://www.ncbi.nlm.nih.gov/pubmed/571861",
        "http://www.ncbi.nlm.nih.gov/pubmed/10359344",
        "http://www.ncbi.nlm.nih.gov/pubmed/26726880",
        "http://www.ncbi.nlm.nih.gov/pubmed/10901471",
        "http://www.ncbi.nlm.nih.gov/pubmed/24827370",
        "http://www.ncbi.nlm.nih.gov/pubmed/26997786",
        "http://www.ncbi.nlm.nih.gov/pubmed/1426078"
      ]
    },
    {
      "id": "643c446357b1c7a31500002f",
      "type": "yesno",
      "body": "Can reinfection occur after SARS-CoV-2 infection?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36357676",
          "text": "Whether reinfection adds to risks incurred after first infection is unclear.",
          "offsetInBeginSection": 184,
          "offsetInEndSection": 260,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33315061",
          "text": "on with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown. We assessed the risk and incidence rate of documented SARS-CoV-2 rein",
          "offsetInBeginSection": 28,
          "offsetInEndSection": 178,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33257644",
          "text": "and IgG antibodies were all positive. CONCLUSIONS Reinfection with SARS-CoV-2 is a strong possibility. This case raises concerns that asymptomatic inf",
          "offsetInBeginSection": 1236,
          "offsetInEndSection": 1386,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34908003",
          "text": "evere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can be followed by reinfection. The protection conferred by prior infection among coronavi",
          "offsetInBeginSection": 55,
          "offsetInEndSection": 205,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36442059",
          "text": "BACKGROUND\nThe durability of the antibody response after SARS-CoV-2 infection and the role of antibodies in protection against reinfection are unclear.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35743421",
          "text": "al SARS-CoV-2 clinical presentation, but there are no data about the risk change after SARS-CoV-2 vaccination. We evaluated the rate of reinfection in",
          "offsetInBeginSection": 53,
          "offsetInEndSection": 203,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35380632",
          "text": "at, the impact of prior infection on incident SARS-CoV-2 reinfection is unclear. Therefore, we examined the long-term protection of naturally acquired",
          "offsetInBeginSection": 242,
          "offsetInEndSection": 392,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35262003",
          "text": "Conclusion\nComparative genomic analyses from 14 patients confirm that SARS-CoV-2 reinfection can occur.",
          "offsetInBeginSection": 1681,
          "offsetInEndSection": 1784,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34908003",
          "text": "CI 83.09-90.26%], respectively).\n\n\nCONCLUSIONS\nThe rate of reinfection with SARS-CoV-2 is relatively low. The protection against SARS-CoV-2 after natu",
          "offsetInBeginSection": 1107,
          "offsetInEndSection": 1257,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35935779",
          "text": "Background\nReinfection with SARS-CoV-2 has been well documented, yet little is known about the degree of protection a previous infection provides against reinfection, especially against Variants of Concern (VOC).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 212,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33895814",
        "http://www.ncbi.nlm.nih.gov/pubmed/35262003",
        "http://www.ncbi.nlm.nih.gov/pubmed/36357676",
        "http://www.ncbi.nlm.nih.gov/pubmed/35743421",
        "http://www.ncbi.nlm.nih.gov/pubmed/35380632",
        "http://www.ncbi.nlm.nih.gov/pubmed/35738346",
        "http://www.ncbi.nlm.nih.gov/pubmed/34468184",
        "http://www.ncbi.nlm.nih.gov/pubmed/34908003",
        "http://www.ncbi.nlm.nih.gov/pubmed/33315049",
        "http://www.ncbi.nlm.nih.gov/pubmed/34521025"
      ]
    },
    {
      "id": "644009c557b1c7a315000041",
      "type": "factoid",
      "body": "What is the mode of inheritance of Friedreich\u2019s ataxia?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16082159",
          "text": "d have a similar phenotype. The mode of inheritance appears to be autosomal recessive. We think that the affected siblings may have a new type of auto",
          "offsetInBeginSection": 775,
          "offsetInEndSection": 925,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18418679",
          "text": "In all ataxia patients with proven or suspected autosomal dominant mode of inheritance, the available molecular genetic tests for SCA mutations should be performed.",
          "offsetInBeginSection": 798,
          "offsetInEndSection": 962,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/4075075",
          "text": "There were 24 patients (10 families) with hereditary spastic paraplegia (HSP), 13 (9 families) with early onset cerebellar ataxia with retained tendon reflexes (EOCA), 3 with Friedreich's ataxia (FA), 5 (1 family) with late onset cerebellar ataxia (LOCA) with pigmentary retinal degeneration and autosomal dominant inheritance, 6 single cases of LOCA and 1 with ataxia telangiectasia.",
          "offsetInBeginSection": 405,
          "offsetInEndSection": 789,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1000412",
          "text": "The increased parental consanguinity, the lack of affected individuals in other generations, and the lack of significance of extrinsic etiological variables, all suggested an autosomal recessive mode of inheritance, and this was confirmed by formal genetic analyses, employing several different methods.",
          "offsetInBeginSection": 289,
          "offsetInEndSection": 592,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/4003033",
          "text": "d PEG show cerebellar atrophy. The pedigree analysis indicates an autosomal recessive mode of inheritance. The condition falls between the ataxic synd",
          "offsetInBeginSection": 415,
          "offsetInEndSection": 565,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2718740",
          "text": " peripheral neuropathy. Mode of inheritance was in all likelihood autosomal dominant. Blood components were typed for 19 conventional chromosome marke",
          "offsetInBeginSection": 341,
          "offsetInEndSection": 491,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31586945",
          "text": "All of these mutations are either transmitted in an autosomal-dominant mode or found as de novo events.",
          "offsetInBeginSection": 194,
          "offsetInEndSection": 297,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/857157",
          "text": "f a kindred in which spinocerebellar ataxia was segregating in an autosomal dominant inheritance pattern. The ataxia locus was located on chromosome 6",
          "offsetInBeginSection": 168,
          "offsetInEndSection": 318,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3760830",
          "text": "ecify the transmission inheritance for each clinical type. Autosomic recessive transmission has been observed for Friedreich's ataxia (68 out of 69 fa",
          "offsetInBeginSection": 125,
          "offsetInEndSection": 275,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7341602",
          "text": "The study of the pedigree and our observations of the progeny of 2 affected dogs indicated that the mode of inheritance of this ataxia is compatible with an autosomal recessive trait.",
          "offsetInBeginSection": 796,
          "offsetInEndSection": 979,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/16376507",
        "http://www.ncbi.nlm.nih.gov/pubmed/17112370",
        "http://www.ncbi.nlm.nih.gov/pubmed/3469025",
        "http://www.ncbi.nlm.nih.gov/pubmed/8296522",
        "http://www.ncbi.nlm.nih.gov/pubmed/4003033",
        "http://www.ncbi.nlm.nih.gov/pubmed/16149098",
        "http://www.ncbi.nlm.nih.gov/pubmed/16082159",
        "http://www.ncbi.nlm.nih.gov/pubmed/4075075",
        "http://www.ncbi.nlm.nih.gov/pubmed/2718740",
        "http://www.ncbi.nlm.nih.gov/pubmed/7341602"
      ]
    },
    {
      "id": "641790a3690f196b5100002c",
      "type": "summary",
      "body": "What is the difference between Duchenne muscular Dystrophy and Becker muscular dystrophy?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10422002",
          "text": "e and Becker muscular dystrophy concerning the age of onset, severity of disease and rate of progression. Electromyographic signs of myopathic changes",
          "offsetInBeginSection": 603,
          "offsetInEndSection": 753,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12507416",
          "text": "Some of these share pathogenetic mechanisms with other forms of muscular dystrophy, such as the sarcoglycanopathies (LGMD 2C-F) and the dystrophinopathies (Duchenne and Becker muscular dystrophy).",
          "offsetInBeginSection": 216,
          "offsetInEndSection": 412,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18056690",
          "text": "Patients with Becker muscular dystrophy demonstrate a less homogeneous cognitive phenotype than that seen in Duchenne muscular dystrophy.",
          "offsetInBeginSection": 1665,
          "offsetInEndSection": 1802,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/164552",
          "text": "Ribosome concentration was normal in Duchenne and facioscapulohumeral and decreased in Becker muscular dystrophy.",
          "offsetInBeginSection": 358,
          "offsetInEndSection": 471,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19555515",
          "text": "The most common are Duchenne muscular dystrophy and Becker muscular dystrophy, which result from mutations within the gene encoding dystrophin; myotonic dystrophy type 1, which results from an expanded trinucleotide repeat in the myotonic dystrophy protein kinase gene; and facioscapulohumeral dystrophy, which is associated with contractions in the subtelomeric region of human chromosome 1.",
          "offsetInBeginSection": 127,
          "offsetInEndSection": 519,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/164552",
          "text": "ne and Becker muscular dystrophies suggests that these conditions are non-allelic. In facioscapulohumeral muscular dystrophy the changes in protein sy",
          "offsetInBeginSection": 1500,
          "offsetInEndSection": 1650,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1898245",
          "text": " with Duchenne muscular dystrophy or Becker muscular dystrophy have gene deletions. The identification of a deletion allows the disease to be confirme",
          "offsetInBeginSection": 223,
          "offsetInEndSection": 373,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26022172",
          "text": "lestones, or elevated serum transaminases. Becker muscular dystrophy is milder, often presenting after age 5, with ambulation frequently preserved pas",
          "offsetInBeginSection": 438,
          "offsetInEndSection": 588,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22103559",
          "text": "remities and muscle function parameters.\n\n\nCONCLUSIONS\nThe differences in BMD between patients with Duchenne and Becker as well as between different b",
          "offsetInBeginSection": 850,
          "offsetInEndSection": 1000,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2590130",
          "text": "deletion frequency for the eight boys with Becker muscular dystrophy was 38%. Members of families in which these disorders result from a deletion can ",
          "offsetInBeginSection": 382,
          "offsetInEndSection": 532,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/8894415",
        "http://www.ncbi.nlm.nih.gov/pubmed/28393671",
        "http://www.ncbi.nlm.nih.gov/pubmed/10422002",
        "http://www.ncbi.nlm.nih.gov/pubmed/19834452",
        "http://www.ncbi.nlm.nih.gov/pubmed/14989756",
        "http://www.ncbi.nlm.nih.gov/pubmed/2590130",
        "http://www.ncbi.nlm.nih.gov/pubmed/1898245",
        "http://www.ncbi.nlm.nih.gov/pubmed/26022172",
        "http://www.ncbi.nlm.nih.gov/pubmed/22103559",
        "http://www.ncbi.nlm.nih.gov/pubmed/33458572"
      ]
    },
    {
      "id": "63f56dc533942b094c000001",
      "type": "summary",
      "body": "What is Lance-Adams syndrome?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/369491",
          "text": "A patient with postanoxic action myoclonus (Lance-Adams syndrome) was severely disabled with this movement disorder.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137720",
          "text": "INTRODUCTION\nChronic post-anoxic myoclonus, also known as Lance-Adams syndrome, may develop following hypoxic brain injury, and is resistant to pharmacological therapy.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9422152",
          "text": "Posthypoxic myoclonus (Lance-Adams' syndrome) is a rare complication of cardiorespiratory arrest.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 97,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27630463",
          "text": "Posthypoxic myoclonus (Lance-Adams syndrome) is characterized by myoclonus involving multiple muscle groups which is resistant to most conventional antiepileptic drugs.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25885623",
          "text": "Accurate distinction between MSE and Lance-Adams syndrome (LAS) is very important as both have very different prognosis.",
          "offsetInBeginSection": 313,
          "offsetInEndSection": 433,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23494722",
          "text": "Although in literature almost 150 patients with Lance-Adams Syndrome (LAS) have been reported, neuroradiological evaluations were often performed in late stages and there is no serial study evaluating LAS from early stages.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 223,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32117660",
          "text": "Lance-Adams syndrome (LAS) is chronic\u00a0post-hypoxic myoclonus that is often associated with sudden lapses in muscle tone (negative myoclonus) in the legs, causing a disabling \"bouncy gait.\"",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 188,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27708982",
          "text": "monstrate different syndromic features from classic Lance-Adams syndrome (LAS). The aim of this review is to provide up-to-date information about the ",
          "offsetInBeginSection": 198,
          "offsetInEndSection": 348,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19764456",
          "text": "We report a 17-year-old female patient with Lance-Adams syndrome caused by anoxic encephalopathy during a severe attack of bronchial asthma.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33842137",
          "text": "Lance-Adams syndrome (LAS) is chronic post-hypoxic myoclonus after a\u00a0hypoxic encephalopathy.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 92,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26137720",
        "http://www.ncbi.nlm.nih.gov/pubmed/36367330",
        "http://www.ncbi.nlm.nih.gov/pubmed/27118765",
        "http://www.ncbi.nlm.nih.gov/pubmed/1436253",
        "http://www.ncbi.nlm.nih.gov/pubmed/24949053",
        "http://www.ncbi.nlm.nih.gov/pubmed/35530854",
        "http://www.ncbi.nlm.nih.gov/pubmed/23494722",
        "http://www.ncbi.nlm.nih.gov/pubmed/369491",
        "http://www.ncbi.nlm.nih.gov/pubmed/11697066",
        "http://www.ncbi.nlm.nih.gov/pubmed/35415010"
      ]
    },
    {
      "id": "643def7057b1c7a31500003a",
      "type": "summary",
      "body": "What does mitapivat do?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35417638",
          "text": "In a phase 2 study, mitapivat, an oral, first-in-class activator of erythrocyte pyruvate kinase, increased the hemoglobin level in patients with pyruvate kinase deficiency.",
          "offsetInBeginSection": 121,
          "offsetInEndSection": 293,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35964609",
          "text": "We aimed to investigate the safety and efficacy of mitapivat (Agios Pharmaceuticals, Cambridge, MA, USA), a pyruvate kinase activator, in adults with non-transfusion-dependent (NTD) \u03b1-thalassaemia or NTD \u03b2-thalassaemia.",
          "offsetInBeginSection": 258,
          "offsetInEndSection": 477,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35366607",
          "text": "mitapivat yielded potential benefits in HbSS mice. Mitapivat further increased ATP without significantly changing 2,3-DPG or hemoglobin levels, and de",
          "offsetInBeginSection": 945,
          "offsetInEndSection": 1095,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35988546",
          "text": "INTERPRETATION\nMitapivat represents a novel therapy that can reduce transfusion burden in some adults with pyruvate kinase deficiency receiving regular transfusions, and is the first disease-modifying agent approved in this disease.",
          "offsetInBeginSection": 2352,
          "offsetInEndSection": 2584,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33822774",
          "text": " expression, and diminished liver iron overload. Mitapivat reduced duodenal Dmt1 expression potentially by activating the pyruvate kinase M2-HIF2\u03b1 axi",
          "offsetInBeginSection": 974,
          "offsetInEndSection": 1124,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35576529",
          "text": "This study provides proof of concept that mitapivat has disease-modifying potential in patients with SCD.",
          "offsetInBeginSection": 1564,
          "offsetInEndSection": 1669,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35417638",
          "text": "CONCLUSIONS\nIn patients with pyruvate kinase deficiency, mitapivat significantly increased the hemoglobin level, decreased hemolysis, and improved patient-reported outcomes.",
          "offsetInBeginSection": 1915,
          "offsetInEndSection": 2088,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31483964",
          "text": "Mitapivat is an oral, small-molecule allosteric activator of pyruvate kinase in red cells.",
          "offsetInBeginSection": 111,
          "offsetInEndSection": 201,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36260990",
          "text": "Kuo and colleagues1 evaluated the safety and efficacy of mitapivat, an oral pyruvate kinase activator, in\u00a0adults with non-transfusion-dependent \u03b1-thalassemia or \u03b2-thalassemia.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 175,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35366607",
          "text": "These factors can be modulated by mitapivat, which activates erythrocyte pyruvate kinase (PKR) and improves sickling kinetics in SCD patients.",
          "offsetInBeginSection": 324,
          "offsetInEndSection": 466,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35988546",
        "http://www.ncbi.nlm.nih.gov/pubmed/35417638",
        "http://www.ncbi.nlm.nih.gov/pubmed/35366607",
        "http://www.ncbi.nlm.nih.gov/pubmed/31483964",
        "http://www.ncbi.nlm.nih.gov/pubmed/35964609",
        "http://www.ncbi.nlm.nih.gov/pubmed/35576529",
        "http://www.ncbi.nlm.nih.gov/pubmed/33822774",
        "http://www.ncbi.nlm.nih.gov/pubmed/34987744",
        "http://www.ncbi.nlm.nih.gov/pubmed/36260990"
      ]
    },
    {
      "id": "64371a4257b1c7a315000029",
      "type": "factoid",
      "body": "In prokaryotes, functionally related genes are sometimes positioned adjacent to each other in the genome and can be under the control of the same regulatory machinery. What are these called?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17671982",
          "text": ", there is a need for an alternative to gold standards. The presence of operons (polycistronic transcription units formed of functionally related gene",
          "offsetInBeginSection": 753,
          "offsetInEndSection": 903,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/17671982"
      ]
    },
    {
      "id": "6440377c57b1c7a315000049",
      "type": "factoid",
      "body": "What is the active ingredient of Xipere?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36018461",
          "text": "Triamcinolone acetonide injectable suspension for suprachoroidal use (Xipere\u00ae; SCS triamcinolone acetonide) is a corticosteroid approved in the USA for the treatment of macular edema associated with uveitis.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 207,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31326750",
          "text": "Worms were exposed to different concentrations of the active ingredient (glyphosate in monoisopropylamine salt) and its commercial formulation.",
          "offsetInBeginSection": 737,
          "offsetInEndSection": 880,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31326750",
        "http://www.ncbi.nlm.nih.gov/pubmed/36018461"
      ]
    },
    {
      "id": "64163568690f196b5100001b",
      "type": "list",
      "body": "What are the most common mutation locations in dystrophin gene in Duchenne muscular dystrophy?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24643206",
          "text": "ystrophin gene that ablate functional protein expression. Although exonic deletions are the most common Duchenne muscular dystrophy lesion, duplicatio",
          "offsetInBeginSection": 91,
          "offsetInEndSection": 241,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26754139",
          "text": "Large deletions and duplications are most common, but small mutations have been found as well.",
          "offsetInBeginSection": 125,
          "offsetInEndSection": 219,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10675908",
          "text": "Dystrophin, the product of the DMD gene, is found in neurones, where it is associated with the postsynaptic membrane.",
          "offsetInBeginSection": 202,
          "offsetInEndSection": 319,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19158079",
          "text": "rties of the isolated repeat 23 bearing single or double mutations E2910V and N2912D found in muscle dystrophy with severity grading. No dramatic effe",
          "offsetInBeginSection": 575,
          "offsetInEndSection": 725,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29581631",
          "text": "BACKGROUND\nNonsense mutations in the dystrophin gene usually result in a severe Duchenne muscular dystrophy phenotype.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8190471",
          "text": "The purpose of this study is to define completely the ocular phenotype associated with mutations at Xp21, the Duchenne muscular dystrophy gene locus.",
          "offsetInBeginSection": 138,
          "offsetInEndSection": 287,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12488597",
          "text": "Mutations in the DMD gene are thought to be responsible, with the shorter isoforms of dystrophin implicated in its molecular brain pathogenesis.",
          "offsetInBeginSection": 249,
          "offsetInEndSection": 393,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7833192",
          "text": "lar defects and the cardiac phenotypes has not yet been established. New mutations in the dystrophin gene are common and such mutations cause one thir",
          "offsetInBeginSection": 622,
          "offsetInEndSection": 772,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28802771",
          "text": "It is due to mutations in the dystrophin gene leading to absence of full-length dystrophin protein.",
          "offsetInBeginSection": 148,
          "offsetInEndSection": 247,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15528407",
          "text": "Most mutations in the dystrophin gene create a frameshift or a stop in the mRNA and are associated with severe Duchenne muscular dystrophy.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29581631",
        "http://www.ncbi.nlm.nih.gov/pubmed/19158079",
        "http://www.ncbi.nlm.nih.gov/pubmed/24643206",
        "http://www.ncbi.nlm.nih.gov/pubmed/18160999",
        "http://www.ncbi.nlm.nih.gov/pubmed/25677308",
        "http://www.ncbi.nlm.nih.gov/pubmed/27506452",
        "http://www.ncbi.nlm.nih.gov/pubmed/21402533",
        "http://www.ncbi.nlm.nih.gov/pubmed/12488597",
        "http://www.ncbi.nlm.nih.gov/pubmed/33039804",
        "http://www.ncbi.nlm.nih.gov/pubmed/8190471"
      ]
    },
    {
      "id": "63ee5eeaf36125a426000002",
      "type": "yesno",
      "body": "Does mutation of ARTEMIS gene causes severe combined immunodeficiency?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15032591",
          "text": "Mutations in nine different genes have been found to cause the human severe combined immunodeficiency syndrome.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14628082",
          "text": "factor, Artemis, has been identified. Mutations in the ARTEMIS gene cause human severe combined immunodeficiency with increased radiosensitivity (RS-S",
          "offsetInBeginSection": 570,
          "offsetInEndSection": 720,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15723659",
          "text": "A defect in Artemis causes human radiosensitive-severe combined immunodeficiency.",
          "offsetInBeginSection": 205,
          "offsetInEndSection": 286,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24144642",
          "text": " lack of T and B cells and is caused by defects in genes required for T- and B-cell receptor gene rearrangement. Several of these genes are also invol",
          "offsetInBeginSection": 75,
          "offsetInEndSection": 225,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27611239",
          "text": " nonhomologous end-joining. Mutations in DCLRE1C, the gene encoding Artemis, cause T-B-NK+ severe combined immunodeficiency (ART-SCID) and also confer",
          "offsetInBeginSection": 178,
          "offsetInEndSection": 328,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21663454",
          "text": "epair and V(D)J recombination. Deficiency of Artemis results in a B- T- radiosensitive severe combined immunodeficiency, which may potentially be trea",
          "offsetInBeginSection": 84,
          "offsetInEndSection": 234,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17062750",
          "text": "Artemis gene mutations are responsible for the development of a severe combined immunodeficiency [radiation-sensitive (RS) SCID] characterized by a severe B and T cell deficiency and a normal natural killer cell population.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 223,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19953608",
          "text": "Patients with mutations in the DCLRE1C gene, which encodes ARTEMIS, suffer from radiosensitive B(-/low) T(-/low) severe combined immunodeficiency (SCID) or radiosensitive Omenn syndrome.",
          "offsetInBeginSection": 198,
          "offsetInEndSection": 384,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15811628",
          "text": "Mutations in the Artemis gene are causative in a subset of human severe combined immunodeficiencies (SCIDs) and Artemis-deficient cells exhibit radiation sensitivity and defective V(D)J recombination, implicating Artemis function in non-homologous end joining (NHEJ).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 267,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31720302",
          "text": "Genetic deficiency of the nuclease DCLRE1C/Artemis causes radiosensitive severe combined immunodeficiency (RS-SCID) with lack of peripheral T and B cells and increased sensitivity to ionizing radiations.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 203,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21147755",
        "http://www.ncbi.nlm.nih.gov/pubmed/24144642",
        "http://www.ncbi.nlm.nih.gov/pubmed/31720302",
        "http://www.ncbi.nlm.nih.gov/pubmed/26361272",
        "http://www.ncbi.nlm.nih.gov/pubmed/26476407",
        "http://www.ncbi.nlm.nih.gov/pubmed/19011808",
        "http://www.ncbi.nlm.nih.gov/pubmed/18560421",
        "http://www.ncbi.nlm.nih.gov/pubmed/15456891",
        "http://www.ncbi.nlm.nih.gov/pubmed/19075392",
        "http://www.ncbi.nlm.nih.gov/pubmed/15723659"
      ]
    },
    {
      "id": "640c821c201352f04a000023",
      "type": "yesno",
      "body": "Is Wilson's disease described as an iron storage disease?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16998622",
          "text": " was found to be different between cuprothionein and iron complexes. Iron overload in Wilson's disease might be worsened after treatment because of th",
          "offsetInBeginSection": 1151,
          "offsetInEndSection": 1301,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19640812",
          "text": "BACKGROUND\nHypocaeruloplasminaemia can lead to tissue iron storage in Wilson's disease and the possibility of iron overload in long-term overtreated patients should be considered.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17505988",
          "text": "Hereditary deposition of iron (primary haemochromatosis) or copper (Wilson's disease) are autosomal recessive metabolic disease characterized by progressive liver pathology and subsequent involvement of various other organs.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 224,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11054133",
          "text": "More than 60 mutations of the Wilson's disease gene have been described so far.",
          "offsetInBeginSection": 53,
          "offsetInEndSection": 132,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/16998622",
        "http://www.ncbi.nlm.nih.gov/pubmed/17505988",
        "http://www.ncbi.nlm.nih.gov/pubmed/19640812",
        "http://www.ncbi.nlm.nih.gov/pubmed/11054133"
      ]
    },
    {
      "id": "643c9b4057b1c7a315000032",
      "type": "summary",
      "body": "What are promoters?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11158302",
          "text": "n of the promoter that accompanies transactivation by HS2 is highly directed and specific. However, global acetylation of histones in vivo by trichost",
          "offsetInBeginSection": 1218,
          "offsetInEndSection": 1368,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9926457",
          "text": "The effects of the growth promoters avoparcin and avilamycin and the ionophore anticoccidials maduramicin, narasin and monensin on the growth of Clostridium perfringens (Cp) in the caeca and on performance of broiler chickens were tested in 2 experiments.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 255,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10801867",
          "text": "activity raised the question of what mechanisms return promoters to inactive states. By exchanging or directing co-occupancy of protein complexes boun",
          "offsetInBeginSection": 624,
          "offsetInEndSection": 774,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25830507",
          "text": "ic 7 base pair sequence element that is present in the promoters of regulated genes. The three principal regulators of virulence gene expression in F.",
          "offsetInBeginSection": 1135,
          "offsetInEndSection": 1285,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12168619",
          "text": "species with between-species mixtures of Bicoid homeodomains and hunchback or tailless promoters. We observed that components taken from different spe",
          "offsetInBeginSection": 716,
          "offsetInEndSection": 866,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22392219",
          "text": "They vary greatly in terms of associated regulatory elements, sequence motifs, the choice of transcription start sites and other features.",
          "offsetInBeginSection": 43,
          "offsetInEndSection": 181,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7768327",
          "text": "We have engineered GH3 cells with reporter genes under control of the growth hormone and prolactin promoters and measured protein production.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23776535",
          "text": "nscription. This observation is supported at the level of individual regulatory interactions on promoters, even if we exclude the promoters regulated ",
          "offsetInBeginSection": 711,
          "offsetInEndSection": 861,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8585944",
          "text": "Our studies of the promoters of the myeloid CSF receptors (M, GM, and G) in cell lines have led to the findings that the promoters are small, and are all activated by the PU.1 and C/EBP proteins.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 195,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27358391",
          "text": "We found that promoters of the reproductive genes BOULE and DAZL exhibit differential DNA methylation, consistent with their gonad-specific expression in humans and mice.",
          "offsetInBeginSection": 370,
          "offsetInEndSection": 540,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25830507",
        "http://www.ncbi.nlm.nih.gov/pubmed/32197056",
        "http://www.ncbi.nlm.nih.gov/pubmed/27979920",
        "http://www.ncbi.nlm.nih.gov/pubmed/3112923",
        "http://www.ncbi.nlm.nih.gov/pubmed/27557757",
        "http://www.ncbi.nlm.nih.gov/pubmed/8585944",
        "http://www.ncbi.nlm.nih.gov/pubmed/22914767",
        "http://www.ncbi.nlm.nih.gov/pubmed/24492846",
        "http://www.ncbi.nlm.nih.gov/pubmed/3315851",
        "http://www.ncbi.nlm.nih.gov/pubmed/25708710"
      ]
    },
    {
      "id": "6440084357b1c7a31500003e",
      "type": "yesno",
      "body": "Is omaveloxolone an activator of NFkB?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31118567",
          "text": "ter oral administration of omaveloxolone, which was associated with Nrf2 activation. Further, systemic exposures to omaveloxolone that produce Nrf2 ac",
          "offsetInBeginSection": 1664,
          "offsetInEndSection": 1814,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30656180",
          "text": "Omaveloxolone, an Nrf2 activator and NF-kB suppressor, targets dysfunctional inflammatory, metabolic, and bioenergetic pathways.",
          "offsetInBeginSection": 194,
          "offsetInEndSection": 322,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19129371",
          "text": "In conclusion, the canonical activation of NFKB pathway is deregulated and may have reduced transcriptional function affecting NFKBIA and IL6 expression, genes related local proinflammatory processes.",
          "offsetInBeginSection": 1285,
          "offsetInEndSection": 1485,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17117296",
          "text": "OPG binds to the receptor activator of NFkB and prevents osteoclast differentiation, activity and survival.",
          "offsetInBeginSection": 364,
          "offsetInEndSection": 471,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33068037",
          "text": "degenerative disorder with no approved treatment. Omaveloxolone, an Nrf2 activator, improves mitochondrial function, restores redox balance, and reduc",
          "offsetInBeginSection": 63,
          "offsetInEndSection": 213,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35308167",
          "text": "e in the regulation of microglial polarization. Recently, the novel Nrf2 activator omaveloxolone (Omav) has been validated to improve neurological fun",
          "offsetInBeginSection": 228,
          "offsetInEndSection": 378,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30656180",
        "http://www.ncbi.nlm.nih.gov/pubmed/31118567",
        "http://www.ncbi.nlm.nih.gov/pubmed/33068037",
        "http://www.ncbi.nlm.nih.gov/pubmed/35308167",
        "http://www.ncbi.nlm.nih.gov/pubmed/17117296",
        "http://www.ncbi.nlm.nih.gov/pubmed/19129371"
      ]
    },
    {
      "id": "6441057657b1c7a315000052",
      "type": "factoid",
      "body": "What is the most commonly used pain scale for the measurement of pain in children?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20921070",
          "text": " data. When given a choice between faces scales, children preferred the WBFPRS. Confounding of pain intensity with affect caused by use of smiling and",
          "offsetInBeginSection": 1320,
          "offsetInEndSection": 1470,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31246094",
          "text": "The commonly used scales of measurement were examined: VAS, VSN, CAS, FPS and the Oucher SCALE.",
          "offsetInBeginSection": 1164,
          "offsetInEndSection": 1259,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16128995",
          "text": "CONCLUSIONS\nThe results suggest that a list of adjectives provides the most discriminating measure of discomfort.",
          "offsetInBeginSection": 1683,
          "offsetInEndSection": 1796,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36131255",
          "text": "The median NPRS for average pain intensity was 4 (IQR 2), the median for pain frequency was 2-3 times/week, and the median frequency of school absence due to pain was 2-3 times per month.",
          "offsetInBeginSection": 1107,
          "offsetInEndSection": 1294,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30508221",
          "text": "Pain is more prevalent in females, older age groups, and children in Gross Motor Function Classification System level V.",
          "offsetInBeginSection": 1444,
          "offsetInEndSection": 1564,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30179284",
          "text": "Of the 312 trials that reported pain intensity, 303 (97%) also specified pain assessment tools, in which the most common was the visual analogue scale (24%) followed by the Children's Hospital of Eastern Ontario Pain Scale (18%).",
          "offsetInBeginSection": 1103,
          "offsetInEndSection": 1332,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36131255",
          "text": "Participants answered a standardised interview including five pre-structured questions, and the Numeric Pain Rating Scale (NPRS), the Pain Interference Index, and a questionnaire concerning self-perceived health status the Patient Reported Outcomes Measurement Information System Pediatric-25 Profile v1.1 (PROMIS-25).",
          "offsetInBeginSection": 576,
          "offsetInEndSection": 894,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31246094",
          "text": "used scales of measurement were examined: VAS, VSN, CAS, FPS and the Oucher SCALE. The different pathologies of head and neck and their characteristic",
          "offsetInBeginSection": 1177,
          "offsetInEndSection": 1327,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34300223",
          "text": "ensity rated, and the only tool used for this assessment was the numeric rating scale (NRS). Children with burns most frequently received a single ana",
          "offsetInBeginSection": 720,
          "offsetInEndSection": 870,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30180088",
          "text": "tate an update of this work, most notably growing use of the 11-point numeric rating scale (NRS-11). Our aim was to review the measurement properties ",
          "offsetInBeginSection": 438,
          "offsetInEndSection": 588,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30179284",
        "http://www.ncbi.nlm.nih.gov/pubmed/34300223",
        "http://www.ncbi.nlm.nih.gov/pubmed/30180088",
        "http://www.ncbi.nlm.nih.gov/pubmed/15723913",
        "http://www.ncbi.nlm.nih.gov/pubmed/21574503",
        "http://www.ncbi.nlm.nih.gov/pubmed/16128995",
        "http://www.ncbi.nlm.nih.gov/pubmed/3619964",
        "http://www.ncbi.nlm.nih.gov/pubmed/36131255",
        "http://www.ncbi.nlm.nih.gov/pubmed/16489954",
        "http://www.ncbi.nlm.nih.gov/pubmed/17877522"
      ]
    },
    {
      "id": "6402c71f201352f04a00000a",
      "type": "summary",
      "body": "What is the mechanism of action of daridorexant?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36473030",
          "text": ", 1.21-3.36; P\u2009=\u20090.007). Daridorexant is superior to placebo in improving sleep quality. However, the drug resulted in a slightly higher incidence of ",
          "offsetInBeginSection": 1135,
          "offsetInEndSection": 1285,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34002356",
          "text": "In addition, the metabolic ratios (parent to metabolite), i.e., a marker of CYP 3A4 activity, of the two most abundant daridorexant metabolites were higher in patients with liver cirrhosis compared with healthy subjects.",
          "offsetInBeginSection": 2186,
          "offsetInEndSection": 2406,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34480579",
          "text": "daridorexant was consistent with earlier trials indicating quick absorption and elimination.\n\n\nCONCLUSIONS\nIn this large, valid human abuse potential ",
          "offsetInBeginSection": 1462,
          "offsetInEndSection": 1612,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36046352",
          "text": "Data Synthesis: Daridorexant works through antagonism of the dual orexin receptor.",
          "offsetInBeginSection": 516,
          "offsetInEndSection": 598,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32134851",
          "text": "Daridorexant dose-dependently reduced vigilance, attention, visuomotor coordination, and postural stability.",
          "offsetInBeginSection": 1241,
          "offsetInEndSection": 1349,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36046352",
          "text": "Daridorexant, at a dose of 25 mg to 50 mg, was shown to be effective in improving sleep parameters in phase 3 clinical studies and was well tolerated.",
          "offsetInBeginSection": 707,
          "offsetInEndSection": 857,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35065036",
          "text": "We aimed to assess safety and efficacy of daridorexant, a novel orexin receptor antagonist, on night-time and daytime symptoms of insomnia.",
          "offsetInBeginSection": 220,
          "offsetInEndSection": 359,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32341187",
          "text": "CLASSIFICATION OF EVIDENCE\nThis study provides Class I evidence that, for elderly people with insomnia, daridorexant reduced WASO.",
          "offsetInBeginSection": 1590,
          "offsetInEndSection": 1720,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31953863",
          "text": "OBJECTIVE\nTo evaluate the dose-response relationship of daridorexant, a new dual orexin receptor antagonist, on sleep variables in subjects with insomnia disorder.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36355586",
          "text": "This first column in a 2-part series focuses on the pharmacokinetics of the 3 Food and Drug Administration-approved dual orexin receptor antagonists, daridorexant, lemborexant, and suvorexant, specifically as they relate to their use as sleep medications.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 255,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36046352",
        "http://www.ncbi.nlm.nih.gov/pubmed/32134851",
        "http://www.ncbi.nlm.nih.gov/pubmed/33417730",
        "http://www.ncbi.nlm.nih.gov/pubmed/34098518",
        "http://www.ncbi.nlm.nih.gov/pubmed/36473030",
        "http://www.ncbi.nlm.nih.gov/pubmed/32341187",
        "http://www.ncbi.nlm.nih.gov/pubmed/36098936",
        "http://www.ncbi.nlm.nih.gov/pubmed/34002356",
        "http://www.ncbi.nlm.nih.gov/pubmed/36355586",
        "http://www.ncbi.nlm.nih.gov/pubmed/36045942"
      ]
    },
    {
      "id": "64257c9c690f196b5100004b",
      "type": "factoid",
      "body": "What is DILI-CAT used for?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36174069",
          "text": "ver injury can be assessed and used to quantitatively develop a computer-assisted DILI causality assessment-tool (DILI-CAT). Therefore, we evaluated d",
          "offsetInBeginSection": 89,
          "offsetInEndSection": 239,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35266155",
          "text": "CONCLUSION\nDILI-CAT, a clinically intuitive, data-driven, computer-assisted scoring algorithm, is a useful tool for early detection of drug's hepatotoxicity in clinical drug development.",
          "offsetInBeginSection": 1629,
          "offsetInEndSection": 1815,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36174069",
          "text": "iven, diagnostic tool built to define drug-specific phenotypes for DILI adjudication. The data provide proof of principle that a drug-specific, data-d",
          "offsetInBeginSection": 1491,
          "offsetInEndSection": 1641,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35266155",
          "text": "rug-specific liver injury phenotypes, to examine potential DILI in early phase ximelagatran clinical development.\n\n\nMETHODS\nWe conducted a retrospecti",
          "offsetInBeginSection": 215,
          "offsetInEndSection": 365,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35266155",
        "http://www.ncbi.nlm.nih.gov/pubmed/36174069"
      ]
    },
    {
      "id": "6429e1b857b1c7a315000008",
      "type": "summary",
      "body": "What is the significance of a persistently positive RT-PCR for weeks after illness?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33053181",
          "text": "Age > = 60 years was associated with prolonged RT-PCR positivity (statistically significant).",
          "offsetInBeginSection": 1257,
          "offsetInEndSection": 1350,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33537743",
          "text": "Age > = 60 years was associated with prolonged RT-PCR positivity (statistically significant).",
          "offsetInBeginSection": 1257,
          "offsetInEndSection": 1350,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33537743",
        "http://www.ncbi.nlm.nih.gov/pubmed/33053181"
      ]
    },
    {
      "id": "644029f857b1c7a315000042",
      "type": "summary",
      "body": "What is the genetic cause of Freidreich's ataxia?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29325611",
          "text": "The most common of these diseases is Friedreich ataxia, caused by mutation of the frataxin gene, but recent advances in genetic analysis have greatly broadened the ever-expanding number of causative genes to over 50.",
          "offsetInBeginSection": 366,
          "offsetInEndSection": 582,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11843630",
          "text": "It is well established that GAA/TTC base triplet expansion is the cause of degenerative disorder in Freidreich's Ataxia.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22894632",
          "text": "With the discovery of the underlying genetic mutation, a variety of novel therapies are now progressing into clinical trials.",
          "offsetInBeginSection": 280,
          "offsetInEndSection": 405,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9527151",
          "text": "Molecular genetic analysis showed the absence of the frataxin gene expansion.",
          "offsetInBeginSection": 419,
          "offsetInEndSection": 496,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16806050",
          "text": "ess, encephalopathy, Freidreich's ataxia, and diseases due to mitochondrial DNA mutations. We also describe several genetic approaches for gene manipu",
          "offsetInBeginSection": 658,
          "offsetInEndSection": 808,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23242090",
          "text": "The genetic testing disclosed expanded GAA repeat length on both alleles of FXN gene.",
          "offsetInBeginSection": 563,
          "offsetInEndSection": 648,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12020255",
          "text": "Friedreich ataxia results from a deficiency of functional frataxin, a protein that appears to be involved in mitochondrial iron homeostasis.",
          "offsetInBeginSection": 164,
          "offsetInEndSection": 304,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19566498",
          "text": "At the age of 45 re-evaluation and re-examination was performed and genetic analysis of the Frataxin gene was negative.",
          "offsetInBeginSection": 623,
          "offsetInEndSection": 742,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36046423",
          "text": "Genetic studies suggest RFC1 expansions may be the most common genetic cause of ataxia and are likely underdiagnosed.",
          "offsetInBeginSection": 623,
          "offsetInEndSection": 740,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9677705",
          "text": "The defective genes have been identified for Friedreich ataxia, the major recessive \"hereditary ataxia of unknown cause,\" and for five dominantly inherited \"hereditary ataxias of unknown cause.\"",
          "offsetInBeginSection": 912,
          "offsetInEndSection": 1106,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36046423",
        "http://www.ncbi.nlm.nih.gov/pubmed/16806050",
        "http://www.ncbi.nlm.nih.gov/pubmed/22894632",
        "http://www.ncbi.nlm.nih.gov/pubmed/11843630",
        "http://www.ncbi.nlm.nih.gov/pubmed/9527151",
        "http://www.ncbi.nlm.nih.gov/pubmed/28724389",
        "http://www.ncbi.nlm.nih.gov/pubmed/25765228",
        "http://www.ncbi.nlm.nih.gov/pubmed/19566498",
        "http://www.ncbi.nlm.nih.gov/pubmed/9677705",
        "http://www.ncbi.nlm.nih.gov/pubmed/12020255"
      ]
    },
    {
      "id": "6442869857b1c7a31500005d",
      "type": "list",
      "body": "Which diagnostic tests are used for the diagnosis of FSHD?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33303865",
          "text": "ilobase repeats, termed D4Z4, located on chromosome 4q35. Assessment of size of D4Z4 alleles is commonly used for FSHD diagnosis. However, the extende",
          "offsetInBeginSection": 182,
          "offsetInEndSection": 332,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15645183",
          "text": "e FSHD being exclusively linked to chromosome 4. Complementary allele typing and segregation analysis confirmed the clinical diagnosis of FSHD by reve",
          "offsetInBeginSection": 480,
          "offsetInEndSection": 630,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10544225",
          "text": " caused by the size reduction of a polymorphic repeat array on 4q35. Probe p13E-11 recognises this chromosomal rearrangement and is generally used for",
          "offsetInBeginSection": 48,
          "offsetInEndSection": 198,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21920844",
          "text": "4q35 and the homologous 10q26 regions were also detected.\n\n\nCONCLUSION\nMolecular diagnosis of FSHD became a routine approach in Hungary thus supportin",
          "offsetInBeginSection": 1302,
          "offsetInEndSection": 1452,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21567298",
          "text": " number of repetitive elements (D4Z4) on chromosome 4q35 (4qA allele). Molecular diagnostic testing is appropriate to confirm the diagnosis of FSHD wi",
          "offsetInBeginSection": 576,
          "offsetInEndSection": 726,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34071558",
          "text": "Here, we present a comprehensive analysis of the currently used diagnostic methods (Southern blotting and molecular combing) against a new qPCR-based approach for FSHD1 diagnosis.",
          "offsetInBeginSection": 277,
          "offsetInEndSection": 456,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12778451",
          "text": "CONCLUSION\nIt was rather good to use <38 kb as a standard for diagnosis of FSHD.",
          "offsetInBeginSection": 682,
          "offsetInEndSection": 762,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10544225",
          "text": "and sensitivity of conventional FSHD diagnosis to the values obtained by PFGE based diagnosis of FSHD. Moreover, this study delimits the FSHD candidat",
          "offsetInBeginSection": 1455,
          "offsetInEndSection": 1605,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19501370",
          "text": "5.7+/-12.3 years (range: 26-72). The diagnosis of FSHD was confirmed by genetic tests. All patients underwent medical and neurological evaluations, su",
          "offsetInBeginSection": 418,
          "offsetInEndSection": 568,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19383939",
          "text": "The genetic lesion that is diagnostic for facioscapulohumeral muscular dystrophy (FSHD) results in an epigenetic misregulation of gene expression, which ultimately leads to the disease pathology.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 195,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26115655",
        "http://www.ncbi.nlm.nih.gov/pubmed/19383939",
        "http://www.ncbi.nlm.nih.gov/pubmed/10544225",
        "http://www.ncbi.nlm.nih.gov/pubmed/10864616",
        "http://www.ncbi.nlm.nih.gov/pubmed/17060574",
        "http://www.ncbi.nlm.nih.gov/pubmed/12928911",
        "http://www.ncbi.nlm.nih.gov/pubmed/34071558",
        "http://www.ncbi.nlm.nih.gov/pubmed/26862222",
        "http://www.ncbi.nlm.nih.gov/pubmed/21920844",
        "http://www.ncbi.nlm.nih.gov/pubmed/9192267"
      ]
    },
    {
      "id": "64040d73201352f04a000010",
      "type": "yesno",
      "body": "Can Efgartigimod be used for myasthenia gravis?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32833750",
          "text": "Three new biologic agents showed promising results in phase-II controlled myasthenia gravis trials: Zilucoplan, a subcutaneous macrocyclic peptide inhibiting complement C5; Efgartigimod, an IgG1-derived Fc fragment binding to neonatal FcRn receptor; and Rozanolixizumab, a high-affinity anti-FcRn monoclonal antibody.",
          "offsetInBeginSection": 959,
          "offsetInEndSection": 1276,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31118245",
          "text": "OBJECTIVE\nTo investigate safety and explore efficacy of efgartigimod (ARGX-113), an anti-neonatal Fc receptor immunoglobulin G1 Fc fragment, in patients with generalized myasthenia gravis (gMG) with a history of anti-acetylcholine receptor (AChR) autoantibodies, who were on stable standard-of-care myasthenia gravis (MG) treatment.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 332,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30573759",
          "text": "No consensus has been reached on the ideal therapeutic algorithm for myasthenia gravis (MG).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 92,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34146511",
          "text": "INTERPRETATION\nEfgartigimod was well tolerated and efficacious in patients with generalised myasthenia gravis.",
          "offsetInBeginSection": 2957,
          "offsetInEndSection": 3067,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35892247",
          "text": "EXPERT OPINION\nEfgartigimod was efficacious and safe for generalized myasthenia patients with AChR antibody-positive patients.",
          "offsetInBeginSection": 1143,
          "offsetInEndSection": 1269,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36033123",
          "text": "The result is that the present ICER pricing claims for eculizumab and efgartigimod in myasthenia gravis should not be applied without consideration of more relevant evidence.",
          "offsetInBeginSection": 675,
          "offsetInEndSection": 849,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30851266",
          "text": "We therefore tested efgartigimod (ARGX-113), a new neonatal Fc receptor blocker, in a mouse model for MuSK myasthenia gravis.",
          "offsetInBeginSection": 974,
          "offsetInEndSection": 1099,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35349079",
          "text": "The FcRn blocker efgartigimod, a humanized IgG1-derived Fc fragment, which competitively inhibits the FcRn, has recently been approved for the treatment of myasthenia gravis and is currently under investigation in CIDP.",
          "offsetInBeginSection": 1777,
          "offsetInEndSection": 1996,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24141560",
          "text": "A recent retrospective series suggests that, as in adult myasthenia gravis, thymectomy is a viable therapeutic option for selected cases of generalized juvenile myasthenia gravis.",
          "offsetInBeginSection": 673,
          "offsetInEndSection": 852,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10870923",
          "text": "Autoantibodies can be used to serologically distinguish paraneoplastic myasthenia gravis from Lambert-Eaton syndrome.",
          "offsetInBeginSection": 760,
          "offsetInEndSection": 877,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30851266",
        "http://www.ncbi.nlm.nih.gov/pubmed/35892247",
        "http://www.ncbi.nlm.nih.gov/pubmed/31118245",
        "http://www.ncbi.nlm.nih.gov/pubmed/36033123",
        "http://www.ncbi.nlm.nih.gov/pubmed/30573759",
        "http://www.ncbi.nlm.nih.gov/pubmed/24141560",
        "http://www.ncbi.nlm.nih.gov/pubmed/10870923",
        "http://www.ncbi.nlm.nih.gov/pubmed/35349079",
        "http://www.ncbi.nlm.nih.gov/pubmed/34146511",
        "http://www.ncbi.nlm.nih.gov/pubmed/32833750"
      ]
    },
    {
      "id": "6422e7ba690f196b51000044",
      "type": "yesno",
      "body": "Have Quercetin-biapigenin nanoparticles been shown to be effective in penetrating the blood-brain barrier",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29088799",
          "text": " to evaluate their effectiveness at damaging tumor cells. Nanoparticles were highly effective at penetrating the blood-brain barrier and delivering a ",
          "offsetInBeginSection": 675,
          "offsetInEndSection": 825,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29088799"
      ]
    },
    {
      "id": "6429e85e57b1c7a315000009",
      "type": "factoid",
      "body": "What process involves metabolite-sensing mRNAs to control gene expression?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15610857",
          "text": "th small ligands and direct expression of the genes involved in their metabolism. Riboswitches contain sensing \"aptamer\" modules, capable of ligand-in",
          "offsetInBeginSection": 69,
          "offsetInEndSection": 219,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12665241",
          "text": "Degradation of messenger RNAs (mRNAs) is a universal process that occurs in every cell and has important implications for nucleotide metabolism and gene expression.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 164,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/15610857",
        "http://www.ncbi.nlm.nih.gov/pubmed/12665241"
      ]
    },
    {
      "id": "6440360557b1c7a315000047",
      "type": "summary",
      "body": "What is Concerta\u00ae?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23297867",
          "text": ". Primary analysis was by intention-to-treat (ITT). The study drug, methylphenidate (as Concerta(\u00ae) ), was up-titrated over 2 weeks to a maximum dose ",
          "offsetInBeginSection": 557,
          "offsetInEndSection": 707,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29708762",
          "text": "Participants underwent a 4-week trial of long-acting MPH treatment (Concerta\u00ae), with weekly dosing increases until a therapeutic dose was reached.",
          "offsetInBeginSection": 429,
          "offsetInEndSection": 575,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18561524",
          "text": "An 18-year-old obese man with a body mass index of 40, diagnosed with attention-deficit hyperactivity disorder and treated with methylphenidate (Concerta) was acutely admitted to hospital with hypoxia and dyspnoea.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 214,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17046131",
          "text": "This study evaluated the efficacy and tolerability in the initiation treatment of Concerta (OROS methylphenidate HCl) in Korean children with Attention-Deficit/Hyperactivity Disorder (AD/HD).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 191,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12240794",
          "text": "This study compared the effect of a high-fat breakfast on early drug exposure from a morning dose of two extended-release stimulant formulations: the osmotic-controlled OROS tablet of methylphenidate HCI (CONCERTA) and the capsule containing extended-release beads of mixed amphetamine salts (ADDERALL XR).",
          "offsetInBeginSection": 503,
          "offsetInEndSection": 809,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11389303",
          "text": "mmediate-release (IR) MPH 3 times a day (tid), and Concerta, a once-daily MPH formulation. Three dosing levels of medication were used: 5 mg IR MPH ti",
          "offsetInBeginSection": 779,
          "offsetInEndSection": 929,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21432608",
          "text": "after ingestion of 21 long-acting methylphenidate (MPH) 54-mg tablets (1,134 mg Concerta(\u00ae)). At admission signs of sympathomimetic syndrome were obse",
          "offsetInBeginSection": 93,
          "offsetInEndSection": 243,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11768842",
          "text": "OBJECTIVE\nThe goal of this study was to estimate the total expected costs for the treatment and management of school-age children with ADHD using 6 commonly prescribed pharmacotherapies: methylphenidate immediate-release/extended-release (MPH IR/ER), methylphenidate immediate-release (MPH IR), Metadate CD (branded MPH IR/ER), Concerta (branded MPH ER), Ritalin (branded MPH IR), and Adderall (a combination of dextroamphetamine and amphetamine salts).",
          "offsetInBeginSection": 404,
          "offsetInEndSection": 857,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22583957",
          "text": "ith fluoxetine 40 mg daily. Finally, on a dosage of 378 mg extended-release methylphenidate (Concerta\u00ae), his symptoms of Attention Deficit Hyperactivi",
          "offsetInBeginSection": 1637,
          "offsetInEndSection": 1787,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22972578",
          "text": "Equasym\u00ae is more effective in the morning, whereas other formulations, such as Concerta\u00ae, allow greater control of the symptoms in the afternoon.",
          "offsetInBeginSection": 1114,
          "offsetInEndSection": 1259,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20015823",
        "http://www.ncbi.nlm.nih.gov/pubmed/27536342",
        "http://www.ncbi.nlm.nih.gov/pubmed/11768842",
        "http://www.ncbi.nlm.nih.gov/pubmed/16350601",
        "http://www.ncbi.nlm.nih.gov/pubmed/17046131",
        "http://www.ncbi.nlm.nih.gov/pubmed/11389303",
        "http://www.ncbi.nlm.nih.gov/pubmed/12240794",
        "http://www.ncbi.nlm.nih.gov/pubmed/25120227",
        "http://www.ncbi.nlm.nih.gov/pubmed/29708762",
        "http://www.ncbi.nlm.nih.gov/pubmed/18561524"
      ]
    },
    {
      "id": "641794e7690f196b51000036",
      "type": "list",
      "body": "What are the most common neuropsychiatric disorders associated with Duchenne muscular dystrophy?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29795071",
          "text": "In males with Duchenne muscular dystrophy, neuropsychiatric disorders have also been observed: attention deficit disorder and hyperactivity, autism spectrum disorders, and obsessive-compulsive disorder.",
          "offsetInBeginSection": 194,
          "offsetInEndSection": 396,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33741226",
          "text": "Neuropsychiatric phenotype associated to DMD gene mutations include now low IQ scores, epilepsy, autism, and attention deficit disorder.",
          "offsetInBeginSection": 107,
          "offsetInEndSection": 243,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32591735",
          "text": "of genetic disease, among which Duchenne muscular dystrophy and Spinal muscular atrophy are most common. Recently, the great breakthroughs of gene tar",
          "offsetInBeginSection": 42,
          "offsetInEndSection": 192,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18354150",
          "text": "Using a questionnaire-based study, we assessed the parent-reported prevalence of attention-deficit hyperactivity disorders (ADHDs), autism spectrum disorders, and obsessive-compulsive disorders in a group of 351 males with Duchenne muscular dystrophy.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 251,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32616576",
          "text": " prominent nonmotor manifestations, such as a low intelligence quotient and neuropsychiatric disturbance. We investigated WM integrity in patients wit",
          "offsetInBeginSection": 123,
          "offsetInEndSection": 273,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9850730",
          "text": " of heart and brain dystrophin-glycoprotein complexes in cardiomyopathy and brain deficiencies associated with muscular dystrophy. Furthermore, many i",
          "offsetInBeginSection": 754,
          "offsetInEndSection": 904,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28954035",
          "text": "We concluded that embryo analysis using associated techniques of PCR and array CGH seems to be safe for embryo selection in cases of X-linked disorders, such as Duchenne muscular dystrophy.",
          "offsetInBeginSection": 1268,
          "offsetInEndSection": 1457,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19555515",
          "text": "d wasting. The most common are Duchenne muscular dystrophy and Becker muscular dystrophy, which result from mutations within the gene encoding dystrop",
          "offsetInBeginSection": 116,
          "offsetInEndSection": 266,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9111186",
          "text": "Duchenne muscular dystrophy (DMD) is one of the most common X-linked genetic disorders.",
          "offsetInBeginSection": 74,
          "offsetInEndSection": 161,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10675908",
          "text": "Several forms of inherited muscular dystrophy are associated with brain abnormalities and cognitive impairment.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/9111186",
        "http://www.ncbi.nlm.nih.gov/pubmed/19555515",
        "http://www.ncbi.nlm.nih.gov/pubmed/10675908",
        "http://www.ncbi.nlm.nih.gov/pubmed/29795071",
        "http://www.ncbi.nlm.nih.gov/pubmed/28954035",
        "http://www.ncbi.nlm.nih.gov/pubmed/18354150",
        "http://www.ncbi.nlm.nih.gov/pubmed/33741226",
        "http://www.ncbi.nlm.nih.gov/pubmed/32616576",
        "http://www.ncbi.nlm.nih.gov/pubmed/12474683",
        "http://www.ncbi.nlm.nih.gov/pubmed/9850730"
      ]
    },
    {
      "id": "63ee5c78f36125a426000001",
      "type": "list",
      "body": "Which interleukins are affected by Dupilumab?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35174052",
          "text": "ients with moderate-to-severe atopic dermatitis, inhibits interleukins 4 and 13. It is an effective treatment option for atopic dermatitis, but facial",
          "offsetInBeginSection": 113,
          "offsetInEndSection": 263,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34622875",
          "text": "Alternatively, the paramount interleukins 4 and 13 may be antagonized by the monoclonal antibody dupilumab.",
          "offsetInBeginSection": 369,
          "offsetInEndSection": 476,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35238115",
          "text": "Dupilumab is a monoclonal antibody against interleukins 4 and 13 currently FDA approved for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents and severe AD in children aged 6-11\u2009years.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 219,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26836729",
          "text": "OBJECTIVE\nTo assess inhibition of interleukins 4 and 13 with dupilumab in patients with chronic sinusitis and nasal polyposis.",
          "offsetInBeginSection": 151,
          "offsetInEndSection": 277,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35078645",
          "text": "Dupilumab is a recombinant monoclonal IgG4 type antibody which inhibits IL4 and IL13 signaling.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 95,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31917498",
          "text": "Dupilumab is a recombinant complete human monoclonal antibody modulating the signaling of interleukin-4 and interleukin-13 pathways and has been approved for the treatment of moderate/severe atopic dermatitis.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 209,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35657197",
          "text": "w possible with this monoclonal antibody directed against interleukins 4 and 13. Since that time, other agents such as tralokinumab arrived on the mar",
          "offsetInBeginSection": 221,
          "offsetInEndSection": 371,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31564057",
          "text": "n monoclonal antibody, blocks the shared receptor unit for interleukin-4 and interleukin-13. International phase II and III studies have evaluated the",
          "offsetInBeginSection": 28,
          "offsetInEndSection": 178,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34572281",
          "text": " capable of inhibiting intracellular signaling of both interleukin (IL)-4 and IL-13. These are two molecules that, together with other proinflammatory",
          "offsetInBeginSection": 51,
          "offsetInEndSection": 201,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29939132",
          "text": "Dupilumab inhibits the biological effects of the cytokines IL-4 and IL-13, which are key drivers in the TH2 response.",
          "offsetInBeginSection": 680,
          "offsetInEndSection": 797,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36334079",
        "http://www.ncbi.nlm.nih.gov/pubmed/35657197",
        "http://www.ncbi.nlm.nih.gov/pubmed/35350765",
        "http://www.ncbi.nlm.nih.gov/pubmed/35174052",
        "http://www.ncbi.nlm.nih.gov/pubmed/36451848",
        "http://www.ncbi.nlm.nih.gov/pubmed/36214355",
        "http://www.ncbi.nlm.nih.gov/pubmed/35238115",
        "http://www.ncbi.nlm.nih.gov/pubmed/31564057",
        "http://www.ncbi.nlm.nih.gov/pubmed/35674510",
        "http://www.ncbi.nlm.nih.gov/pubmed/35222408"
      ]
    },
    {
      "id": "64316f8e57b1c7a315000016",
      "type": "list",
      "body": "What cells are used to regenerate cartilage?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16625212",
          "text": " to maintain its functional phenotype for a long period. Utilizing tissue stem cells is one approach to overcome such difficulties. We show here the p",
          "offsetInBeginSection": 98,
          "offsetInEndSection": 248,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32430067",
          "text": "HLA-ABC immunofluorescence staining demonstrated that hWJMSCs participated in the repair and regeneration of articular cartilage and escaped surveillance and clearance by the caprine immune system.",
          "offsetInBeginSection": 1986,
          "offsetInEndSection": 2183,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28692374",
          "text": "ver, current surgical therapies have a number of disadvantages. Mesenchymal stem cells have been suggested as a potential alternative therapy, with a ",
          "offsetInBeginSection": 377,
          "offsetInEndSection": 527,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27282532",
          "text": "Here we explore a new generation of smart, living implants, combining not only active therapeutics but also stem cells, as a novel strategy to regenerate stabilised cartilage and avoid prostheses.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 196,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23637149",
          "text": "Regenerated cartilage can be derived from various cell types, including chondrocytes, pluripotent stem cells, and mesenchymal stem cells.",
          "offsetInBeginSection": 684,
          "offsetInEndSection": 821,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28129782",
          "text": "CONCLUSIONS\nThis study reveals the potential of CBMC-hiPSCs as a promising candidate for cartilage regeneration.",
          "offsetInBeginSection": 1823,
          "offsetInEndSection": 1935,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35473517",
          "text": "Mesenchymal stem cells (MSCs) represent a promising therapy for cartilage regeneration.",
          "offsetInBeginSection": 418,
          "offsetInEndSection": 505,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30603587",
          "text": "BACKGROUND\nMesenchymal stem cells (MSCs) and/or biological scaffolds have been used to regenerate articular cartilage with variable success.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33628274",
          "text": "Regenerative medicine involving stem cells has entered a new stage and is considered the most promising way to regenerate articular cartilage.",
          "offsetInBeginSection": 249,
          "offsetInEndSection": 391,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29766656",
          "text": "Histologically, empty defects contained fibrous tissue; microbeads without cells were still present in defects and were surrounded by fibrous tissue; nondegradable beads with rbASCs initiated cartilage regeneration; degradable microbeads with cells produced immature bone-like tissue, also demonstrated by microCT; and autografts appeared as normal auricular cartilage but were not fully integrated with the tissue surrounding the defect.",
          "offsetInBeginSection": 1112,
          "offsetInEndSection": 1550,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32430067",
        "http://www.ncbi.nlm.nih.gov/pubmed/29766656",
        "http://www.ncbi.nlm.nih.gov/pubmed/28951745",
        "http://www.ncbi.nlm.nih.gov/pubmed/17473529",
        "http://www.ncbi.nlm.nih.gov/pubmed/17333068",
        "http://www.ncbi.nlm.nih.gov/pubmed/34993186",
        "http://www.ncbi.nlm.nih.gov/pubmed/19929469",
        "http://www.ncbi.nlm.nih.gov/pubmed/17851169",
        "http://www.ncbi.nlm.nih.gov/pubmed/26881220",
        "http://www.ncbi.nlm.nih.gov/pubmed/22784026"
      ]
    },
    {
      "id": "6429eb8457b1c7a31500000a",
      "type": "yesno",
      "body": "Is adenosine methylation an epigenetic modification?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25723394",
          "text": "es discriminating between methylated and unmethylated miRNAs. The epigenetic modification of an epigenetic modifier as described here adds a new layer",
          "offsetInBeginSection": 456,
          "offsetInEndSection": 606,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31188932",
          "text": "Methylation of the N6 position of adenosine (m6A) is a post-transcriptional epigenetic modification of RNA.",
          "offsetInBeginSection": 116,
          "offsetInEndSection": 223,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32961299",
          "text": "on the block: RNA adenosine methylation. This juxtaposition is indeed superficial, and a deep exploration toward the fundamental requirements for thes",
          "offsetInBeginSection": 163,
          "offsetInEndSection": 313,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22608085",
          "text": "Methylation of the N(6) position of adenosine (m(6)A) is a posttranscriptional modification of RNA with poorly understood prevalence and physiological relevance.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19175412",
          "text": "As a consequence, the methylation state of specific adenosine moieties can affect DNA-protein interactions.",
          "offsetInBeginSection": 673,
          "offsetInEndSection": 780,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23863710",
          "text": "These data demonstrate that pathological changes in DNA methylation homeostasis may underlie epileptogenesis and reversal of these epigenetic changes with adenosine augmentation therapy may halt disease progression.",
          "offsetInBeginSection": 1210,
          "offsetInEndSection": 1425,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32961299",
        "http://www.ncbi.nlm.nih.gov/pubmed/23863710",
        "http://www.ncbi.nlm.nih.gov/pubmed/25723394",
        "http://www.ncbi.nlm.nih.gov/pubmed/19175412",
        "http://www.ncbi.nlm.nih.gov/pubmed/31188932",
        "http://www.ncbi.nlm.nih.gov/pubmed/22608085"
      ]
    },
    {
      "id": "6440393157b1c7a31500004a",
      "type": "factoid",
      "body": "Which year was XIPERE approved by the FDA?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32927064",
          "text": "nistration (FDA) green-lighted the marketing of 53 therapeutic agents in 2019. This rate of approvals was consistent with the 5-year running average. ",
          "offsetInBeginSection": 25,
          "offsetInEndSection": 175,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32927064"
      ]
    },
    {
      "id": "64412c2757b1c7a315000055",
      "type": "yesno",
      "body": "Can breastfeeding be used to alleviate the procedural pain in neonates?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27420164",
          "text": "Control interventions included no treatment, water, glucose, breast milk, breastfeeding, local anaesthetic, pacifier, positioning/containing or acupuncture.",
          "offsetInBeginSection": 1448,
          "offsetInEndSection": 1604,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17661578",
          "text": " and oxygen saturation change compared to the placebo.\n\n\nCONCLUSIONS\nIf available, breastfeeding or breastmilk should be used to alleviate pain in neo",
          "offsetInBeginSection": 1326,
          "offsetInEndSection": 1476,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27792244",
          "text": "As the breastfeeding intervention cannot be blinded, we rated all studies as being at high risk of bias for blinding of participants and personnel.",
          "offsetInBeginSection": 3045,
          "offsetInEndSection": 3192,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16856069",
          "text": " or supplemental breast milk for pain relief.\n\n\nAUTHORS' CONCLUSIONS\nIf available, breastfeeding or breast milk should be used to alleviate procedural",
          "offsetInBeginSection": 3669,
          "offsetInEndSection": 3819,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23235618",
          "text": " or supplemental breast milk for pain relief.\n\n\nAUTHORS' CONCLUSIONS\nIf available, breastfeeding or breast milk should be used to alleviate procedural",
          "offsetInBeginSection": 4327,
          "offsetInEndSection": 4477,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31535510",
          "text": "Breast feeding reduces pain during minor painful procedures in neonates.",
          "offsetInBeginSection": 1166,
          "offsetInEndSection": 1238,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33664472",
          "text": "CONCLUSION\nSucrose 24% gel with non-nutritive sucking seems to be a valid alternative when breastfeeding is not possible.",
          "offsetInBeginSection": 855,
          "offsetInEndSection": 976,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21091580",
          "text": "RESULTS\nThere was a 21% overall improvement in the number of infants receiving breastfeeding or sucrose for procedural pain, however, breastfeeding rates remain poorly utilised.",
          "offsetInBeginSection": 772,
          "offsetInEndSection": 949,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22014760",
          "text": "Breastfeeding during blood collection did not reduce pain indices or interfere with the acquisition of breastfeeding skills.",
          "offsetInBeginSection": 1454,
          "offsetInEndSection": 1578,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31535510",
          "text": "breastfeeding is shorter than without breast feeding during BCG immunization. Breast feeding reduces pain during minor painful procedures in neonates.",
          "offsetInBeginSection": 1088,
          "offsetInEndSection": 1238,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29123341",
        "http://www.ncbi.nlm.nih.gov/pubmed/28904545",
        "http://www.ncbi.nlm.nih.gov/pubmed/33664472",
        "http://www.ncbi.nlm.nih.gov/pubmed/31535510",
        "http://www.ncbi.nlm.nih.gov/pubmed/21091580",
        "http://www.ncbi.nlm.nih.gov/pubmed/27792244",
        "http://www.ncbi.nlm.nih.gov/pubmed/23235618",
        "http://www.ncbi.nlm.nih.gov/pubmed/19851165",
        "http://www.ncbi.nlm.nih.gov/pubmed/18715388",
        "http://www.ncbi.nlm.nih.gov/pubmed/27420164"
      ]
    },
    {
      "id": "64042000201352f04a000020",
      "type": "yesno",
      "body": "Can lenacapavir be used for HIV?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34370418",
          "text": "Studies examining the resistance patterns of existing antiretroviral therapy (ART) agents were presented, as were resistance mechanisms of novel agents such as lenacapavir and resistance patterns among individuals who seroconverted while on preexposure prophylaxis.",
          "offsetInBeginSection": 878,
          "offsetInEndSection": 1143,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35495642",
          "text": "We inferred the p24 consensus sequence for HIV-1 and for each group to analyze the overall conservation in p24 main structural regions, reporting the percentage of substitutions per variant affecting the capsid assembly and molecule-binding, including those associated with resistance to the new capsid-inhibitor lenacapavir, and the key residues involved in lenacapavir-p24 interaction, according to the bibliography.",
          "offsetInBeginSection": 967,
          "offsetInEndSection": 1385,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35495642",
          "text": " region among the 4 HIV-1 groups and group M variants, revealing no natural resistance to lenacapavir in any HIV-1 variant. We present a thorough anal",
          "offsetInBeginSection": 1964,
          "offsetInEndSection": 2114,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33625040",
          "text": "ly being tested in phase 2-3 clinical trials; if successful, this may allow six-monthly dosing schedules.\n\n\nSUMMARY\nHowever, despite evidence that sug",
          "offsetInBeginSection": 657,
          "offsetInEndSection": 807,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33337617",
          "text": "ly being tested in phase 2-3 clinical trials; if successful, this may allow six-monthly dosing schedules.\n\n\nSUMMARY\nHowever, despite evidence that sug",
          "offsetInBeginSection": 657,
          "offsetInEndSection": 807,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35544387",
          "text": "CONCLUSIONS\nIn patients with multidrug-resistant HIV-1 infection, those who received lenacapavir had a greater reduction from baseline in viral load than those who received placebo.",
          "offsetInBeginSection": 2235,
          "offsetInEndSection": 2416,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36082606",
          "text": "BACKGROUND\nLenacapavir (LEN) is a first-in-class inhibitor of human immunodeficiency virus type 1 (HIV-1) capsid function in clinical development for the treatment of heavily treatment-experienced (HTE) people with HIV (PWH) harboring multidrug resistance (MDR) in combination with an optimized background regimen (OBR).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 320,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34871187",
          "text": "SUMMARY\nOngoing studies are evaluating long-acting dosing of lenacapavir for treating HIV-1 in combination with other antiretrovirals and preventing HIV-1 as a single agent.",
          "offsetInBeginSection": 845,
          "offsetInEndSection": 1018,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35746673",
          "text": "Therefore, we sought to determine whether combination of lenacapavir with islatravir, rilpivirine, or cabotegravir displayed synergy, additivity, or antagonism.",
          "offsetInBeginSection": 535,
          "offsetInEndSection": 695,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34742581",
          "text": "In this review, we provide an overview on currently available anti-HIV drugs and the latest developments in antiretroviral therapy, focused on new antiretroviral agents acting on known and unexploited antiviral targets, prevention therapies aimed to improve available drug combinations, and research on new long-acting therapies, particularly those involving novel drug candidates such as lenacapavir or islatravir.",
          "offsetInBeginSection": 432,
          "offsetInEndSection": 847,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36082606",
        "http://www.ncbi.nlm.nih.gov/pubmed/34742581",
        "http://www.ncbi.nlm.nih.gov/pubmed/35544387",
        "http://www.ncbi.nlm.nih.gov/pubmed/33337617",
        "http://www.ncbi.nlm.nih.gov/pubmed/33625040",
        "http://www.ncbi.nlm.nih.gov/pubmed/35746673",
        "http://www.ncbi.nlm.nih.gov/pubmed/35495642",
        "http://www.ncbi.nlm.nih.gov/pubmed/34370418",
        "http://www.ncbi.nlm.nih.gov/pubmed/34871187"
      ]
    },
    {
      "id": "6415b3b4690f196b51000009",
      "type": "factoid",
      "body": "What color light does the the inhibitory receptor halorhodopsin (eNpHR) respond to?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28650460",
          "text": "By using Cal-Light to drive expression of the inhibitory receptor halorhodopsin (eNpHR), which responds to yellow light, we temporarily inhibit the lever-pressing behavior, confirming that the labeled neurons mediate the behavior.",
          "offsetInBeginSection": 661,
          "offsetInEndSection": 891,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30948823",
          "text": "fy the first channelrhodopsins as well as a halorhodopsin that respond to red light in the peripheral nerve. Combining two channelrhodopsins with spec",
          "offsetInBeginSection": 500,
          "offsetInEndSection": 650,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21483674",
          "text": " retino-tectal pathway. We introduced enhanced halorhodopsin (eNpHR), a yellow light-sensitive, membrane-targeting chloride pump, into mouse retinal g",
          "offsetInBeginSection": 441,
          "offsetInEndSection": 591,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22441034",
          "text": "The eNpHR-expressing PCs were then illuminated by orange laser (593 nm) either during 30\u00b0 head-up or 30\u00b0 head-down tilts.",
          "offsetInBeginSection": 1327,
          "offsetInEndSection": 1448,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21483674",
          "text": "Several weeks after the injection, whole-cell recordings made from sSC neurons in slice preparations revealed that yellow laser illumination of the eNpHR-expressing retino-tectal axons, putatively synapsing onto the recorded cells, effectively inhibited EPSCs evoked by electrical stimulation of the optic nerve layer.",
          "offsetInBeginSection": 724,
          "offsetInEndSection": 1042,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21850224",
          "text": " ChR2-transduced rats increased frequency of simple spike in response to blue laser illumination. Similarly, most light-responsive PCs (93.8%) in eNpH",
          "offsetInBeginSection": 901,
          "offsetInEndSection": 1051,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6746588",
          "text": "Halorhodopsin in the membrane fragments of Halobacterium halobium Y1 showed an absorption band at 576 nm, the intensity of which decreased on irradiation with red light at 0 degrees C (Ogurusu, T., Maeda, A., Sasaki, N., & Yoshizawa, T. (1981) J. Biochem.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 255,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21925140",
          "text": "The expressed HsHR had no color in the E. coli membrane, but turned purple after solubilization in the presence of all-trans retinal.",
          "offsetInBeginSection": 156,
          "offsetInEndSection": 289,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/6746588",
        "http://www.ncbi.nlm.nih.gov/pubmed/21925140",
        "http://www.ncbi.nlm.nih.gov/pubmed/21850224",
        "http://www.ncbi.nlm.nih.gov/pubmed/21483674",
        "http://www.ncbi.nlm.nih.gov/pubmed/22441034",
        "http://www.ncbi.nlm.nih.gov/pubmed/30948823",
        "http://www.ncbi.nlm.nih.gov/pubmed/28650460"
      ]
    },
    {
      "id": "6429fad757b1c7a31500000e",
      "type": "factoid",
      "body": "What regulatory element promotes RNA polymerase II binding as well as the binding of factors that facilitate the unwinding of DNA prior to translation?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17994103",
          "text": "The general transcription factors (GTFs) of eukaryotic RNA polymerase II, in a process facilitated by regulatory and accessory factors, target promoters through synergistic interactions with core elements.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 205,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19292868",
          "text": "Furthermore, we found evidence of sterol-regulated binding of SREBP-1 and RNA polymerase II to HCFC1 and FLNA.",
          "offsetInBeginSection": 1074,
          "offsetInEndSection": 1184,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11758455",
          "text": "ing of the remaining GTFs, RNA polymerase II and associated regulatory proteins. Activators function to increase binding of the transcription machiner",
          "offsetInBeginSection": 490,
          "offsetInEndSection": 640,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18286208",
          "text": "We propose that these parameters, more than transcription or RNA polymerase II binding, determine the maintenance of long-range DNA interactions.",
          "offsetInBeginSection": 997,
          "offsetInEndSection": 1142,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26486725",
          "text": "Recent studies have identified promoter-distal RNA polymerase II (RNAP2) binding at enhancer elements, suggesting that these interactions may serve as a marker for active regulatory sequences.",
          "offsetInBeginSection": 401,
          "offsetInEndSection": 593,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8565069",
          "text": "contains RNA polymerase II, a subset of general transcription factors and SRB regulatory proteins. We report here that SWI and SNF gene products, prev",
          "offsetInBeginSection": 33,
          "offsetInEndSection": 183,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3027566",
          "text": "exerted by cis-acting regulatory DNA elements classified as promoter and enhancer sequences. These elements are composed of a number of different prot",
          "offsetInBeginSection": 91,
          "offsetInEndSection": 241,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9113125",
          "text": "Pol III synthesize ribosomal RNA and various small RNAs, respectively. Enhancer is another class of cis-element for Pol II to which transcription regu",
          "offsetInBeginSection": 502,
          "offsetInEndSection": 652,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8133894",
          "text": "unts of RNA polymerase II, a subset of general transcription factors, and SRB regulatory proteins. Transcription by this holoenzyme is stimulated by t",
          "offsetInBeginSection": 673,
          "offsetInEndSection": 823,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8413225",
          "text": "nable it to form a complex with promoter-bound TFIID. The protease-susceptible amino terminus appears to contain components responsible for direct int",
          "offsetInBeginSection": 627,
          "offsetInEndSection": 777,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26486725",
        "http://www.ncbi.nlm.nih.gov/pubmed/9113125",
        "http://www.ncbi.nlm.nih.gov/pubmed/17994103",
        "http://www.ncbi.nlm.nih.gov/pubmed/26089518",
        "http://www.ncbi.nlm.nih.gov/pubmed/14744435",
        "http://www.ncbi.nlm.nih.gov/pubmed/8006019",
        "http://www.ncbi.nlm.nih.gov/pubmed/24453987",
        "http://www.ncbi.nlm.nih.gov/pubmed/8565069",
        "http://www.ncbi.nlm.nih.gov/pubmed/18286208",
        "http://www.ncbi.nlm.nih.gov/pubmed/3027566"
      ]
    },
    {
      "id": "64402e7757b1c7a315000044",
      "type": "factoid",
      "body": "How many patients with Friedreich's ataxia were included in each cohort of the phase I/II double-blind, comparator-controlled trial of RT001.",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3465425",
          "text": "Vigabatrin (gamma-vinyl GABA; GVG), an irreversible inhibitor of GABA-transaminase, at a daily dose of 2-4 g, and a placebo were each administered orally for 4 months to 14 patients with cerebellar ataxia (9 with Friedreich's ataxia, 5 with olivopontocerebellar atrophy), in a double-blind, placebo-controlled crossover study.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 326,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8795596",
          "text": "OBJECTIVE\nA group of 27 patients with Friedreich's ataxia and another group of 30 patients with olivopontocerebellar atrophies were each randomly divided into two subgroups, one receiving placebo and the other amantadine hydrochloride (AH; 200 mg daily) for three to four months.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 279,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19384216",
          "text": "the placebo group and time to death was significantly shorter. A total of 214 patients (147 male) were included in the trial, mean age 59 years (range",
          "offsetInBeginSection": 1292,
          "offsetInEndSection": 1442,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7229661",
          "text": "nd crossover trial in 20 patients with ataxia. These patients, who include 7 with Friedreich's ataxia, 7 with mixed spinocerebellar ataxia and 6 will ",
          "offsetInBeginSection": 149,
          "offsetInEndSection": 299,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26321318",
          "text": "h's ataxia in the riluzole group, and 19 with spinocerebellar ataxia and eight with Friedreich's ataxia in the placebo group). The proportion with dec",
          "offsetInBeginSection": 1306,
          "offsetInEndSection": 1456,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29624723",
          "text": "or-controlled trial with 2 doses of RT001 in Friedreich's ataxia patients (9 subjects each cohort). Subjects were randomized 2:1 to receive either RT0",
          "offsetInBeginSection": 403,
          "offsetInEndSection": 553,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7733838",
          "text": "ective follow-up study at two university hospitals.\n\n\nPATIENTS\nWe studied 19 patients with Friedreich's ataxia, 13 with cerebellar atrophy, and seven ",
          "offsetInBeginSection": 411,
          "offsetInEndSection": 561,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15480852",
          "text": "We performed a placebo-controlled triple-phase crossover trial of L-carnitine (3 g/d) and creatine (6.75 g/d) in 16 patients with genetically confirmed FA.",
          "offsetInBeginSection": 198,
          "offsetInEndSection": 353,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7733839",
          "text": "s placebo.\n\n\nSETTING\nTwelve centers in research hospitals.\n\n\nPATIENTS\nTwenty-six patients were included; 19 completed the study (mean +/- SD age of pa",
          "offsetInBeginSection": 218,
          "offsetInEndSection": 368,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12368988",
          "text": "patients with Friedreich's ataxia.\n\n\nMETHODS\n\n\n\nDESIGN\nopen-label trial. Nine Friedreich's ataxia patients (age range 11 - 19 years) were treated with",
          "offsetInBeginSection": 130,
          "offsetInEndSection": 280,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27839651",
        "http://www.ncbi.nlm.nih.gov/pubmed/15480852",
        "http://www.ncbi.nlm.nih.gov/pubmed/12368988",
        "http://www.ncbi.nlm.nih.gov/pubmed/7229661",
        "http://www.ncbi.nlm.nih.gov/pubmed/29624723",
        "http://www.ncbi.nlm.nih.gov/pubmed/3465425",
        "http://www.ncbi.nlm.nih.gov/pubmed/19384216",
        "http://www.ncbi.nlm.nih.gov/pubmed/7733839",
        "http://www.ncbi.nlm.nih.gov/pubmed/7733838",
        "http://www.ncbi.nlm.nih.gov/pubmed/8795596"
      ]
    },
    {
      "id": "64425ce357b1c7a315000059",
      "type": "factoid",
      "body": "What is the incidence of Facioscapulohumeral Muscular Dystrophy?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10655933",
          "text": "phy (FSHD), an autosomal dominant disorder with an incidence of 10-20 cases per million. In this patient, sensitivity to an initial dose of vecuronium",
          "offsetInBeginSection": 187,
          "offsetInEndSection": 337,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2299071",
          "text": "strophy is an autosomal dominant disorder with an incidence of 3 to 10 cases per million. The only type of cardiac involvement ascribed to this neurom",
          "offsetInBeginSection": 31,
          "offsetInEndSection": 181,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8614537",
          "text": "n with facioscapulohumeral muscular dystrophy who had congenital anomalies and mental retardation. Southern blot analysis, using the probe p13E-11, di",
          "offsetInBeginSection": 26,
          "offsetInEndSection": 176,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3728255",
          "text": "dystrophy is similar to but milder than Duchenne muscular dystrophy. The rare facioscapulohumeral muscular dystrophy has an autosomal dominant mode of",
          "offsetInBeginSection": 168,
          "offsetInEndSection": 318,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21496633",
          "text": "e, with a prevalence of around 4 per 100000 and an incidence of about 1 in 20000. Overall lifespan is not affected significantly. The scapuloperoneal ",
          "offsetInBeginSection": 193,
          "offsetInEndSection": 343,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17986494",
          "text": "Facioscapulohumeral dystrophy (FSHD) is the third most common inherited muscular dystrophy after Duchenne dystrophy and myotonic dystrophy.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3472424",
          "text": "The age-adjusted prevalence rates, on 31 December 1985, per 100,000 population were 6 for Duchenne dystrophy, 3.7 for limb-girdle dystrophy, 0.8 for facioscapulohumeral dystrophy, 0.6 for opthalmoplegia-plus and 7.9 for HMSN (6.4 and 1.5 for Types I and II, respectively).",
          "offsetInBeginSection": 452,
          "offsetInEndSection": 724,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9098670",
          "text": "Twelve patients with a scapuloperoneal syndrome were investigated and compared with seventeen patients with facioscapulohumeral dystrophy.",
          "offsetInBeginSection": 296,
          "offsetInEndSection": 434,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16508966",
          "text": "Although FSHD is considered a relatively benign dystrophy by some, as many as 20% of patients eventually become wheelchair-bound.",
          "offsetInBeginSection": 509,
          "offsetInEndSection": 638,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32703466",
          "text": "Facioscapulohumeral muscular dystrophy is the second most common adult muscular dystrophy and is caused by DUX4 protein.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35791708",
        "http://www.ncbi.nlm.nih.gov/pubmed/25156185",
        "http://www.ncbi.nlm.nih.gov/pubmed/6593433",
        "http://www.ncbi.nlm.nih.gov/pubmed/24250856",
        "http://www.ncbi.nlm.nih.gov/pubmed/8614537",
        "http://www.ncbi.nlm.nih.gov/pubmed/12868502",
        "http://www.ncbi.nlm.nih.gov/pubmed/11761483",
        "http://www.ncbi.nlm.nih.gov/pubmed/9098670",
        "http://www.ncbi.nlm.nih.gov/pubmed/2299071",
        "http://www.ncbi.nlm.nih.gov/pubmed/17986494"
      ]
    },
    {
      "id": "63f581e933942b094c000007",
      "type": "factoid",
      "body": "Risdiplam is used for treatment of which disease?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34620695",
          "text": "l of motor neuron 2 mRNA splicing modifier for the treatment of spinal muscular atrophy. The approach taken to characterize the absorption, distributi",
          "offsetInBeginSection": 1701,
          "offsetInEndSection": 1851,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33919699",
          "text": "Recently, a small-molecule splicing modifier, risdiplam, was also approved for the treatment of SMA, highlighting small molecules as important warheads in the arsenal for regulating RNA splicing.",
          "offsetInBeginSection": 555,
          "offsetInEndSection": 750,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35567422",
          "text": "These safety data provide further support for the use of risdiplam in the treatment of adult and pediatric patients with SMA.",
          "offsetInBeginSection": 1543,
          "offsetInEndSection": 1668,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36244364",
          "text": "motor neuron 2 (SMN2) gene and is approved for the treatment of spinal muscular atrophy. The FIREFISH study is investigating the safety and efficacy o",
          "offsetInBeginSection": 106,
          "offsetInEndSection": 256,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35352647",
          "text": "isdiplam, three gene therapeutic drugs are available for the treatment of SMA showing improvement in motor function. But in the pivotal studies, sever",
          "offsetInBeginSection": 703,
          "offsetInEndSection": 853,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30302786",
          "text": "Based on these data, Phase 2/3 studies of risdiplam in patients with SMA are now ongoing.",
          "offsetInBeginSection": 1498,
          "offsetInEndSection": 1587,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34620695",
          "text": "ines Agency for the treatment of patients \u22652 months of age with spinal muscular atrophy-is presented here as a case study. Risdiplam is a low-turnover",
          "offsetInBeginSection": 659,
          "offsetInEndSection": 809,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34942136",
          "text": "BACKGROUND\nRisdiplam is an oral small molecule approved for the treatment of patients with spinal muscular atrophy, with approval for use in patients with type 2 and type 3 spinal muscular atrophy granted on the basis of unpublished data.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 238,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35040693",
          "text": "comparisons between risdiplam and other approved treatments for spinal muscular atrophy (SMA). Patients & methods: Individual patient data from risdip",
          "offsetInBeginSection": 35,
          "offsetInEndSection": 185,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34368854",
          "text": "These studies indicate that drugs such as risdiplam will be optimally therapeutic when given as early as possible after diagnosis and potentially will be required for the life of an SMA patient.",
          "offsetInBeginSection": 1373,
          "offsetInEndSection": 1567,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36157294",
        "http://www.ncbi.nlm.nih.gov/pubmed/33919699",
        "http://www.ncbi.nlm.nih.gov/pubmed/36103897",
        "http://www.ncbi.nlm.nih.gov/pubmed/30302786",
        "http://www.ncbi.nlm.nih.gov/pubmed/36382958",
        "http://www.ncbi.nlm.nih.gov/pubmed/33892848",
        "http://www.ncbi.nlm.nih.gov/pubmed/32419578",
        "http://www.ncbi.nlm.nih.gov/pubmed/34347881",
        "http://www.ncbi.nlm.nih.gov/pubmed/30044619",
        "http://www.ncbi.nlm.nih.gov/pubmed/33098622"
      ]
    },
    {
      "id": "641c5201690f196b51000040",
      "type": "list",
      "body": "Please list the diseases associated with elevations in the plasma Neurofilament Light chain (NfL).",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35750882",
          "text": "ker of disease severity in many neurological disorders, including infectious diseases. So far NfL has not been assessed in cerebral malaria in human o",
          "offsetInBeginSection": 108,
          "offsetInEndSection": 258,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34480363",
          "text": "bstantially (Spearman r\u00a0=\u00a00.64, P\u2009<\u20090.001); NfL was highest in neurocognitive disorders. PD participants with high plasma NfL were more likely to deve",
          "offsetInBeginSection": 889,
          "offsetInEndSection": 1039,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35750882",
        "http://www.ncbi.nlm.nih.gov/pubmed/34480363"
      ]
    },
    {
      "id": "643c183b57b1c7a31500002c",
      "type": "list",
      "body": "What are the most common assays to profile chromatin accessibility?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10435575",
          "text": "ctivation of V(D)J recombination. Here, we used a combination of in vitro and in vivo assays to explore the mechanisms that regulate immunoglobulin mu",
          "offsetInBeginSection": 105,
          "offsetInEndSection": 255,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30598689",
          "text": "ibility at promoter regions is strongly associated with transcription and active histone marks. However, root-specific chromatin accessibility is prim",
          "offsetInBeginSection": 2053,
          "offsetInEndSection": 2203,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27008018",
          "text": "DNase-seq and the more recent ATAC-seq are two assays that are gaining popularity.",
          "offsetInBeginSection": 688,
          "offsetInEndSection": 770,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32912294",
          "text": "Genome-wide chromatin accessibility and histone modification assays are commonly used as a proxy for identifying putative enhancers and for describing their activity levels and dynamics.",
          "offsetInBeginSection": 302,
          "offsetInEndSection": 488,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26846207",
          "text": "considered an informative proxy for protein-DNA interactions. DNase I and Tn5 transposase assays require thousands to millions of fresh cells for comp",
          "offsetInBeginSection": 83,
          "offsetInEndSection": 233,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25827879",
          "text": "ival and disease, most assays of chromatin structure recover only population averages. We have developed DNA methyltransferases (MTases) as probing ag",
          "offsetInBeginSection": 196,
          "offsetInEndSection": 346,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32604817",
          "text": "We present an overview of the most used approaches to generate data on chromatin accessibility and then focus on emerging methods that utilize mass spectrometry to quantify the accessibility of histones and the rest of the chromatin bound proteome.",
          "offsetInBeginSection": 621,
          "offsetInEndSection": 869,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35906698",
          "text": "dentified distinct patterns of genome-wide chromatin accessibility in ILC and IDC. Inferred patient-specific transcription factor (TF) motif activitie",
          "offsetInBeginSection": 669,
          "offsetInEndSection": 819,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29982337",
          "text": "Assay of Transposase-Accessible Chromatin by deep sequencing (ATAC-seq) has been widely used to profile the chromatin accessibility genome-wide.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25849986",
          "text": "We observed thousands of chromatin accessibility changes as CGNs differentiated, and verified, using H3K27ac ChIP-seq, reporter gene assays and CRISPR-mediated activation, that many of these regions function as neuronal enhancers.",
          "offsetInBeginSection": 371,
          "offsetInEndSection": 601,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/10435575",
        "http://www.ncbi.nlm.nih.gov/pubmed/33125076",
        "http://www.ncbi.nlm.nih.gov/pubmed/30598689",
        "http://www.ncbi.nlm.nih.gov/pubmed/27008018",
        "http://www.ncbi.nlm.nih.gov/pubmed/29982337",
        "http://www.ncbi.nlm.nih.gov/pubmed/26846207",
        "http://www.ncbi.nlm.nih.gov/pubmed/35906698",
        "http://www.ncbi.nlm.nih.gov/pubmed/28538187",
        "http://www.ncbi.nlm.nih.gov/pubmed/27398095",
        "http://www.ncbi.nlm.nih.gov/pubmed/32912294"
      ]
    },
    {
      "id": "64402f6f57b1c7a315000045",
      "type": "list",
      "body": "What doses of RT001 were used in the phase I/II double-blind, comparator-controlled trial of Friedreich's ataxia patients?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29624723",
          "text": "DESIGN/METHODS\nWe conducted a phase I/II double-blind, comparator-controlled trial with 2 doses of RT001 in Friedreich's ataxia patients (9 subjects each cohort).",
          "offsetInBeginSection": 340,
          "offsetInEndSection": 502,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29624723",
          "text": "Subjects were randomized 2:1 to receive either RT001 (1.8 or 9.0 g/day), or a matching dose of nondeuterated ethyl linoleate as comparator for 28 days.",
          "offsetInBeginSection": 503,
          "offsetInEndSection": 654,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35765222",
          "text": "RESULTS\nSixteen participants received RT001 (5.6\u2009\u00b1\u20091.6 g/day; dose range, 1.92 to 8.64\u2009g/day) for a mean period of 10.8\u2009\u00b1\u20097.1\u00a0months.",
          "offsetInBeginSection": 699,
          "offsetInEndSection": 832,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29624723",
        "http://www.ncbi.nlm.nih.gov/pubmed/35765222"
      ]
    },
    {
      "id": "6440f85c57b1c7a315000051",
      "type": "list",
      "body": "What are the most common pain scales used to measure pain in neonates?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36291504",
          "text": "A cornerstone in pain assessment is the use of scales such as COMFORT, PIPP-R, NIPS and N-PASS.",
          "offsetInBeginSection": 427,
          "offsetInEndSection": 522,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26553356",
          "text": "INTRODUCTION\nClinical scales are currently the best method to assess pain in the neonate, given the impossibility of self-report in this age group.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19005869",
          "text": "Pain was measured by three pain assessment tools (Bernese Pain Scale for Neonates, Premature Infant Pain Profile and Visual Analogue Scale)\n\n\nRESULTS\nMorphine did not lead to any pain relief from ETS as measured by three pain scales.",
          "offsetInBeginSection": 782,
          "offsetInEndSection": 1015,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31947346",
          "text": "Neonatal pain assessment has gained more and more attention from clinical care, and pain scales are usually adopted as the main assistants for neonatal pain rankings.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17905184",
          "text": "n caregivers to assess and manage pain on their behalf. Behavioral and physiological indicators, often used in pain assessment in this population, are",
          "offsetInBeginSection": 114,
          "offsetInEndSection": 264,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31513054",
          "text": "dings were coded using 5 observational pain assessment tools and numeric rating scales for pain and distress. We simultaneously collected heart rate, ",
          "offsetInBeginSection": 614,
          "offsetInEndSection": 764,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18446656",
          "text": "RESULTS\nThe highest correlation between the crying time and each of the three different neonatal pain scales was found for NIPS (r = 0.74, p<0.001), while similar results were found for the DAN scale (r = 0.67, p <0.001) and the NFCS (r = 0.67, p<0.001).",
          "offsetInBeginSection": 723,
          "offsetInEndSection": 977,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18368832",
          "text": "e most common manipulation in hospital units. Pain control using the rating scales for neonatal acute pain and its analgesia are necessary as the cons",
          "offsetInBeginSection": 40,
          "offsetInEndSection": 190,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29945293",
          "text": "se of the Premature Infant Pain Profile-Revised. The Neonatal Pain, Agitation, and Sedation Scale was mostly preferred by 55.9% of the nurses, followe",
          "offsetInBeginSection": 1783,
          "offsetInEndSection": 1933,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26474183",
          "text": "atient's report on the pain sensation. Verbal scales, visual analog scales (VAS) or numeric rating scales (NRS) count among the most common tools, whi",
          "offsetInBeginSection": 141,
          "offsetInEndSection": 291,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25756556",
        "http://www.ncbi.nlm.nih.gov/pubmed/31513054",
        "http://www.ncbi.nlm.nih.gov/pubmed/18446656",
        "http://www.ncbi.nlm.nih.gov/pubmed/29282767",
        "http://www.ncbi.nlm.nih.gov/pubmed/31947346",
        "http://www.ncbi.nlm.nih.gov/pubmed/27607517",
        "http://www.ncbi.nlm.nih.gov/pubmed/30534623",
        "http://www.ncbi.nlm.nih.gov/pubmed/19005869",
        "http://www.ncbi.nlm.nih.gov/pubmed/17905184",
        "http://www.ncbi.nlm.nih.gov/pubmed/36291504"
      ]
    },
    {
      "id": "6402c3fd201352f04a000009",
      "type": "yesno",
      "body": "Was prehospital transdermal glyceryl trinitrate effective for stroke in the RIGHT-2 trial?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36058230",
          "text": "l group (adjusted OR 0\u00b787 [0\u00b718-4\u00b717]).\n\n\nINTERPRETATION\nWe found no sign of benefit of transdermal glyceryl trinitrate started within 3 h of symptom ",
          "offsetInBeginSection": 3464,
          "offsetInEndSection": 3614,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25465108",
          "text": "rate lowered blood pressure and had acceptable safety but did not improve functional outcome. We show no evidence to support continuing prestroke anti",
          "offsetInBeginSection": 2022,
          "offsetInEndSection": 2172,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31973594",
          "text": "However, in a large prehospital trial with treatment within 4 h, GTN did not influence clinical outcomes.Expert opinion: Transdermal GTN is an easy to administer BP-lowering therapy, which is safe when given after 2 h of stroke onset, may improve outcome when initiated within 2-6 h, but should be avoided (outside of a clinical trial) in the ultra-acute period within 2 h of stroke onset.",
          "offsetInBeginSection": 793,
          "offsetInEndSection": 1182,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9014793",
          "text": "CONCLUSIONS\nTransdermal glyceryl trinitrate (10 mg per day), unlike intracoronary glyceryl trinitrate, did not alleviate the myocardial ischaemia produced by balloon inflation during coronary angioplasty.",
          "offsetInBeginSection": 1569,
          "offsetInEndSection": 1773,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8096389",
          "text": "CONCLUSIONS\nIntermittent transdermal treatment with glyceryl trinitrate is not associated with the rebound phenomenon in patients maintained on beta blockers for stable angina pectoris.",
          "offsetInBeginSection": 1337,
          "offsetInEndSection": 1522,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24003041",
          "text": "ng) for 7 days with the first dose given by paramedics. The primary outcome was SBP at 2 hours.\n\n\nRESULTS\nOf a planned 80 patients, 41 (25 GTN, 16 no ",
          "offsetInBeginSection": 561,
          "offsetInEndSection": 711,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1909152",
          "text": "increase during intermittent treatment.\n\n\nCONCLUSION\nTolerance to glyceryl trinitrate was avoided by the use of individually titrated doses administer",
          "offsetInBeginSection": 1632,
          "offsetInEndSection": 1782,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/8096389",
        "http://www.ncbi.nlm.nih.gov/pubmed/25465108",
        "http://www.ncbi.nlm.nih.gov/pubmed/9014793",
        "http://www.ncbi.nlm.nih.gov/pubmed/36058230",
        "http://www.ncbi.nlm.nih.gov/pubmed/31973594",
        "http://www.ncbi.nlm.nih.gov/pubmed/24003041",
        "http://www.ncbi.nlm.nih.gov/pubmed/1909152"
      ]
    },
    {
      "id": "6431f7de57b1c7a31500001b",
      "type": "factoid",
      "body": "What gene is mutated in Friedreich's ataxia?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17659792",
          "text": "able expansion of GAA repeats in the first intron of the gene encoding frataxin on chromosome 9 (9q13). We reported a case of hypertrophic cardiomyopa",
          "offsetInBeginSection": 153,
          "offsetInEndSection": 303,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30624801",
          "text": "BACKGROUND\nFriedreich's ataxia is an autosomal-recessive cerebellar ataxia caused by mutation of the frataxin gene, resulting in decreased frataxin expression, mitochondrial dysfunction, and oxidative stress.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 208,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12174969",
          "text": "een described as a feature of the disease. The association between the frataxin gene mutation and mitochondrial myopathy in this case suggests that se",
          "offsetInBeginSection": 582,
          "offsetInEndSection": 732,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11748752",
          "text": "d for the clinical presentation of FA and for the presence of the mutated FA gene. The relationship of the expanded gene sequence to the severity of d",
          "offsetInBeginSection": 552,
          "offsetInEndSection": 702,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9241270",
          "text": "Friedreich's ataxia is due to loss of function mutations in the gene encoding frataxin (FRDA).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 94,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12420100",
          "text": "The molecular analysis showed that the affected individuals were homozygous for the mutation in the X25 gene, characteristic of Friedreich's ataxia.",
          "offsetInBeginSection": 182,
          "offsetInEndSection": 330,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8815938",
          "text": "BACKGROUND\nFriedreich's ataxia, the most common inherited ataxia, is associated with a mutation that consists of an unstable expansion of GAA repeats in the first intron of the frataxin gene on chromosome 9, which encodes a protein of unknown function.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 252,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9271239",
          "text": "Deletion of YDL120, the yeast homologue of the human gene responsible for Friedreich's ataxia, elicits decreased cellular respiration associated with decreased cytochrome c oxidase activity and, in certain nuclear backgrounds, mitochondrial DNA is lost.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 253,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9448568",
          "text": "In contrast, in one family with typical Friedreich's ataxia phenotype we did not find an expanded allele; this suggests that there can be either point mutations in the X25 gene on both chromosomes or locus heterogeneity in Friedreich's ataxia.",
          "offsetInBeginSection": 978,
          "offsetInEndSection": 1221,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11111058",
          "text": "The commonest mutation causing this disorder is an expanded GAA repeat in the gene for this protein.",
          "offsetInBeginSection": 709,
          "offsetInEndSection": 809,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/9271239",
        "http://www.ncbi.nlm.nih.gov/pubmed/9241270",
        "http://www.ncbi.nlm.nih.gov/pubmed/12174969",
        "http://www.ncbi.nlm.nih.gov/pubmed/8815938",
        "http://www.ncbi.nlm.nih.gov/pubmed/11111058",
        "http://www.ncbi.nlm.nih.gov/pubmed/9448568",
        "http://www.ncbi.nlm.nih.gov/pubmed/12420100",
        "http://www.ncbi.nlm.nih.gov/pubmed/23935342",
        "http://www.ncbi.nlm.nih.gov/pubmed/11748752",
        "http://www.ncbi.nlm.nih.gov/pubmed/30624801"
      ]
    },
    {
      "id": "643ff48a57b1c7a31500003d",
      "type": "yesno",
      "body": "Is omaveloxolone a suppressor of Nrf2?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24322982",
          "text": "Cell-based and in vitro biochemical analyses demonstrated that despite its inability to suppress NRF2 activity, the R320Q \"superbinder\" mutant maintained the ability to ubiquitinate NRF2.",
          "offsetInBeginSection": 1043,
          "offsetInEndSection": 1230,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30656180",
          "text": "Omaveloxolone, an Nrf2 activator and NF-kB suppressor, targets dysfunctional inflammatory, metabolic, and bioenergetic pathways.",
          "offsetInBeginSection": 194,
          "offsetInEndSection": 322,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32986742",
          "text": "tivate or suppress NRF2, respectively, most of which have not been previously reported to modulate NRF2 activity. Using a NRF2-responsive reporter gen",
          "offsetInBeginSection": 1411,
          "offsetInEndSection": 1561,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17602169",
          "text": "To explore whether Nrf2 and the tumor suppressor p53 cooperatively act in tumor prevention, we investigated the susceptibility of Nrf2-/-::p53+/- mice to BBN-induced urinary bladder carcinogenesis.",
          "offsetInBeginSection": 251,
          "offsetInEndSection": 448,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36032663",
          "text": "Omaveloxolone (RTA408) is a second-generation oleanane triterpenoid Nrf2 inducer with antioxidant and anti-inflammatory properties and was reported to improve mitochondrial bioenergetics.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 187,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30656180",
        "http://www.ncbi.nlm.nih.gov/pubmed/36032663",
        "http://www.ncbi.nlm.nih.gov/pubmed/17602169",
        "http://www.ncbi.nlm.nih.gov/pubmed/32986742",
        "http://www.ncbi.nlm.nih.gov/pubmed/24322982"
      ]
    },
    {
      "id": "64410f8057b1c7a315000054",
      "type": "yesno",
      "body": "Can salivary cortisol be used to evaluate pain in neonates?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15919580",
          "text": "es, 30 min after awakening and 12h later. The salivary cortisol levels were quantified by enzyme immunoassay. The recent use of glucocorticoids in the",
          "offsetInBeginSection": 598,
          "offsetInEndSection": 748,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18948108",
          "text": " human-animal interactions in dogs and other species. While it can be a very useful measure, there are a number of saliva collection issues made evide",
          "offsetInBeginSection": 122,
          "offsetInEndSection": 272,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19183121",
          "text": "nt Pain Profile (PIPP) and the Visual Analogue Scale (VAS). Salivary cortisol was analysed.\n\n\nRESULTS\n72-94% of the variability was within-subject var",
          "offsetInBeginSection": 486,
          "offsetInEndSection": 636,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15115248",
          "text": "The possible interference of sweet solutions with the measurement of salivary cortisol has not yet been documented.",
          "offsetInBeginSection": 577,
          "offsetInEndSection": 692,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30612596",
          "text": "rom the cot into the transport incubator.\n\n\nCONCLUSIONS\nSalivary cortisol values were variable. Behavioural measurement of stress provided a more sens",
          "offsetInBeginSection": 1589,
          "offsetInEndSection": 1739,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19183121",
        "http://www.ncbi.nlm.nih.gov/pubmed/15115248",
        "http://www.ncbi.nlm.nih.gov/pubmed/18948108",
        "http://www.ncbi.nlm.nih.gov/pubmed/15919580",
        "http://www.ncbi.nlm.nih.gov/pubmed/30612596"
      ]
    },
    {
      "id": "6402c0d5201352f04a000008",
      "type": "yesno",
      "body": "Does nintedanib improve response rate in patients with bladder cancer?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30010751",
          "text": "Median follow-up was 13.4\u2009months (interquartile range 11.1-15.7). OS was not improved [median OS 6.4\u2009months with nintedanib versus 6.0\u2009months with pla",
          "offsetInBeginSection": 1195,
          "offsetInEndSection": 1345,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32193228",
          "text": "CONCLUSIONS\nAlthough tolerated, neoadjuvant nintedanib plus chemotherapy did not increase MPR rate compared with chemotherapy historical controls.",
          "offsetInBeginSection": 1449,
          "offsetInEndSection": 1595,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25312396",
          "text": "There were zero complete and three partial responses for an overall response rate of 9.4% (90% 2-sided CI=2.6-22.5%).",
          "offsetInBeginSection": 870,
          "offsetInEndSection": 987,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30010751",
          "text": "Nintedanib did not improve OS and was associated with a significant but modest increase in PFS versus placebo.",
          "offsetInBeginSection": 1950,
          "offsetInEndSection": 2060,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30952642",
          "text": " 14.2 months [95% confidence interval (CI), 10.8 months-NR]. Nintedanib was well tolerated; grade \u2265 3 toxicities were uncommon and included grade 3 hy",
          "offsetInBeginSection": 1041,
          "offsetInEndSection": 1191,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30603797",
          "text": "Significant clinical activity was observed, including in bevacizumab-pretreated patients, suggesting nintedanib can overcome bevacizumab resistance.",
          "offsetInBeginSection": 1678,
          "offsetInEndSection": 1826,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35421369",
          "text": "We investigated the effect of adding nintedanib to neoadjuvant chemotherapy on response and survival in muscle-invasive bladder cancer.",
          "offsetInBeginSection": 121,
          "offsetInEndSection": 256,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30929823",
          "text": "overall survival were 1.8 and 16\u202fmonths, respectively. Response rate was 7.4% (2/27 PR). Thirty-seven percent (10/27) had stable disease, while 56% (1",
          "offsetInBeginSection": 1054,
          "offsetInEndSection": 1204,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29748012",
          "text": " bid plus cisplatin/gemcitabine was manageable, with AEs consistent with previous observations. PK data demonstrated no interaction, and preliminary a",
          "offsetInBeginSection": 1568,
          "offsetInEndSection": 1718,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30929823",
          "text": "nselected bevacizumab-resistant EOC population. Nintedanib was tolerable and toxicities were manageable. Plasma CD73, IL6, and VEGFD were identified a",
          "offsetInBeginSection": 1588,
          "offsetInEndSection": 1738,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31900121",
        "http://www.ncbi.nlm.nih.gov/pubmed/29119292",
        "http://www.ncbi.nlm.nih.gov/pubmed/30952642",
        "http://www.ncbi.nlm.nih.gov/pubmed/29748012",
        "http://www.ncbi.nlm.nih.gov/pubmed/34015154",
        "http://www.ncbi.nlm.nih.gov/pubmed/30010751",
        "http://www.ncbi.nlm.nih.gov/pubmed/30603797",
        "http://www.ncbi.nlm.nih.gov/pubmed/25312396",
        "http://www.ncbi.nlm.nih.gov/pubmed/9749086",
        "http://www.ncbi.nlm.nih.gov/pubmed/30929823"
      ]
    },
    {
      "id": "6419fa3d690f196b5100003c",
      "type": "summary",
      "body": "What is the difference between siRNA and Antisense oligonucleotide therapeutics",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36332914",
          "text": "Unique clinical pharmacology characteristics represent a differentiating factor for this class of therapeutics.",
          "offsetInBeginSection": 1732,
          "offsetInEndSection": 1843,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23932248",
          "text": "Efficient and targeted cellular delivery of small interfering RNAs (siRNAs) and antisense oligonucleotides (AONs) is a major challenge facing oligonucleotide-based therapeutics.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21702481",
          "text": "ion is critical to developing stable and potent drugs. For unmodified small interfering RNA (siRNA), DNA antisense oligonucleotide (AON) and locked nu",
          "offsetInBeginSection": 113,
          "offsetInEndSection": 263,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23932248",
          "text": "-RNA backbone chemical modifications improve siRNA and AON potency and duration of activity. Importantly, delivery of these nucleic acids on the exter",
          "offsetInBeginSection": 940,
          "offsetInEndSection": 1090,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27084936",
          "text": "However, effective delivery of oligonucleotides to their intracellular sites of action remains a major issue.",
          "offsetInBeginSection": 250,
          "offsetInEndSection": 359,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25662226",
          "text": "The therapeutic use of antisense and siRNA oligonucleotides has been constrained by the limited ability of these membrane-impermeable molecules to reach their intracellular sites of action.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 189,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15294073",
          "text": "It is often believed that small interfering RNA (siRNA) is at least 10-fold more effective than the single-stranded antisense oligonucleotide for silencing the same target gene in the same cells.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 195,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36332914",
          "text": "rapeutics in various ways including both its mechanism of action and clinical pharmacology characteristics. These unique characteristics, along with e",
          "offsetInBeginSection": 169,
          "offsetInEndSection": 319,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16101440",
          "text": "llular cascade is quite different. siRNA could prove to be more powerful and longer lasting than antisense. Several DNA therapeutics are currently bei",
          "offsetInBeginSection": 1143,
          "offsetInEndSection": 1293,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33314011",
          "text": "CONCLUSIONS\nAvoiding suppression of off-target genes by a thorough bioinformatics screen should strongly reduce the risk for toxicities caused by antisense oligonucleotide-mediated off-target RNA suppression and finally result in safer antisense oligonucleotide-based therapeutics.",
          "offsetInBeginSection": 1444,
          "offsetInEndSection": 1725,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25662226",
        "http://www.ncbi.nlm.nih.gov/pubmed/15539157",
        "http://www.ncbi.nlm.nih.gov/pubmed/17009857",
        "http://www.ncbi.nlm.nih.gov/pubmed/22353142",
        "http://www.ncbi.nlm.nih.gov/pubmed/16101440",
        "http://www.ncbi.nlm.nih.gov/pubmed/36332914",
        "http://www.ncbi.nlm.nih.gov/pubmed/15294073",
        "http://www.ncbi.nlm.nih.gov/pubmed/23932248",
        "http://www.ncbi.nlm.nih.gov/pubmed/27084936",
        "http://www.ncbi.nlm.nih.gov/pubmed/18483081"
      ]
    },
    {
      "id": "644036cf57b1c7a315000048",
      "type": "summary",
      "body": "What is Yutiq?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35793136",
          "text": "PURPOSE\nTo evaluate the efficacy of the fluocinolone acetonide intravitreal implant (Yutiq) as monotherapy for uveitis.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31663454",
          "text": "This article will review the pharmacology and preliminary clinical data of the 0.18\u00a0mg fluocinolone acetonide intravitreal implant (YUTIQ\u2122), to show its efficacy and safety in the treatment of noninfectious posterior uveitis.",
          "offsetInBeginSection": 568,
          "offsetInEndSection": 793,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36444172",
          "text": "Purpose\nOur case emphasizes the utility of long-acting intravitreal fluocinolone implants (YUTIQ) for managing recalcitrant forms of non-infectious posterior uveitis, NIPU.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31663454",
        "http://www.ncbi.nlm.nih.gov/pubmed/35793136",
        "http://www.ncbi.nlm.nih.gov/pubmed/36444172"
      ]
    },
    {
      "id": "643f9eeb57b1c7a31500003c",
      "type": "factoid",
      "body": "What is the incidence of Duchenne Muscular Dystrophy?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28802771",
          "text": "scular dystrophy in childhood, with a worldwide incidence of one in 5000 live male births. It is due to mutations in the dystrophin gene leading to ab",
          "offsetInBeginSection": 57,
          "offsetInEndSection": 207,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25752877",
          "text": "Duchenne muscular dystrophy, an X-linked disorder, has an incidence of one in 5000 boys and presents in early childhood with proximal muscle weakness.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25996334",
          "text": "INTRODUCTION\nDuchenne muscular dystrophy is the most common form of muscular dystrophy, with an incidence of 1/3300 male live births and a prevalence rate in the total population of 3/100000 individuals.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 203,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1303286",
          "text": "The incidence is unknown because of its clinical similarity to Duchenne muscular dystrophy (DMD).",
          "offsetInBeginSection": 93,
          "offsetInEndSection": 190,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7922631",
          "text": "ur region too. The incidence of Duchenne muscular dystrophy was 1 in 4827 liveborn boys. The figure is in the range of the published data of the incid",
          "offsetInBeginSection": 577,
          "offsetInEndSection": 727,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1994843",
          "text": "Smooth muscle degeneration may occur in Duchenne muscular dystrophy. We measured fasting orocaecal transit time in patients with advanced Duchenne mus",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33012180",
          "text": "METHODS\nOnline surveys were sent to three groups: (a) people with a confirmed diagnosis of Duchenne muscular dystrophy (\u226514 years), (b) parents and guardians and (c) neuromuscular clinicians in the UK NorthStar Clinical Network.",
          "offsetInBeginSection": 417,
          "offsetInEndSection": 645,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7334342",
          "text": "ular dystrophies the authors estimate the incidence of DMD at 1/6500 living new born boys. The number of false positives (1,5 p. 1000) is little and, ",
          "offsetInBeginSection": 258,
          "offsetInEndSection": 408,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1745328",
          "text": "The incidence of DMD in the period 1957-1985 was 15.41 X 10(-5) live-born males (LBM) and 3.21 X 10(-5) LBM for BMD.",
          "offsetInBeginSection": 789,
          "offsetInEndSection": 905,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1342481",
          "text": "The incidence in different countries varies from 130 to 390 per million male live births.",
          "offsetInBeginSection": 82,
          "offsetInEndSection": 171,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/1303286",
        "http://www.ncbi.nlm.nih.gov/pubmed/7922631",
        "http://www.ncbi.nlm.nih.gov/pubmed/28954035",
        "http://www.ncbi.nlm.nih.gov/pubmed/30796500",
        "http://www.ncbi.nlm.nih.gov/pubmed/26697447",
        "http://www.ncbi.nlm.nih.gov/pubmed/34064562",
        "http://www.ncbi.nlm.nih.gov/pubmed/8190471",
        "http://www.ncbi.nlm.nih.gov/pubmed/33012180",
        "http://www.ncbi.nlm.nih.gov/pubmed/7322666",
        "http://www.ncbi.nlm.nih.gov/pubmed/29877606"
      ]
    },
    {
      "id": "6402ba49201352f04a000004",
      "type": "list",
      "body": "Which drugs were studied in the TRICOTEL study?",
      "snippets": [],
      "documents": []
    },
    {
      "id": "6431f6a857b1c7a315000018",
      "type": "summary",
      "body": "How is amniotic fluid produced?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9618058",
          "text": "It is produced by the decidua and by fetal tissues, and it is thought to play an important role in fetal growth.",
          "offsetInBeginSection": 126,
          "offsetInEndSection": 238,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/4087096",
          "text": "h and gastric function were reversed by infusion of amniotic fluid intragastrically. We conclude that amniotic fluid provides 10% to 14% of the nutrit",
          "offsetInBeginSection": 929,
          "offsetInEndSection": 1079,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1471670",
          "text": "ere produced in the amniotic fluid of the rabbit after intracervical inoculation with Escherichia coli.\n\n\nSTUDY DESIGN\nTimed pregnant rabbits on day 2",
          "offsetInBeginSection": 151,
          "offsetInEndSection": 301,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8789556",
          "text": "METHOD\nA cross-sectional study was designed using parameters that included gestational age, results of amniotic fluid (AF) cultures, and labor status at the time of amniocentesis.",
          "offsetInBeginSection": 544,
          "offsetInEndSection": 723,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17303237",
          "text": "Amniotic fluid is created by the flow of fluid from the fetal lung and bladder.",
          "offsetInBeginSection": 225,
          "offsetInEndSection": 304,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17254633",
          "text": "Amniotic fluid is created by the flow of fluid from the fetal lung and bladder.",
          "offsetInBeginSection": 225,
          "offsetInEndSection": 304,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7270010",
          "text": "Since both foetal and maternal prolactin secretion are suppressed by bromocriptine our results suggest that amniotic fluid prolactin is produced by extrapituitary tissues, which do not contain dopamine receptors.",
          "offsetInBeginSection": 277,
          "offsetInEndSection": 489,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2497808",
          "text": "of ten samples of amniotic fluid produced one or two immunoprecipitin bands against antiserum to UTM-proteins. Each band fused with immunoprecipitin b",
          "offsetInBeginSection": 322,
          "offsetInEndSection": 472,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8726860",
          "text": "produce PTHrP has also been conducted. Amniotic fluid was obtained by amniocentesis from women: (1) at term, not in labour; (2) in normal term labour;",
          "offsetInBeginSection": 189,
          "offsetInEndSection": 339,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10229907",
          "text": "CONCLUSIONS\nThe results indicate that amniotic fluid contains high concentrations of inhibins (A and B), activin A and follistatin in early pregnancy suggesting that these hormones are produced by the fetal membranes and may be involved in the development of the fetus.",
          "offsetInBeginSection": 1182,
          "offsetInEndSection": 1451,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/4087096",
        "http://www.ncbi.nlm.nih.gov/pubmed/15301282",
        "http://www.ncbi.nlm.nih.gov/pubmed/24285455",
        "http://www.ncbi.nlm.nih.gov/pubmed/9512316",
        "http://www.ncbi.nlm.nih.gov/pubmed/1915224",
        "http://www.ncbi.nlm.nih.gov/pubmed/1471670",
        "http://www.ncbi.nlm.nih.gov/pubmed/2497808",
        "http://www.ncbi.nlm.nih.gov/pubmed/10229907",
        "http://www.ncbi.nlm.nih.gov/pubmed/22439042",
        "http://www.ncbi.nlm.nih.gov/pubmed/6416072"
      ]
    },
    {
      "id": "6415c252690f196b51000011",
      "type": "factoid",
      "body": "Which cancer is the BCG vaccine used for?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19058494",
          "text": "ition, BCG vaccine is supplied like an immunomodulator in treatment of melanoma. It is important to continue with the study of the BCG strains for its",
          "offsetInBeginSection": 461,
          "offsetInEndSection": 611,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6347154",
          "text": "Fifty-two patients with locally advanced squamous cell cancer were entered into a randomized trial of BCG vaccine following definitive local therapy.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30085482",
          "text": "Data on the principles of BCG vaccine action on the cancer of bladder are presented.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 84,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36084845",
          "text": "ogous infections, including BCG and COVID-19, the effect of BCG against cancer, and BCG against auto-immune and inflammatory diseases. To discuss thes",
          "offsetInBeginSection": 978,
          "offsetInEndSection": 1128,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27749923",
          "text": "nia, and C-reactive protein increased) shared by the BCG TB vaccine and bladder cancer vaccine. Furthermore, our deep investigation of 24 BCG-associat",
          "offsetInBeginSection": 1686,
          "offsetInEndSection": 1836,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1421654",
          "text": "t BCG is superior to thiotepa, doxorubicin, and mitomycin in preventing bladder tumor recurrence and tumor progression. Local cystitis is an adverse e",
          "offsetInBeginSection": 1212,
          "offsetInEndSection": 1362,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34983348",
          "text": "Evidence from multiple scientific studies suggests that the Bacillus Calmette-Gu\u00e9rin (BCG) vaccine, widely used worldwide as a preventive measure against tuberculosis, also offers crossprotection against other pathogens.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 220,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7984457",
          "text": "This paper describes how it can be used as an alternative to cytotoxic agents in the treatment of bladder cancer.",
          "offsetInBeginSection": 57,
          "offsetInEndSection": 170,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21977071",
          "text": "Herein, we describe gluteal tuberculosis abscess due to inadvertently injected BCG a patient with bladder cancer.",
          "offsetInBeginSection": 97,
          "offsetInEndSection": 210,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34875601",
          "text": "ific protection from various infections and is used in the treatment of bladder cancer. By 2020, at least five technologies had already been establish",
          "offsetInBeginSection": 770,
          "offsetInEndSection": 920,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/1421654",
        "http://www.ncbi.nlm.nih.gov/pubmed/34593271",
        "http://www.ncbi.nlm.nih.gov/pubmed/34875601",
        "http://www.ncbi.nlm.nih.gov/pubmed/34627626",
        "http://www.ncbi.nlm.nih.gov/pubmed/28197393",
        "http://www.ncbi.nlm.nih.gov/pubmed/33262028",
        "http://www.ncbi.nlm.nih.gov/pubmed/20224496",
        "http://www.ncbi.nlm.nih.gov/pubmed/34983348",
        "http://www.ncbi.nlm.nih.gov/pubmed/12649188",
        "http://www.ncbi.nlm.nih.gov/pubmed/35832066"
      ]
    },
    {
      "id": "641791b9690f196b51000030",
      "type": "list",
      "body": "What are the most common congenital muscular dystrophies?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31308722",
          "text": "s and degeneration apparent at birth or in the first 6 months of life. LAMA2 MD is the most common congenital muscular dystrophy, affecting approximat",
          "offsetInBeginSection": 386,
          "offsetInEndSection": 536,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29933045",
          "text": "In this review, we summarize the clinical features of two of the most common congenital muscular dystrophies, COL6-related dystrophies and LAMA2-related dystrophies, which are caused by mutations in muscle ECM and basement membrane proteins.",
          "offsetInBeginSection": 630,
          "offsetInEndSection": 871,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23288328",
          "text": "Dystroglycanopathies are a clinically and genetically diverse group of recessively inherited conditions ranging from the most severe of the congenital muscular dystrophies, Walker-Warburg syndrome, to mild forms of adult-onset limb-girdle muscular dystrophy.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 258,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10734260",
          "text": "Fukuyama congenital muscular dystrophy is one of the most common autosomal recessive disorders in the Japanese population, characterized by congenital muscular dystrophy in combination with cortical dysgenesis (micropolygyria).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 227,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29376585",
          "text": "s in Laminin a2. Turk J Pediatr 2017; 59: 338-341. Laminin \u03b12 related congenital muscular dystrophy is one of the most common congenital muscular dyst",
          "offsetInBeginSection": 157,
          "offsetInEndSection": 307,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8000914",
          "text": "Congenital muscular dystrophy is one of the most frequent and severe childhood muscular dystrophies.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 100,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23622361",
          "text": "This chapter reviews the most common forms of congenital muscular dystrophies, including laminin \u03b1-2 (merosin) deficiency, Ullrich congenital muscular dystrophy, fukutin-related proteinopathy, rigid spine syndrome, and glycosylation disorders of \u03b1-dystroglycan.",
          "offsetInBeginSection": 190,
          "offsetInEndSection": 451,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31309178",
          "text": "The most common type of CMD in Europe is Merosin-deficient CMD caused by mutations in laminin-\u03b12 protein.",
          "offsetInBeginSection": 126,
          "offsetInEndSection": 231,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25653289",
          "text": "The most common forms were those with \u03b1-dystroglycan glycosylation deficiency (40.18%) followed by those with laminin \u03b12 deficiency (24.11%) and collagen VI deficiency (20.24%).",
          "offsetInBeginSection": 607,
          "offsetInEndSection": 784,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36334577",
          "text": "LAMA2-related congenital muscular dystrophy (MDC1A), the most commonly recognized type of congenital muscular dystrophies, is a severe neonatal onset muscle disease caused by recessive mutations in the LAMA2 gene.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 213,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32444167",
        "http://www.ncbi.nlm.nih.gov/pubmed/25653289",
        "http://www.ncbi.nlm.nih.gov/pubmed/31105770",
        "http://www.ncbi.nlm.nih.gov/pubmed/31308722",
        "http://www.ncbi.nlm.nih.gov/pubmed/35562158",
        "http://www.ncbi.nlm.nih.gov/pubmed/33200426",
        "http://www.ncbi.nlm.nih.gov/pubmed/24223098",
        "http://www.ncbi.nlm.nih.gov/pubmed/36334577",
        "http://www.ncbi.nlm.nih.gov/pubmed/31309178",
        "http://www.ncbi.nlm.nih.gov/pubmed/23288328"
      ]
    },
    {
      "id": "63eeed0af36125a426000007",
      "type": "factoid",
      "body": "What disease can be treated with Teclistamab?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34388396",
          "text": "clistamab is a novel treatment approach for relapsed or refractory multiple myeloma. At the recommended phase 2 dose, teclistamab showed promising eff",
          "offsetInBeginSection": 2701,
          "offsetInEndSection": 2851,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36321843",
          "text": "-cell engager teclistamab for patients with relapsed or refractory multiple myeloma. In the clinical trial that led to its approval, patients had an o",
          "offsetInBeginSection": 37,
          "offsetInEndSection": 187,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34388396",
          "text": "METHODS\nThis open-label, single-arm, phase 1 study enrolled patients with multiple myeloma who were relapsed, refractory, or intolerant to established therapies.",
          "offsetInBeginSection": 434,
          "offsetInEndSection": 595,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32956453",
          "text": "rrant further evaluation of this bispecific antibody for the treatment of MM. Phase 1 clinical trials (monotherapy, #NCT03145181; combination therapy,",
          "offsetInBeginSection": 1514,
          "offsetInEndSection": 1664,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35749004",
          "text": "-1) is evaluating teclistamab in patients with relapsed/refractory multiple myeloma.\n\n\nPATIENTS AND METHODS\nTo estimate the efficacious therapeutic do",
          "offsetInBeginSection": 260,
          "offsetInEndSection": 410,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35661166",
          "text": "ponse in patients with triple-class-exposed relapsed or refractory multiple myeloma. Cytopenias and infections were common; toxic effects that were co",
          "offsetInBeginSection": 2023,
          "offsetInEndSection": 2173,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36352205",
          "text": "y Janssen Research and Development for the treatment of relapsed or refractory multiple myeloma. Teclistamab was recently granted conditional approval",
          "offsetInBeginSection": 122,
          "offsetInEndSection": 272,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34388396",
          "text": "BACKGROUND\nThere is a need for novel therapies for relapsed or refractory multiple myeloma, and B-cell maturation antigen (BCMA) is a validated target.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19484412",
          "text": "PATIENTS\nA group of 276 consecutive patients, whose mean age was 9.50 years, diagnosed with various types of malocclusion, whose records were complete, and who were treated solely with removable appliances.",
          "offsetInBeginSection": 104,
          "offsetInEndSection": 310,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35749004",
          "text": "re was maintained above the mean EC90. All patients who responded to the RP2D of teclistamab had exposure above the maximum EC90 in both serum and bon",
          "offsetInBeginSection": 1355,
          "offsetInEndSection": 1505,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35661166",
        "http://www.ncbi.nlm.nih.gov/pubmed/32956453",
        "http://www.ncbi.nlm.nih.gov/pubmed/36321843",
        "http://www.ncbi.nlm.nih.gov/pubmed/36352205",
        "http://www.ncbi.nlm.nih.gov/pubmed/34388396",
        "http://www.ncbi.nlm.nih.gov/pubmed/19484412",
        "http://www.ncbi.nlm.nih.gov/pubmed/9148449",
        "http://www.ncbi.nlm.nih.gov/pubmed/35749004"
      ]
    },
    {
      "id": "643d3e6157b1c7a315000034",
      "type": "list",
      "body": "Please list the natriuretic peptides.",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7496058",
          "text": "The natriuretic peptide family consists of three members: atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16565701",
          "text": "Cardiac natriuretic peptides (including ANP, BNP, CNP and urodilatin) constitute a family of peptide hormones and neurotransmitters, sharing similar chemical structure (characterized by a cysteine bridge) and biological function.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 229,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11476733",
          "text": "The natriuretic peptides - atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide - comprise a family of proteins that participate in the integrated control of intravascular volume and arterial blood pressure.",
          "offsetInBeginSection": 111,
          "offsetInEndSection": 351,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16548773",
          "text": "Natriuretic peptides (atrial natriuretic peptide, brain natriuretic peptide and C-type natriuretic peptide) are cardiac and vascular peptides with vasodilatory, diuretic, natriuretic, anti-inflammatory, antifibrotic and antimitogenic actions.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 242,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11405605",
          "text": "Natriuretic peptides, atrial natriuretic peptide and brain natriuretic peptide, are key regulators in the homeostasis of salt and water excretion and in the maintenance of blood pressure.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 187,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17965966",
          "text": "The natriuretic peptide family comprises atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), C-type natriuretic peptide (CNP), dendroaspis natriuretic peptide (DNP), and urodilatin.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 196,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8967430",
          "text": " that activate receptor guanylate cyclases, namely, natriuretic peptide receptor (NPR)-A and NPR-B. Exposure of cells to atrial natriuretic peptide (A",
          "offsetInBeginSection": 183,
          "offsetInEndSection": 333,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31771521",
          "text": "BACKGROUND\nIn mammals, the natriuretic system contains three natriuretic peptides, NPPA, NPPB and NPPC, that bind to three transmembrane receptors, NPR1, NPR2 and NPR3.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8392634",
          "text": "Natriuretic peptides family consists of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and C-type natriuretic peptide (CNP), while receptors for these natriuretic peptides comprise at least three subtypes, i.e.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 229,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12783635",
          "text": "They consist of atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide and are elevated in patients with left ventricular dysfunction.",
          "offsetInBeginSection": 128,
          "offsetInEndSection": 293,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/11476739",
        "http://www.ncbi.nlm.nih.gov/pubmed/16548773",
        "http://www.ncbi.nlm.nih.gov/pubmed/11405605",
        "http://www.ncbi.nlm.nih.gov/pubmed/32444692",
        "http://www.ncbi.nlm.nih.gov/pubmed/12783635",
        "http://www.ncbi.nlm.nih.gov/pubmed/11476733",
        "http://www.ncbi.nlm.nih.gov/pubmed/8392634",
        "http://www.ncbi.nlm.nih.gov/pubmed/8967430",
        "http://www.ncbi.nlm.nih.gov/pubmed/17965966",
        "http://www.ncbi.nlm.nih.gov/pubmed/16565701"
      ]
    },
    {
      "id": "63f9ee5c33942b094c000014",
      "type": "yesno",
      "body": "Does SRRM4 regulate neuronal-specific microexon splicing of TAF1 mRNA?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29759485",
          "text": "The neural-specific RNA splicing factor, SRRM4, promotes Bif-1b and Bif-1c splicing, and the expression of SRRM4 in tumors is strongly associated with Bif-1b/-1c levels.",
          "offsetInBeginSection": 740,
          "offsetInEndSection": 909,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382513",
          "text": "rostate cancer and may help drive key stages of disease progression. Up-regulation of SRRM4 establishes neuronal splicing patterns in neuroendocrine p",
          "offsetInBeginSection": 1360,
          "offsetInEndSection": 1510,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33207694",
          "text": "r, Serine/arginine repetitive matrix 4 (SRRM4). Overexpressing SRRM4, known for regulating ME inclusion in mRNAs critical for neural differentiation, ",
          "offsetInBeginSection": 1224,
          "offsetInEndSection": 1374,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29759485",
        "http://www.ncbi.nlm.nih.gov/pubmed/33207694",
        "http://www.ncbi.nlm.nih.gov/pubmed/28382513"
      ]
    },
    {
      "id": "644281e557b1c7a31500005b",
      "type": "summary",
      "body": "What is the difference between Facioscapulohumeral Muscular Dystrophy type 1 (FSHD1) and type 2 (FSHD2)?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34743704",
          "text": "pe\u00a01 (FSHD1) are gaining an increasing awareness, but data on cardiac involvement are conflicting. The aim of this study was to determine a progressio",
          "offsetInBeginSection": 169,
          "offsetInEndSection": 319,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24755953",
          "text": "iate expression of DUX4 in skeletal muscle. Clinical severity is inversely related to the number of repeats. In contrast, FSHD2 patients also have ina",
          "offsetInBeginSection": 182,
          "offsetInEndSection": 332,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24882751",
          "text": " identified displaying identical clinical phenotype but different genetic and epigenetic basis. Autosomal dominant FSHD1 (95% of patients) is characte",
          "offsetInBeginSection": 191,
          "offsetInEndSection": 341,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34711481",
          "text": " repeat contraction on chromosome 4. Phenotypically FSHD2 shows virtually no difference from FSHD1 and both forms of FSHD arise via a common downstrea",
          "offsetInBeginSection": 282,
          "offsetInEndSection": 432,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27822859",
          "text": "In unaffected individuals the number of 3.3 kb D4Z4 units varies between 8 and 100, whereas 1-10 units are seen in FSHD1 cases.",
          "offsetInBeginSection": 153,
          "offsetInEndSection": 280,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30666819",
          "text": "ively common autosomal dominant adult muscular dystrophy with variable disease penetrance. The disease is caused by shortening of a D4Z4 repeat array ",
          "offsetInBeginSection": 72,
          "offsetInEndSection": 222,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23969240",
          "text": " an identical clinical phenotype but associated with a different (epi)genetic defect.\n\n\nSTATE OF THE ART\nIn the large majority of FSHD1 patients, the ",
          "offsetInBeginSection": 277,
          "offsetInEndSection": 427,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24128691",
          "text": "t region on chromosome 4q35 that is the hallmark of FSHD1. However, hypomethylation of this region is common to both subtypes. Recently, mutations in ",
          "offsetInBeginSection": 148,
          "offsetInEndSection": 298,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27855411",
          "text": "CONCLUSION\nMuscle involvement appears to be independent of type, confirming a similar pathophysiological pathway in FSHD1 and FSHD2.",
          "offsetInBeginSection": 948,
          "offsetInEndSection": 1080,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23143600",
          "text": " the D4Z4 array, whereas the genetic determinants and inheritance of D4Z4 array contraction-independent FSHD2 are unclear. Here, we show that mutation",
          "offsetInBeginSection": 267,
          "offsetInEndSection": 417,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23143600",
        "http://www.ncbi.nlm.nih.gov/pubmed/23969240",
        "http://www.ncbi.nlm.nih.gov/pubmed/27855411",
        "http://www.ncbi.nlm.nih.gov/pubmed/24882751",
        "http://www.ncbi.nlm.nih.gov/pubmed/24755953",
        "http://www.ncbi.nlm.nih.gov/pubmed/30666819",
        "http://www.ncbi.nlm.nih.gov/pubmed/27822859",
        "http://www.ncbi.nlm.nih.gov/pubmed/34743704",
        "http://www.ncbi.nlm.nih.gov/pubmed/24128691",
        "http://www.ncbi.nlm.nih.gov/pubmed/34711481"
      ]
    },
    {
      "id": "63f03ea0f36125a426000020",
      "type": "factoid",
      "body": "SER-109 is developed for prevention of which disease?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26908752",
          "text": "CONCLUSIONS\nSER-109 successfully prevented CDI and had a favorable safety profile, supporting a novel microbiome-based intervention as a potential therapy for recurrent CDI.",
          "offsetInBeginSection": 1444,
          "offsetInEndSection": 1617,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36158136",
          "text": "We report that the manufacturing steps for SER-109, a purified investigational microbiome therapeutic developed to reduce risk of Clostridioides difficile recurrence, inactivate porcine epidemic diarrhea virus, a model coronavirus for SARS-CoV-2.",
          "offsetInBeginSection": 218,
          "offsetInEndSection": 464,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36140013",
          "text": " its rigorous manufacturing process, which mitigates the risk of pathogen transmission. Additionally, we discuss compositional and functional changes ",
          "offsetInBeginSection": 1423,
          "offsetInEndSection": 1573,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35045228",
          "text": "CONCLUSIONS\nIn patients with symptom resolution of C. difficile infection after treatment with standard-of-care antibiotics, oral administration of SER-109 was superior to placebo in reducing the risk of recurrent infection.",
          "offsetInBeginSection": 2028,
          "offsetInEndSection": 2252,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32255488",
          "text": "CONCLUSIONS\nEarly SER-109 engraftment was associated with reduced CDI recurrence and favorable safety was observed.",
          "offsetInBeginSection": 1560,
          "offsetInEndSection": 1675,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35045228",
          "text": "The primary efficacy objective was to show superiority of SER-109 as compared with placebo in reducing the risk of C. difficile infection recurrence up to 8 weeks after treatment.",
          "offsetInBeginSection": 657,
          "offsetInEndSection": 836,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35045228",
          "text": "ssociated with bile-acid profiles that are known to inhibit C. difficile spore germination.\n\n\nCONCLUSIONS\nIn patients with symptom resolution of C. di",
          "offsetInBeginSection": 1934,
          "offsetInEndSection": 2084,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26908752",
          "text": "BACKGROUND\nPatients with recurrent Clostridium difficile infection (CDI) have a \u226560% risk of relapse, as conventional therapies do not address the underlying gastrointestinal dysbiosis.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 185,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36140013",
          "text": "SER-109 was superior to a placebo in reducing CDI recurrence at Week 8 (12% vs. 40%, respectively; p &lt; 0.001) in adults with a history of recurrent CDI with a favorable observed safety profile.",
          "offsetInBeginSection": 1112,
          "offsetInEndSection": 1308,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36140013",
        "http://www.ncbi.nlm.nih.gov/pubmed/32255488",
        "http://www.ncbi.nlm.nih.gov/pubmed/26908752",
        "http://www.ncbi.nlm.nih.gov/pubmed/36158136",
        "http://www.ncbi.nlm.nih.gov/pubmed/35045228"
      ]
    },
    {
      "id": "6431f71057b1c7a315000019",
      "type": "yesno",
      "body": "In twin-twin transfusion syndrome, are the twins identical?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7880435",
          "text": "pregnancies in whom twin-to-twin transfusion syndrome was suspected. Chorionicity and the presence of placental vascular anastomoses were assessed pos",
          "offsetInBeginSection": 104,
          "offsetInEndSection": 254,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7789711",
          "text": "The twin-twin transfusion syndrome is a rare but severe complication in monozygotic twins.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12665487",
          "text": "how discordant intertwin vascular compliance in childhood despite identical genotype. We hypothesized that discordance is prevented by intrauterine en",
          "offsetInBeginSection": 126,
          "offsetInEndSection": 276,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29796818",
          "text": "These results show that dissimilar genetic material and separate in utero environment promote discordance in innate immune protein expressions between twins.",
          "offsetInBeginSection": 1280,
          "offsetInEndSection": 1437,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11109260",
          "text": "This article examines twin-twin transfusion syndrome, a condition in which identical twins share a single placenta with abnormal anastomoses.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22536818",
          "text": "Monochorionic twins are at increased risk for unique complications including twin-twin transfusion syndrome (TTTS), selective intrauterine growth restriction (sIUGR), and twin-reversed arterial perfusion (TRAP) sequence.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 220,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18354242",
          "text": "Twin-twin transfusion syndrome (TTTS) is a severe complication of monozygotic (identical) twin fetuses sharing one single (monochorionic) placenta.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14608856",
          "text": "The ultrasound criterias for diagnosis, in this study, were the presence of twins of the same sex with discordant growth, with oligohydroamnios in one twin sac and polyhydroamnios in the other one, one placenta and thin membrane between twins.",
          "offsetInBeginSection": 802,
          "offsetInEndSection": 1045,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18033069",
          "text": "ement, with higher morbidity and mortality.\n\n\nPATIENTS AND METHODS\nTwo identical twins, I and II (monochorionic placenta, biamniotic), born prematurel",
          "offsetInBeginSection": 248,
          "offsetInEndSection": 398,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33345886",
          "text": "etween donor fetuses in twin-twin transfusion syndrome cases and matched control twins. Secondary outcomes included comparisons of other renal artery ",
          "offsetInBeginSection": 1790,
          "offsetInEndSection": 1940,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/7789711",
        "http://www.ncbi.nlm.nih.gov/pubmed/24512749",
        "http://www.ncbi.nlm.nih.gov/pubmed/848859",
        "http://www.ncbi.nlm.nih.gov/pubmed/33345886",
        "http://www.ncbi.nlm.nih.gov/pubmed/2642349",
        "http://www.ncbi.nlm.nih.gov/pubmed/29796818",
        "http://www.ncbi.nlm.nih.gov/pubmed/11109260",
        "http://www.ncbi.nlm.nih.gov/pubmed/12665487",
        "http://www.ncbi.nlm.nih.gov/pubmed/18033069",
        "http://www.ncbi.nlm.nih.gov/pubmed/7880435"
      ]
    },
    {
      "id": "6414c1ae690f196b51000003",
      "type": "summary",
      "body": "What is the definition of trichotillomania?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31954616",
          "text": "The aim of this study was to examine the association between duration of trichotillomania (defined as time between initial age of onset and current age) and structural brain abnormalities by pooling all available global data.",
          "offsetInBeginSection": 140,
          "offsetInEndSection": 365,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19034750",
          "text": "tual disability, and by definition excludes people with trichotillomania (TTM). Nevertheless, hair-pulling may be one of a number of body-focused repe",
          "offsetInBeginSection": 149,
          "offsetInEndSection": 299,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7389405",
          "text": "ggested if this is not helpful. Trichotillomania by definition implies psychosis. Since this behavior is seldom associated with psychosis, we suggest ",
          "offsetInBeginSection": 522,
          "offsetInEndSection": 672,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27824633",
          "text": "Trichotillomania is characterized by repetitive pulling that causes noticeable hair loss.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 89,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1284254",
          "text": "Trichotillomania is characterized by chronic hair-pulling resulting in noticeable hair loss.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 92,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8340306",
          "text": "illomania. These results suggest that when trichotillomania is a benign habit disorder, the treatment of a covarying habit such as thumb-sucking can b",
          "offsetInBeginSection": 537,
          "offsetInEndSection": 687,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18950408",
          "text": "Trichotillomania in early childhood is considered a benign habit disorder in contrary to older children and adults where trichotillomania is associated with greater psychopathology.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 181,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19034750",
          "text": "gument that trichotillomania can usefully be conceptualized as a stereotypic disorder. Speculatively, this argument may be especially valid in trichot",
          "offsetInBeginSection": 1891,
          "offsetInEndSection": 2041,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2175127",
          "text": "Advances an opinion about the validity of singling out the definition \"a pathological habitual action\" as an independent psychopathological sign of certain varieties of trichotillomania.",
          "offsetInBeginSection": 688,
          "offsetInEndSection": 874,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27086334",
          "text": "AIM\nTrichotillomania is a lack of control of one's hair pulling. It is estimated that about 1% of population develops trichotillomania. In up to 20% o",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24096547",
        "http://www.ncbi.nlm.nih.gov/pubmed/19034750",
        "http://www.ncbi.nlm.nih.gov/pubmed/27086333",
        "http://www.ncbi.nlm.nih.gov/pubmed/30099694",
        "http://www.ncbi.nlm.nih.gov/pubmed/35118122",
        "http://www.ncbi.nlm.nih.gov/pubmed/11891999",
        "http://www.ncbi.nlm.nih.gov/pubmed/24778530",
        "http://www.ncbi.nlm.nih.gov/pubmed/7389405",
        "http://www.ncbi.nlm.nih.gov/pubmed/32633577",
        "http://www.ncbi.nlm.nih.gov/pubmed/20391272"
      ]
    },
    {
      "id": "64179113690f196b5100002e",
      "type": "factoid",
      "body": "Where is the DMD gene located?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19461958",
          "text": "inked recessive disorders caused by mutations of the DMD gene located at Xp21. In DMD patients, dystrophin is virtually absent; whereas BMD patients h",
          "offsetInBeginSection": 77,
          "offsetInEndSection": 227,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12619170",
          "text": "rophy (DMD) is a dystrophinopathy, and its associated gene is located on Xp21. Moreover, utrophin, a recently identified structural homologue of dystr",
          "offsetInBeginSection": 22,
          "offsetInEndSection": 172,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18471087",
          "text": "r disorder caused by mutations in the dystrophin DMD gene located at Xp21.1 region. Up to 65% of the patients present dystrophin gene deletions. Mothe",
          "offsetInBeginSection": 71,
          "offsetInEndSection": 221,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2889148",
          "text": "Long-range physical mapping has shown that the DMD gene, localized in Xp21, is extremely large, exceeding 2 million base pairs.",
          "offsetInBeginSection": 241,
          "offsetInEndSection": 368,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31661024",
          "text": "disease in children, resulting from a defect in the DMD gene located on Xp21.2. The new emerging treatment using exon skipping strategy is tailored to",
          "offsetInBeginSection": 96,
          "offsetInEndSection": 246,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3777020",
          "text": "resent case supports the hypothesis that the DMD gene must be located at Xp21. In this study, involvement of the father's chromosomes in the transloca",
          "offsetInBeginSection": 303,
          "offsetInEndSection": 453,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12145744",
          "text": " only later was it diagnosed as DMD. Because the DMD gene is located at Xp21.2, which is one breakpoint of the inv(X), and because its defects are rar",
          "offsetInBeginSection": 364,
          "offsetInEndSection": 514,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16936400",
          "text": "letion, duplication or point mutation of the dystrophin gene located at Xp 21.2. In the present study DNA from seventy unrelated patients clinically d",
          "offsetInBeginSection": 124,
          "offsetInEndSection": 274,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24014122",
          "text": "The DMD gene, located on Xp21, is the largest human gene in the human genome (2.3 Mb).",
          "offsetInBeginSection": 329,
          "offsetInEndSection": 415,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12488581",
          "text": "inked diseases resulting from a defect in the dystrophin gene located on Xp21. DMD is the most frequent neuromuscular disease in humans (1/3500 male n",
          "offsetInBeginSection": 60,
          "offsetInEndSection": 210,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35359537",
        "http://www.ncbi.nlm.nih.gov/pubmed/12619170",
        "http://www.ncbi.nlm.nih.gov/pubmed/30218397",
        "http://www.ncbi.nlm.nih.gov/pubmed/16936400",
        "http://www.ncbi.nlm.nih.gov/pubmed/2821406",
        "http://www.ncbi.nlm.nih.gov/pubmed/20031025",
        "http://www.ncbi.nlm.nih.gov/pubmed/2889148",
        "http://www.ncbi.nlm.nih.gov/pubmed/28028563",
        "http://www.ncbi.nlm.nih.gov/pubmed/6655672",
        "http://www.ncbi.nlm.nih.gov/pubmed/12145744"
      ]
    },
    {
      "id": "64040c6b201352f04a00000f",
      "type": "summary",
      "body": "What is the mechanism of action of Tolebrutinib?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32726870",
          "text": "SAR442168, PRN2246, or BTK'168) showed significantly reduced disease activity associated with MS. Herein, we report the radiosynthesis of [11 C]Tolebrutinib ([11 C]5) as a potential PET imaging agent for BTK.",
          "offsetInBeginSection": 332,
          "offsetInEndSection": 540,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27324312",
          "text": "However, the cell type that senses O2 (the O2 sensor) and the signalling pathway that couples changes in PO2 to changes in arteriolar tone (the mechanism of action) remain unclear.",
          "offsetInBeginSection": 201,
          "offsetInEndSection": 381,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34724345",
          "text": "emergent adverse events were mild. Tolebrutinib was rapidly absorbed following oral administration with a rapid half-life of ~\u00a02\u00a0h. Peripheral BTK occ",
          "offsetInBeginSection": 1113,
          "offsetInEndSection": 1263,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34418400",
          "text": "BACKGROUND\nTolebrutinib is an oral, CNS-penetrant, irreversible inhibitor of Bruton's tyrosine kinase, an enzyme expressed in B lymphocytes and myeloid cells including microglia, which are major drivers of inflammation in multiple sclerosis.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 241,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34418400",
          "text": " tolebrutinib dose groups (5, 15, 30, and 60 mg administered once daily as an oral tablet). Cohort 1 received tolebrutinib for 12 weeks, then matched ",
          "offsetInBeginSection": 1401,
          "offsetInEndSection": 1551,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34724345",
          "text": "ated treatment emergent adverse events were mild. Tolebrutinib was rapidly absorbed following oral administration with a rapid half-life of ~\u00a02\u00a0h. Per",
          "offsetInBeginSection": 1098,
          "offsetInEndSection": 1248,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31781552",
          "text": "at their main mechanism of action in vivo relies on paracrine signaling and extracellular vesicles. Mesenchymal stromal cell-derived extracellular ves",
          "offsetInBeginSection": 338,
          "offsetInEndSection": 488,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34724345",
        "http://www.ncbi.nlm.nih.gov/pubmed/31781552",
        "http://www.ncbi.nlm.nih.gov/pubmed/34418400",
        "http://www.ncbi.nlm.nih.gov/pubmed/32726870",
        "http://www.ncbi.nlm.nih.gov/pubmed/27324312"
      ]
    },
    {
      "id": "6415b7b8690f196b5100000c",
      "type": "yesno",
      "body": "Optogenetics refers to the study of gene expression optimization",
      "snippets": [],
      "documents": []
    },
    {
      "id": "6415c9e9690f196b51000018",
      "type": "factoid",
      "body": "Which form of breast cancer has Keytruda been FDA approved for?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29273617",
          "text": "The drug was approved to treat patients with HER2-positive breast and metastatic stomach cancers.",
          "offsetInBeginSection": 78,
          "offsetInEndSection": 175,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35745835",
          "text": "PD-1 inhibitor Keytruda combined with chemotherapy for Triple-negative breast cancer (TNBC) has been approved for FDA, successfully representing the combination therapy of immunotherapy and chemotherapy for the first time in 2020.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 230,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34647523",
          "text": "A) for use in pediatric patients with relapsed or refractory classical Hodgkin's lymphoma. However, there is currently no published data regarding the",
          "offsetInBeginSection": 242,
          "offsetInEndSection": 392,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25991424",
          "text": "Multiple drugs have been approved by US-FDA for breast related malignancies.",
          "offsetInBeginSection": 107,
          "offsetInEndSection": 183,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28978559",
          "text": "The FDA has approved abemaciclib for women with advanced or metastatic ER-positive, HER2-negative breast cancer whose disease has progressed on endocrine therapy.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 162,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21502935",
          "text": "Eribulin mesylate (Halaven-Eisai) has been approved by the FDA for treatment of patients with metastatic breast cancer who have previously received at least 2 chemotherapy regimens for metastatic cancer.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 203,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29382645",
          "text": "The FDA has approved olaparib, a PARP inhibitor, for use in patients with metastatic breast cancer who also carry a germline BRCA1 or BRCA2 mutation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32069837",
          "text": "Breast cancer is the most common cancer in women worldwide and the solid tumor type for which the highest number of drugs have been approved to date.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28356261",
          "text": "The FDA has approved ribociclib combined with aromatase inhibitor therapy for women with metastatic HR-positive, HER2-negative breast cancer.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32988260",
          "text": "In March 2019, the combination of nab-paclitaxel and atezolizumab was approved by the US FDA for patients with PD-L1 positive metastatic triple-negative breast cancer based on positive results of the Impassion130 trial.",
          "offsetInBeginSection": 102,
          "offsetInEndSection": 321,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35976445",
        "http://www.ncbi.nlm.nih.gov/pubmed/21502935",
        "http://www.ncbi.nlm.nih.gov/pubmed/24855725",
        "http://www.ncbi.nlm.nih.gov/pubmed/34647523",
        "http://www.ncbi.nlm.nih.gov/pubmed/32988260",
        "http://www.ncbi.nlm.nih.gov/pubmed/25991424",
        "http://www.ncbi.nlm.nih.gov/pubmed/32069837",
        "http://www.ncbi.nlm.nih.gov/pubmed/32846967",
        "http://www.ncbi.nlm.nih.gov/pubmed/29273617",
        "http://www.ncbi.nlm.nih.gov/pubmed/29382645"
      ]
    },
    {
      "id": "64178f94690f196b51000027",
      "type": "summary",
      "body": "What is eteplirsen's mechanism of action?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27324312",
          "text": "However, the cell type that senses O2 (the O2 sensor) and the signalling pathway that couples changes in PO2 to changes in arteriolar tone (the mechanism of action) remain unclear.",
          "offsetInBeginSection": 201,
          "offsetInEndSection": 381,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25544661",
          "text": "In the present study, we posit that normative change is a plausible mechanism and provide a test of this in an eating disorder prevention group program.",
          "offsetInBeginSection": 126,
          "offsetInEndSection": 278,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29178131",
          "text": "However, the presumptive mechanism of action, inhibition of NMDA (N-methyl-D-aspartate) receptors, has recently been challenged.",
          "offsetInBeginSection": 191,
          "offsetInEndSection": 319,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11068911",
          "text": "ialdehyde antimicrobial agent, the mechanism of action of which has been little studied. The aims of this paper are to examine what is currently known",
          "offsetInBeginSection": 46,
          "offsetInEndSection": 196,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25544661",
        "http://www.ncbi.nlm.nih.gov/pubmed/27324312",
        "http://www.ncbi.nlm.nih.gov/pubmed/11068911",
        "http://www.ncbi.nlm.nih.gov/pubmed/29178131"
      ]
    },
    {
      "id": "63f03155f36125a426000019",
      "type": "yesno",
      "body": "Was DNX-2401 tested for treatment of Diffuse Intrinsic Pontine Glioma?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29088386",
          "text": "BACKGROUND\nThere are no effective treatments for diffuse intrinsic pontine gliomas (DIPGs); these tumors cannot be surgical resected, and diagnosis is based on magnetic resonance imaging.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 187,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29475886",
          "text": "In a phase I trial, DNX-2401 is safe and achieves durable responses in patients with recurrent glioma.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26971411",
          "text": "DTI may detect early extrapontine tumor extension in diffuse intrinsic pontine glioma before it becomes apparent on conventional MRI sequences.",
          "offsetInBeginSection": 1466,
          "offsetInEndSection": 1609,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29475886",
        "http://www.ncbi.nlm.nih.gov/pubmed/26971411",
        "http://www.ncbi.nlm.nih.gov/pubmed/29088386"
      ]
    }
  ]
}